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miR-137, schizophrenia and sleep regulation in Drosophila melanogaster 
- Kalon P. Grimes 
Introduction – microRNAs are non-coding DNA sequences, which regulate 
gene expression by promoting the destruction of target mRNAs. The evolutionarily 
conserved miR-137 is expressed in invertebrate and mammalian neuronal tissue and 
there is experimental evidence for mir-137 regulating neurological development, 
synaptic plasticity, and cognitive function. Other genes likely regulated by miR-137 
include members of the dopamine signalling pathway. Furthermore, genome wide 
association studies (GWAS) have linked SNPs in mir-137 with schizophrenia (SZ). 
Modulation of dopaminergic signalling and SZ are associated with abnormal sleep 
quality, suggesting that miR-137 may mediate sleep-wake behaviour.  
Method – This prediction was tested by assessing the diurnal and circadian 
sleep-wake behaviour of Drosophila melanogaster homozygous for a null miR-137 
allele (miR-137KO) or in flies where miR-137 expression had been silenced (miR-
137sponge). Further investigation involved reintroduction of miR-137 expression in 
selected brain regions through use of the Drosophila UAS/Gal4 genetic construct. 
Sleep-wake behaviour was monitored and quantified using a well characterised 
Drosophila activity monitoring system (DAMS). Locomotor behaviour was assessed 
by video tracking flies and quantifying climbing ability in a negative geotaxis assay. 
For gene expression, qualitative PCR (qPCR) Taqman assays were used, and PCR 
genotyping was completed with custom designed primer sets and gel 
electrophoresis. A total transcriptomics assay was conducted and analysed using 
bioinformatical tools, then compared to GWAS datasets. 
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Results – miR-137 null and knockdown genotypes had an extreme sleep 
phenotype characterised by increased total sleep amount. The phenotype was 
attributed to the homeostatic sleep control pathway through activation of the fan-
shaped and mushroom bodies in the brain. Successful knockdown of miR-137 
expression in the brain by the miR-137sponge was verified in qPCR, and PCR 
genotyping confirmed the replacement of miR-137 locus with an inserted wmW.hs 
sequence. There was also a moderate locomotor defect, though this did not account 
for the severity of the sleep phenotype. Additionally, there was a developmental 
delay along with an increased mortality in the pupal stage. There was no evidence 
for circadian disruption or shortening of lifespan because of mir-137 loss of function. 
Comparison of the transcriptome expression changes with sleep and psychiatric 
disorder related GWAS identified a select set of genes which provide putative 
mechanisms for miR-137 function. 
Conclusion – miR-137 is an important conserved microRNA with alleles 
already significantly associated with a major psychiatric disorder in humans. 
Currently, this research demonstrates that miR-137 is responsible for regulating 
pathways ultimately controlling sleep amount, and causing a slight locomotor 
phenotype, both of which are synonymous with some symptoms in the human SZ 
disorder. The project also acts to validate the high efficiency and ability of using 
Drosophila melanogaster as a model for future research into conserved microRNAs. 
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1 Introduction 
The five main psychiatric disorders investigated by the Psychiatric Genomics 
Consortium were: schizophrenia (SZ); bipolar disorder (BD); major depression disorder 
(MDD); attention deficit hyperactive disorder (ADHD) and autism spectrum disorder (ASD) 
(Smoller et al. 2019). Lifetime prevalence rates for these disorders range from 0.7% for SZ to 
12.5% for MDD (Doherty and Owen 2014), with SZ alone having an estimated total of 20 
million sufferers worldwide (GBD 2017). Originally following the introduction of 
antipsychotic drugs in the 1950s, the biological hypotheses of SZ was dominated by the 
dopamine hypothesis (Wise and Stein 1973) before the introduction of newer antipsychotics 
suggested serotonin, GABA and glutamate involvement (McGuffin Owen and Gotesman 
2002). However, since the late 1980s (Murray and Lewis 1987; Weinberger 1987), when the 
neurodevelopmental hypothesis of SZ was re-proposed, it has gained momentum with recent 
genetic studies suggesting a developmental risk factor model of psychosis (Murray et al. 
2017).  A little earlier to the neurodevelopmental hypothesis from the 1980s, it was suspected 
that genetic factors were involved because psychiatric illness was known to run in families. A 
European study by Gottesman and Sheilds (1991) studying families and twins showed this 
disorder is common in the population, with a lifetime risk of 1% and an increased risk for 
relatives of probands with SZ (McGuffin Owen and Gotesman 2002). As our knowledge over 
the last 50 years has grown, it is now clear that we are dealing with highly complex, 
polygenic variants harbouring a range of susceptibilities that when combined with multiple 
environmental, or non-genetic factors, leads to various psychiatric disorders (Lee et al.2013; 
Smoller et al. 2019; FitzGerald et al. 2020).  
One recent SZ genome wide association study (GWAS) (Ripke et al. 2011) identified 
variants from the microRNA miR-137 as statistically associated with this disorder. miR-137 is 
a brain enriched microRNA with recent literature linking it to certain symptoms associated 
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with other neurological diseases and psychiatric disorders (Devanna et al. 2014; Valles et al. 
2014; Duan et al. 2014). In addition, many of the proven and predicted targets of miR-137 
also contain reported SZ risk alleles (Ripke et al. 2011; Duan et al. 2014). However, what 
GWAS studies fail to elucidate is the function of this or other genes within a biological 
system. Currently, the pathways through which miR-137 is involved in SZ risk and 
pathogenesis is unclear and despite its obvious importance, few of its predicted targets have 
been proven or tested in vivo. Equally, the reported associations with ASD and ID (Thomas et 
al 2018), neurological disorders (Chen et al. 2017; Mahmoudi and Cairns 2017; Liang et al. 
2016) and fundamental cellular functions (He et al. 2018; Chen et al. 2017; Tamim et al. 
2014) make miR-137 an ideal candidate for in vivo investigation. 
There are obviously several model organisms available to researchers, e.g. Mus 
musculus, Rattus norvegicus, Danio rerio, Saccharomyces cerevisiae, and all come with 
benefits and caveats. Selecting the correct one requires careful consideration including ease 
or speed of culturing experiments and the percentage of homology with human genes. The 
aim is then to compare model organism results with human genetics studies through DNA 
sequence homolog, inferred similar genetically influenced behaviour or social interactions. 
One way to understand the function of miR-137 is through the use of model organisms. 
In this thesis, the model organism Drosophila melanogaster was used to investigate the 
function of miR-137 by manipulating its gene expression in vivo. The fruit fly was chosen 
because it has an evolutionarily conserved ortholog of the human MIR-137, a quick lifecycle, 
extensive published research, relatively low cost, and many other benefits of a model 
organism (chapter 1.6). It is therefore an ideal organism to investigate the putative role miR-
137 might have within neurons without using costlier and ethically challenging resources 
such as human stem cells. 
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In order to explain the reason miR-137 was chosen for investigation, this chapter will 
review recent literature. Obviously, one of the first questions one might ask is ‘how do genes 
influence risk for psychiatric illness?’. There are various theories postulated, but two that 
show prominence and strengthened by current literature are the neurodevelopmental 
hypothesis (Weinberger et al. 1995) and the threshold model (Gottesman and Gould 2003). 
How is it possible that genetic variation increases or decreases risk associated with disease? 
The following sections will first detail miR-137 and then relate that to the 
neurodevelopmental hypothesis of SZ. There are obvious overlaps with neurological 
disorders, phenotypically distinct yet both caused by dysregulation of the brain. Perhaps the 
threshold model of SZ, suggested to have two levels of risk (Lee et al. 2013) might share 
similar overlap for generalised risk of any neurological or psychiatric disorder, before 
additional risk alleles specify which disease phenotype emerges. 
The power of recent GWAS is reviewed as is the current status of model organisms 
using gene knockout or sequestering methods. Finally, in preparation for the results presented 
in Chapters 4-8, the final section in this introductory chapter presents a brief review of how 
sleep regulation is controlled at a cellular level and how this specific phenotype shares 
dysfunction in both SZ and neurological disorders. 
 
1.1 Transcription and regulation of DNA 
Deoxyribonucleic acid (DNA) is the biological equivalent of computer code. 
Essentially, DNA is a long sequence contained in each individual cell nucleus that encodes 
the development and maintenance of an organism’s life. Much like computer code, without 
the correct instruments to decipher and utilise the information, DNA is useless by itself. The 
DNA sequence is made of a combination of 4 different nucleotides; Adenosine, Guanine, 
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Cytosine, and Thymine. It is known to have a double helix structure made from two 
complimentary strands bound together in a spiral shape, which is very robust and protected 
from degradation or external influences. In humans, the total length of the DNA sequence is 
around 2 billion nucleotides in somatic cells and a copy of it is contained in every cell other 
than red blood cells which do not have a nucleus. 
As genes, are translated into enzymes they then usually leave the protection of the 
nucleus to undergo further modification or directly perform a function. With DNA separated 
into coding and non-coding regions, the latter regarded as junk DNA, each have important 
roles in deciphering and modifying the coded instructions from DNA sequence. 
 
1.1.1 Coding DNA 
Coding DNA is the name given to sections of DNA that contain genes which undergo 
transcription into an mRNA molecule and then translation into a protein before it can perform 
its role. These sections account for approximately only 1% of the human genome, producing 
around 20,000 different genes (Encode consortium 2012). 
In the protein coding regions of DNA, the nucleotide sequence is read in codons (a 
triplet of consecutive nucleotides), which encode 21 different amino acid residues. DNA also 
includes start and stop codons, which are read by RNA-polymerase enzymes in the nucleus. 
Once the RNA-polymerase binds a start codon, it begins synthesis of a complimentary RNA 
molecule (a process called transcription). Once the RNA molecule is complete it undergoes 
splicing to remove unnecessary regions. The resulting messenger RNA (mRNA) molecule 
then leaves the nucleus, travelling to the ribosomes where it is translated into amino acids and 
strung together into proteins. These proteins often undergo post-translational modifications 
which include binding other molecules like phosphate groups or folding the protein into its 
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final functional shape. Examples of proteins include; enzymes, structural proteins, or 
transmembrane channels and receptors. 
 
1.1.2 Non-Coding DNA 
The non-coding regions were originally thought of as “junk DNA” with little or no 
purpose, but research has now that many of these regions have a very important function 
(Alles et al. 2019). Like the coding regions they contain genes, but these perform their 
biological function directly after transcription as an RNA molecule rather than undergoing 
translation into a protein. There are several types of non-coding RNA; which include 
microRNA, small interfering RNA, and transfer RNA. 
 
1.1.2.1 microRNA 
microRNA (miRNA) are one type of the non-coding genes that act as post-
transcriptional regulators of mRNA expression (Hobert 2007; Willemsen et al. 2011; Guella 
et al. 2013). As the volume of research into miRNAs increases, they are becoming 
progressively more significant due to their involvement in key gene signalling pathways, 
dysfunction of which often leads to serious disorders and problems for an individual (Enright 
et al. 2003; Hobert 2007; Xiao et al. 2007; Yin et al. 2014; Juzwik et al. 2018). They are part 
of the genetic regulatory system and operate through associating with an RNA-induced 
silencing complex (RISC), acting as a target guide to bind to the 3’ un-translated region 
(UTR) of specific mRNA (Enright et al. 2003; Lee et al. 2004; Murchison and Hannon 2004; 
Hobert 2007; Xiao et al. 2007; Thomson et al. 2011; Willemsen et al. 2011). This binding 
leads to destruction or modification of the mRNA, ultimately resulting in less translation of 
the mRNA (Lee et al. 2004; Yin et al. 2014). While not a complete ablation of the target 
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mRNA expression, this translational oppression has been shown to be significant enough to 
cause physiological effects (Hobert 2007).  miRNAs are one of the largest classes of gene 
regulatory molecules in animals with an estimated 2,300 distinct miRNA in the human 
genome (Hobert 2007; Alles et al. 2019). Approximately 10% of these are heavily conserved 
across multiple species, demonstrating the biological importance of these molecules (Enright 
et al. 2003). Changes in the sequence or expression of some miRNA have already been 
associated with SZ, BD, cancer, cardiac hypertrophy, multiple sclerosis, and even diabetes 
(Xiao et al. 2007; Ripke et al. 2011; Kandemir et al. 2014; Valles et al. 2014; Duan et al. 
2014; Juzwik et al. 2018).  
As the mechanism of mRNA targeting by miRNA is now relatively well understood it 
has enabled the development of algorithms which generate a list of putative gene targets from 
the DNA sequence of the miRNA and the mRNA (Enright et al. 2003; Agarwal et al. 2015; 
Agarwal et al. 2018). There are several prediction algorithms run by different institutes, but 
they usually operate around the same principles. The seed sequence and mRNA sequence are 
known, and therefore it is possible to predict binding affinity of each miRNA to the mRNA 
molecule (Thomson et al. 2011). The effect of the miRNA binding is dependent upon where 
on the mRNA the binding region is located and degree of homology between the sequence 
and seed sequence. As with all computational methods, the results achieved vary depending 
on factors such as which algorithm or database of mRNA sequences.  
Alongside putative targets created with algorithm calculations are experimental based 
research projects which utilise the outputs to direct research into proving the miRNA 
regulation on some mRNA. These studies vary in approach; some look for direct interactions 
of a select pairing of miRNA and mRNA, others examine the transcriptome with different 
levels of miRNA expression (Hill et al. 2014), and finally some observe phenotypical effects 
of manipulated miRNA expression (Hobert 2007; Karres et al. 2007; Xiao et al. 2007). There 
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are also differences in the situations of the experiments, whether in a whole living organism 
or through in vitro cell cultures. The theory of holistically assessing the effect of miRNA on a 
specific target is that in the absence of the miRNA expression, the phenotype exhibited by the 
organism should mimic that of one which has an overexpression of the target mRNA (Hobert 
2007). Furthermore, overexpression of a miRNA molecule should mimic a phenotype 
resulting from downregulation of the target mRNA as there is more miRNA related 
expression regulation. However, miRNA overexpression assays could produce skewed results 
as the miRNA does not act directly or individually on a target mRNA. Therefore, 
overexpression of the construct may just saturate the RISC complexes available or cause 
fluctuations among other active miRNA levels (Thomson et al. 2011). Furthermore, the 
overexpression increase could likely not be greater than 20-30% variance that many miRNA 
molecules are known to fluctuate in normal conditions (Hobert 2007).  
 
1.1.2.2 Transcription and processing of a microRNA gene 
Many miRNAs start off as a small sequence of a few hundred base pairs after initial 
transcription. This then undergoes post-transcriptional modification until it becomes a 
“mature” sequence that can perform its regulatory roles. miRNA genes are mainly transcribed 
by the enzyme RNA Polymerase II, which results in primary-miRNA (pri-miRNA) molecules 
(Lee et al. 2004). These long pri-miRNA strands are then cleaved by nuclear RNase III 
Drosha enzymes (Lee et al. 2003). The resulting hairpin structures of precursor-miRNA are 
exported out of the cell nucleus by exportin-5 transporters (Bohnsack et al. 2004; Lund et al. 
2004). Once in the cytoplasm the pre-miRNA hairpins are further cleaved by RNase III Dicer 
molecules into 19-25nt double-stranded miRNA strands (Bernstein et al. 2001; Lee et al. 
2004). The duplex-miRNA consists of a passenger strand and a mature strand. The passenger 
strand degrades leaving a mature-miRNA which is recruited as part of an active RISC 
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complex (Rana 2007; Thomson et al. 2011). The process of passenger strand degradation is 
largely unknown, but the selection of passenger or mature strand is decided through strand 
thermodynamic stability and base pairing strength (Khvorova et al. 2003). 
 
1.1.2.3 RISC and downregulation 
RISC complexes are a cluster of several proteins and a mature miRNA construct. The 
RISC complex utilises the complementary binding of the miRNA and mRNA to target which 
sequences to affect. The miRNA binds to the mRNA using a set of 6 base pairs called the 
“seed sequence”, which is commonly nucleotides 2 to 8 of the 5’ region of the mature 
miRNA molecule (Devanna et al. 2014). Argonaute (Ago) proteins are responsible for 
binding to the guide miRNA strand and orientating it to bind with target mRNA (Murchison 
and Hannon 2004; Rana 2007; Alles et al. 2019). Ago proteins also feature an RNase H-like 
fold at the PIWI domain, which can directly cleave target mRNA (Pratt and MacRae 2009). 
Also assimilated within the RISC complex are: Dicer proteins, transactivating response RNA 
binding protein, protein activator of the interferon-induced protein kinase protein, tudor 
staphylococcal nuclease domain containing protein DNA helicase MOV10, and RNA 
recognition motif containing protein TNRC6B (MacRae et al. 2008; Thomson et al. 2011). 
The result of successful binding between the active RISC and target mRNA causes mRNA 
degradation through de-adenylation of the poly-A tail or cleavage by proteins, or reduced 
translation efficiency at the ribosomes (Thomson et al. 2011). This RNA interference is 
employed by each miRNA to successfully regulate multiple genes and pathways involved 
with key cell processes such as apoptosis, cell differentiation, and organ development (Bartel 
2004). It has also been reported that several miRNAs can bind to the same target gene 
cooperatively (Enright et al. 2003; Lewis et al. 2003; Devanna et al. 2014; Juzwik et al. 
2018), increasing the complexity of mRNA regulation by miRNA.  
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1.2 microRNA miR-137  
miR-137 is a miRNA molecule associated with a multitude of diseases and disorders in 
humans. It is predicted to regulate over 1300 targets including some key genetic components 
like gene transcription factors and ion channels, which perform functions vital for cell or 
organism survival (Agarwal et al. 2015). miR-137 is the most abundant miRNA in the brain 
and localises at the synapse where it regulates local target mRNA (Willemsen et al. 2011; 
Yin et al. 2014). Overall; the expression location, predicted and proven targets, and statistical 
links to several debilitating disorders highlight the potential for miR-137 as a miRNA 
molecule of interest with regards to psychiatric disorders. 
 
1.2.1 Gene expression 
miR-137 is widely expressed in the mammalian brain and is used as a biomarker in the 
blood to detect cancer in humans. It is the most abundant miRNA in the brain and localises at 
the synapse where it regulates local target mRNA (Willemsen et al. 2011; Yin et al. 2014). In 
humans, the MIR-137 gene is encoded by a stretch of DNA 102bp long, and then cleaved into 
a mature miRNA molecule just 23bp in length. Orthologs of miR-137 can be found in a 
variety of organisms including fruit flies, mice, bees, and chimps (figure 1.1).  
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Figure 1.1: BLAST results of D. melanogaster miR-137 sequence. 
The sequence for D.melanogaster miR-137 was BLASTed against all other database held species to highlight the homology between species for miR-137. There is region 
between 50 and 78 base pairs highly conserved in all species bar one.
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miR-137 is known to be active during foetal development (Howell and Law 2019) but 
shows an increase in expression beginning around the age of 25, and gradually increasing 
until old age. miR-137 regulates adult neurogenesis, synaptic plasticity, and glutamatergic 
signalling, all processes thought to contribute to the pathobiology (Pacheco et al. 2019). This 
age also corresponds with onset of adult SZ (Foley et al. 2017). 
 
1.2.2 Predicted and proven targets 
There are many targets for each miRNA, and human miR-137 is predicted to have a 
direct influence on over 1300 genes with evolutionarily conserved regions (Agarwal et al. 
2015). Understanding the direct targets and subsequent gene networks is vital for 
understanding how miRNA influence gene expression and neurodevelopment. 
 
1.2.3 Implications for disease 
miR-137 has been reported in many diseases (OMIM 614304; Chen et al. 2020; Lee et 
al. 2019) in vivo, in vitro and in silico. miRNAs are involved in the regulation of multiple 
target mRNAs, therefore issues within a single miRNA gene can have the knock-on effect of 
expression changes of many downstream targets. Such changes are likely to have a 
phenotypical effect synonymous with disease symptoms. Differences in miR-137 expression 
were reported in tumour growth and cancers (Chen et al. 2020; Lee et al. 2019)). Loss of 
miR-137 expression due to hypermethylation was reported in patients with endometrial 
cancer and miR-137 was reactivated with the introduction of epigenetic inhibitors (Zhang et 
al. 2018). 
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miR-137 is one of the most prevalent miRNA molecules expressed within the 
mammalian brain. As such it is not surprising that the gene has been implicated with the 
presentation of symptoms associated with neurological diseases and/or psychiatric disorders. 
Statistically, risk alleles of the human miR-137 gene were also found to be significantly 
associated with SZ in GWAS studies (Ripke et al. 2011; Duan et al. 2014), and rs1702294 
(C) and rs1625579 (T) SNPs have been linked to poorer scores on neuropsychological tests of 
memory performance (Cosgrove et al. 2017; Cummings et al. 2013). miR-137 functions as a 
‘fine-tuning’ agent for synaptic pruning and dendritic arborisation in neural cells and has 
been associated with altered cognitive function (Willemsen et al. 2011; Cummings et al. 
2013; Green et al. 2013; Kuswanto et al. 2015). The miRNA also regulates processes that are 
potentially involved with cognitive dysfunction, in part by acting as a hippocampal gene 
network node, co-ordinating the expression of genes relating to nervous system function and 
development (Olde Loohuis et al. 2017). SZ and BD sufferers have a 30% decrease in miR-
137 expression in prefrontal cortex (Guella et al. 2013), and significant enrichment in 
hippocampal synapses (Willemsen et al. 2011). Problems with the neuron maturation and 
physical development in the hippocampus and prefrontal cortex are associated with the 
development of SZ in humans (Heckers 2001), further associating the proper function of miR-
137 as necessary for prevention of psychiatric or neurological symptoms. 
While miR-137 itself is experimentally linked to neurological symptoms, some of its 
target mRNAs are also known to be involved with neurological function, development, and 
maintenance. These include; RORα (RAR-related orphan receptor alpha), CACNA1C 
(Voltage-gated calcium channel alpha 1c), D2R (Dopamine 2 receptor), and TCF4 
(Transcription factor 4). Many neurological symptoms such as hallucinations, cognitive 
defects, behaviour and emotion changes, and structural brain anomalies have already been 
associated with improper expression of these key genes (Cummings et al. 2013; Devanna and 
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Vernes 2014; Yin et al. 2014; Kong et al. 2015; Marschallinger et al. 2015; Pinggera et al. 
2015; Wang et al. 2015; Gonzalez-Giraldo et al. 2016). miR-137 has also been shown to be a 
major player in regulating synaptic plasticity (Valles et al. 2014), with many of the miRNA 
downstream targets being directly involved in the regulation and proper function of 
membrane potential or vesicle movement (Siegart et al. 2015). Known SZ risk genes 
ZNF804A, CACNA1C, TCF4, and CSMD1 are proven direct targets of human MIR-137 
(Kwon et al. 2011; Kim et al. 2012; Guella et al. 2013), initially highlighted as significantly 
associated with SZ from GWAS studies (Ripke et al. 2011). As many neurological symptoms 
are prevalent in several neurological or psychiatric disorders, genes can be connected to a 
symptom associated with several disorders. Proven targets for miR-137 also include many 
risk factors linked to ASD, such as RORa, NRXN1, SHANK2, SCN2A and CACNA1: many of 
which were previously mentioned as SZ or BD risk genes (Devanna et al. 2014). 
Overall, there are many reports in the literature between neurological diseases, 
psychiatric disorders, and neurological symptoms and miR-137 or its downstream target 
genes. While there are studies into the effect of miR-137 improper expression, much of the 
data is statistical or inferred through research on the downstream targets. Assessing the 
holistic effect of complete loss of function would enable a better understanding of the genes 
miR-137 regulates.  
Expression of miR-137 is necessary to regulate neurogenesis and maintain 
differentiation and proliferation of nerve cells. Neurogenesis is essential for memory, 
learning and mood regulation; disruption of which is seen in SZ (DeCarolis and Eisch, 2010). 
A paper by Wright et al. used TargetScan v6.2 to find 1141 putative targets for miR-137 
(2013). When compared with GeneCards and SZ Gene Resource, only 25 genes matched 
putative SZ genes. 
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Recent studies have investigated miR-137 to elucidate function and target genes in vitro 
and in vivo. A study by Cheng et al. knocked out miR-137 in both mouse germline (gKO) 
and nervous system only (cKO) leading to postnatal lethality (2018). However, they found 
that partial loss of miR-137 in heterozygous nervous system only (cKO) revealed 
dysregulated synaptic plasticity and behavioural phenotypes including repetitive behaviour, 
impaired learning and social behaviour. Further analysis revealed that PDe10a is elevated in 
heterozygous cKO mice and is reduced when a PDe10a inhibitor is administered. 
Interestingly, the behavioural phenotypes noted in the heterozygous cKO improve. 
Conversely, over expression of miR-137 appears to influence schizophrenia-type 
phenotypes in mice (Arakawa et al. 2019). This recent study tested pre-pulse inhibition, 
social and cognitive deficits analogous with SZ symptoms and found down-regulation of 
putative miR-137 target genes. This makes sense, given microRNAs mainly down-regulate 
the expression of target genes by binding to mRNA, targeting transcripts for degradation or 
preventing translation (Pacheco et al. 2019). Although four SNPs were reported to be 
associated with miR-137: rs1625579; rs1198588; rs2660304; and rs1702294 (Ripke et al. 
2011), VNTRs may also influence miR-137 expression. Pacheco et al. investigated a VNTR 
with a repetitive sequence of 15 bases and high GC content (2019). Three repeats appear to 
be the shortest known length and the common allele. However, in-vitro studies show that 
mature miR-137 expression is disproportionally affected by the length of the VNTR. They 
further applied a case-control study in adult and child onset SZ to find that the shorter VNTR 
(higher expression) comes with higher risk of SZ and the longer the VNTR (lower 
expression), the more protective the effect (Pacheco et al. 2019). Interestingly, there is a low 
level of linkage disequilibrium between the VNTR length and the miR-137 SNP associated 
with SZ, with the VNTR not being haplotype dependent. In the presence of such SNPs, the 
SZ risk scores are relatively lowered when with VNTR over 3 repeats in length, an effect 
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likely due to the increase VNTR length shifting the miRNA splicing to exclude the mature 
miR-137 coding sequence. This loss of the mature coding sequence ultimately acts to reduce 
miR-137 expression, an effect that was naturally prevalent in foetal brain tissue which had 
higher frequencies of >3 VNTR repeats when compared to adult brain tissue (Pacheco et al. 
2019). The SNP rs2660304 was found to contribute to risk independently, with 
recombination variants showing distinct changes to the SZ risk score (Pacheco et al. 2019). 
This information reinforces the idea of a complicated pattern of risk architecture in miR-137 
between SNP and VNTR haplotype in increasing susceptibility of SZ diagnosis. 
miR-137 and other genes such as AKT3, DRD2 and AKT1 all point to signalling through 
the AKT/mTOR pathway (Howell and Law 2019). miR-137 gain-of-function appears to be 
implicated in risk for SZ (Pacheco et al. 2019). Therefore, taken together, it suggests that 
miR-137 plays critical roles in the running of cellular development at key stages in life, miR-
137’s biological role in neurogenesis and early neural development and further strengthens 
the neurodevelopmental hypothesis of SZ. 
 
1.3 Schizophrenia 
SZ has a prevalence of approximately 1% of the population, diagnosed using the 
International Classification of Diseases (ICD-11) produced by the World Health Organisation 
(WHO), by a psychiatrist assessing an individual for the presence of ‘positive’ and ‘negative’ 
symptoms. Positive symptoms of SZ are split into hallucinations, delusions, and disorganised 
thinking. The negative symptoms involve a loss of ability or enjoyment in life, including a 
lack of motivation, slow movement, sleep pattern changes, poor hygiene, reduced emotions, 
and low interest in socialising and activities (Jakubowski et al. 2012; Lee et al. 2013). There 
are various subtypes SZ, each with a distinct set of symptoms. For example, paranoid SZ is 
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one of the more common forms, with prominent hallucinations and delusions but largely 
unaffected speech and emotions. Catatonic SZ less common, mute and immobile. 
Hippocampus and prefrontal cortex abnormalities have been implicated in various studies 
(Yin et al. 2014; Aydin et al. 2019). 
SZ is polygenic (Lee et al. 2013). Multiple risk alleles have been identified from 
GWAS. For example, CACNA1C encodes the alpha-1c subunit of the L-type voltage-gated 
calcium ion channel and is implicated in BD and SZ (Ferreira et al. 2008; Green et al. 2010, 
Ripke et al. 2011), enabling fundamental processes such as synaptic transmission and cell 
membrane depolarization (Zheng et al. 1995; Berger and Bartsch 2014). Unfortunately, as the 
field is very large and convoluted, research into the aetiology of SZ has been partially 
impacted by poorly defined phenotypes (Green et al. 2013). 
The morbid risk in the general population of developing SZ is 1% (Gottesman 1991). 
Including SZ spectrum disorders such as schizoaffective disorder, schizotypal personality 
disorder and paranoid personality disorder, the morbid risk increases. The incidence of SZ is 
uniform across populations at 0.2 to 0.4 per 1000 and the lifetime prevalence (risk) is about 
1% (McGuffin et al 1995). Most sufferers of SZ have onset in early adulthood with a similar 
incidence between both sexes, although women do tend to have a higher attainment of social 
functioning, most probably due to the later onset, which in turn confers a better outcome with 
less hospital admissions and a more benign course of illness (Gentile and Fusco 2019). 
Affected individuals may have long periods of illness and are usually unable to work, having 
difficulties sustaining interpersonal relationships. SZ has an enormous impact at a societal 
level through the economic cost of treatment and the social cost: the morbidity and the 
mortality (Costa and Steffen 2019). 
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The first comprehensive descriptions of SZ date from the 19th century by the German 
psychiatrist Emil Kraepelin. He noted syndromes of catatonia and hebephrenia and 
distinguished between manic depressive insanity and dementia praecox. He viewed SZ as a 
single process occurring in youth with dementia as the outcome. Swiss psychiatrist Eugene 
Bleuler used the term SZ in 1911. He felt SZ was more psychological than pathological with 
the core symptoms characterised by deficits in language, deficits in volition and attention and 
by incongruity of affect, ambivalence and ASD (Kaplan et al. 2008). Psychosis was a 
secondary effect. 
Later saw Kurt Schneider publish a list of symptoms that led to a more reliable 
diagnosis of SZ known as first rank symptoms in 1959. Psychiatrists now use two diagnostic 
systems for SZ: ICD-11 and DSM-5. These diagnostic systems are highly complementary 
and have improved reliability of diagnosis of SZ. 
The essential elements of SZ are a mixture of characteristic signs and symptoms that 
have been present for a significant proportion of time during a 1-month period with some 
signs of the disorder persisting for at least 6 months. They involve a range of cognitive and 
emotional dysfunctions in domains that include perception, inferential thinking, language and 
communication, behavioural monitoring, affect, fluency and productivity of thought and 
speech, volition, drive and attention. Individuals differ in symptomology, but diagnosis is 
conferred using a group of these characteristics. 
SZ is characterised by the three overlapping forms of deficit termed positive 
symptoms, negative symptoms and cognitive impairment. Positive symptoms include 
distortions in thought content (delusions), perception (hallucinations), language and thought 
processes (disorganised speech) and self-monitoring of behaviour (grossly disorganised or 
catatonic behaviour). Negative symptoms include restrictions in the range and intensity of 
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emotional expression (affective flattening), in the fluency and productivity of thought and 
speech (alogia) and in the initiation of goal-directed behaviour (avolition). Cognitive deficits 
in performance of tasks involving attention, working memory and executive function are also 
a feature of SZ. 
 
1.3.1 Psychotic symptoms 
Psychotic symptoms involve the loss of contact with reality, including delusions, 
hallucinations or odd behaviour. Hallucinations might be auditory, visual, olfactory, gustatory 
or tactile. Commonly delusions in SZ include persecutory. The severity and presence of 
psychotic symptoms seems to be episodic over time (Lui et al. 2020). 
 
1.3.2 Negative symptoms 
Negative symptoms are deficit states in emotional and behavioural processes, 
diminished or absent influencing affective response (such as immobile facial expression, 
monotonous voice tone), a lack of emotion or pleasure, the ability to initiate and follow 
through plans and a reduced quality of speech. Negative symptoms are more pervasive, tend 
to be stable over time and are strongly associated with poor psychological functioning (Lui et 
al. 2020; Blanchard et al. 2020). 
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1.3.3 Cognitive impairment 
Cognitive impairment in SZ includes problems in attention and concentration, 
psychomotor speed, learning and memory and executive functioning. A decline in cognitive 
performance is present in most people with SZ. This impairment remains stable over time 
(Mollon et al. 2020). 
SZ is effectively a syndrome. At present, researchers have suggested various 
pathways with no firm biological marker to aid in diagnosis. It is accepted that stratifying 
diagnosis on the basis of polygenic risk scores might help in identifying genes and other 
aetiological factors quicker (Ohi et al. 2020). Although there is no clinical utility at the 
moment for aiding ICD-11 or DSM 5. 
Results from family, twin and adoption studies have shown that the phenotype of SZ 
may include a broad spectrum of the other disorders such as schizophreniform disorder and 
schizotypal personality disorder. There is also uncertainty over the relationship of SZ and 
other affective psychoses and nonpsychotic affective disorders (Brink et al. 2019). 
 
1.3.4 Neurodevelopmental hypothesis of schizophrenia 
The neurodevelopmental hypothesis of SZ is now largely accepted. It suggests that an 
early brain lesion in the foetus during pregnancy or at birth, together with a combination of 
polygenic risk alleles gives rise to an increased risk of SZ. A combination of this risk might 
be environmental (Kelleher et al. 2014) or biological (Murray et al. 2017) but genetically is 
the result of subtle abnormal development in the central nervous system in utero or early 
infancy. These lesions seem to be latent until normal nerve cell maturation and neuronal 
pruning, switched on by various pathways, that results in prodromal and eventually clinical 
symptoms of psychosis leading not only to SZ (Jablensky et al.2017) but also depression, 
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suicidal ideas, and anxiety (Kelleher et al.2014). Therefore, if the neuronal scaffolding is 
compromised, you would expect to see deficits in psychophysiological and neurological 
functioning during childhood and early adolescence (Jablensky et al.2017); phenotypes 
originally observed and reported by Barbara Fish in the 1950s. 
At the cellular level, the neurodevelopmental theory of SZ includes oxidative stress, 
excitotoxicity, proinflammatory cytokines during pregnancy and neuronal migration, 
suggesting a ‘polygenic neurodevelopmental diathesis-stress model’ (Jablensky et al. 2017). 
Genetic studies reporting common genetic variation each of very small effect size, with a few 
reported CNVs of larger effect size overlapping between SZ, ASD and learning disability, 
suggest a common neurodevelopmental genetic risk (Owen et al.58). This would be 
consistent with genes involved in basic neuronal scaffolding, migration and synaptic pruning. 
We now know that polygenic risk scores now account for 9% of variance in psychotic cases 
(Vasos et al.2017). So, the remaining variation might be environmental, such as risk of 
psychosis might be increased by adverse social, drug, immunological or hypoxic factors, 
most of which will occur during neural development (Murray et al.2017).  
Therefore, miR-137 fits the neurodevelopmental theory of SZ because 70% of miRNAs 
identified are expressed in the central nervous system (CNS), where specific subtypes are 
brain or brain‐region specific (Rizos et al.2016). miR-137 is crucial to all cells and expressed 
at different stages in the life cycle (Yin et al 2014) but reported to be greater in the amygdala 
and hippocampus at higher expression levels (Zamore et al.2005), and in adult brain regions 
with active neurogenesis, the subgranular cell layer in the hippocampal dentate gyrus 
(Nakahara and Carthew 2004; Yin et al.2014) with overexpression decreasing the number of 
astrocytes and inhibition reducing the number of neurons (Furuta et al.2010). 
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Specifically, miR-137 embryonic expression is controlled by a two gene complex, in a 
negative feedback loop, consisting of the nuclear receptor transcription factor TLX and the 
histone demethylase LSD1 (lysine specific demethylase 1). Binding of this complex inhibits 
the transcription of pre-miR-137 and binding of miR-137 inhibits LSD1, maintaining 
expression at appropriate levels (Yin et al.2014; Kiyohito et al.2015). However, in adult 
neural stem cells, SOX2 and MeCP2 regulate miR-137 expression (Yin et al.2014).  
So, we must be mindful of the many genetic interactions, reportedly associated with 
SZ, and the impact on brain development particularly in cognitive development, at various 
stages of life (Toulopoulou et al.2015). Depending upon the stage of life cycle, genes 
associated with SZ might influencing upstream factors or downstream factors (Murray et 
al.2017). Therefore, as stated by Murray et al. (2017), the neurodevelopmental hypothesis 
should now be regarded as the Developmental Risk Factor Model (Howes et al.2017; Murray 
and Fearon, 1999): 
 
“Thus, liability to psychosis is distributed in the same way as liability to hypertension 
or obesity. If an individual’s blood pressure is persistently above a certain arbitrary level (90 
mmHg in many countries), they are considered hypertensive; if the hypertension is not 
readily responsive to treatment, they may be further diagnosed as having severe or malignant 
hypertension. Similarly, if psychotic symptoms go beyond a certain threshold then a 
diagnosis of clinical psychotic disorder is appropriate, and if this persists and is associated 
with cognitive impairment of developmental origin, then a diagnosis of schizophrenia is 
made.” 
Murray et al.2017 
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1.4 Neurological diseases and psychiatric disorders 
 “Neurological disease” is an umbrella term for disorders or diseases which affect the 
functionality of the brain. Stereotypically these result in behavioural oddities and ultimately a 
lack of ability to function normally within society without intervention. 
A psychiatric disorder is an illness which affects the physiological, physical, or mental 
ability of an individual. It is known that both genetic and epigenetic risk factors contribute to 
the onset of these disorders (Lee et al. 2013), which makes understanding them more 
difficult. Neurological disorders have a multitude of risk alleles associated with their 
development from GWAS. These studies look at a collection of human genomes and 
comparatively assess which alleles are likely to be a factor of the disorder (Lee et al. 2013). 
From this computational analysis, many genes have been implicated and used in further 
research. However, it is important to note that in such a broad field there is still relatively 
little understood. 
The main psychiatric disorders are largely accepted as SZ, ADHD, BD, and MDD 
(Smoller et al. 2013). Each disorder has a set of symptoms an individual must possess to be 
deemed a clinical sufferer. Unfortunately, the disorders often have overlapping symptoms, 
such as impaired motility and behavioural changes, which blur the boundaries between them. 
This overlap can make it difficult to give a correct diagnosis and causes some debate on the 
classification variants of each syndrome. 
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1.5 Genome-wide association studies 
Candidate genes in psychiatry have been studied for decades (Horwitz et al. 2019). 
However, before 2007, many of the studies published had small sample sizes and low 
statistical power to detect variants of major effect. One method of increasing statistical power 
was to pool data sets together to run meta-analyses. However, even these sample sets did not 
provide reproducible results. 
One method of identifying potential risk genes for these disorders is to compare a large 
collection of genomes of cases against the genomes of controls and analyse the allele 
frequency of variants between the two samples sets to determine any statistically significant 
differences. These GWAS are a powerful approach for the discovery of genes for many 
illnesses. This method of scaling-up candidate gene association studies to investigate 
genome-wide association with diseases was first published by a Japanese group (Ozaki et al. 
2002) investigating susceptibility to Myocardial Infarction with Single Nucleotide 
Polymorphisms (SNPs). Using the resources available and understanding at that time of the 
statistical nuances of GWAS (Thomas et al. 2005) gave rise to the possibility of investigating 
other complex genetic conditions (Zeggini et al.2007; Parkes et al. 2007; Todd et al. 2007; 
Samani et al. 2007; Thomson et al. 2007; Sandhu et al. 2008; Barrett et al. 2008) including 
the major psychiatric disorders (WTCCC 2007; Ferreira et al. 2008; Ripke et al. 2011). Over 
the past 12 years, GWAS for psychiatric conditions (Horwitz et al. 2019) has served to 
elucidate the genetic architecture of these disorders by improving classifications and leading 
to targeted interventions, including the genes involved in the pathophysiology of SZ 
(Dennison et al. 2019). There are now many reproducible findings (Sullivan et al. 2019) but 
the field is now at a stage where there is a requirement for the understanding of the functional 
genomic architecture, loci that impact regulatory processes, influencing gene expression and 
the functional co-ordination of genes that control biological processes (Sullivan et al. 2019).  
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1.6 Model organisms 
Model organisms are species which have been selected for research to obtain genetic 
information on humans which cannot be investigated directly. There are many reasons why 
researching a specific organism would be problematic; such as toxicity for viral or bacterial 
cultures, or ethical constraints for many animals including humans. There are several 
different model organisms that have been used to investigate gene function, genetic 
pathways, and molecular interactions. 
For an organism to be useful in such experiments, they must have orthologous genes to 
the human gene targeted in the research. An ortholog is a gene which has a DNA sequence or 
similarity that indicates conserved functions despite being in different organisms, and by 
investigating this gene we can infer a similar behaviour will be seen in the human 
counterpart. Other benefits usually include shorter life cycle and reproduction time, relatively 
inexpensive culturing, and a wealth of knowledge already published on the genome to 
reinforce novel results. Ethical constraints aside, some model organisms are particularly 
useful for developmental research as they have a significantly shorter life cycle and faster 
development rate. Ultimately this would mean that research can progress much further and 
look at multiple generations quickly. There are several “well known” model organisms that 
are used in genetic research, many of which with specific advantages over the others covering 
much of the classification. 
Mice (Mus musculus) and rats (Rattus norvegicus) are classic model vertebrates, used 
in many research fields including toxicology, behavioural analysis, development, and human 
disease modelling. They are also often used for neuroscience and investigating more 
evolutionarily advanced features such as the immune system which is not apparent in simpler 
model organisms. 
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Caenorhabditis elegans (C. elegans) is a nematode worm used to investigate genetic 
control over physiology and development since they normally have a fixed number of cells, 
1031. This species was also the first multicellular organism to have its entire genome 
sequenced in 1998, revealing over 19000 genes and a 40% significant match with proteins in 
other organisms (The C. elegans sequencing consortium 1998). 
Zebrafish (Danio rerio) is a species of fresh-water fish, which have a near-transparent 
body during early development. This provides a unique ability to visually examine the 
internal anatomy while the organism is developing. 
 
1.6.1 Drosophila melanogaster 
One of the first models used was Drosophila melanogaster (D. melanogaster), with 
published studies dating from 1906. Currently this is one of the most researched and well-
documented models, with relevance to a huge variety of research fields (Adams and Sekelsky 
2002; Duffy 2002; St Johnston 2002; Nichols et al. 2012). D. melanogaster feature many 
benefits useful for genetic research; a new generation of flies every 10-14 days at 25°C, a 
small culture space and simple food media, and a well-researched and documented genome 
(Adams et al.2000; Linford et al. 2013). They also have no meiotic recombination in male 
flies, plenty of external features to assess genetic physiological importance in experiments, 
and only 4 chromosomes which can be easily visualized in the large polytene chromosomes 
of the larval salivary glands (St Johnston 2002). There are also many different tried and tested 
assays and behavioural tests that have been published for future research to be comparable to 
existing data (Nichols et al. 2012; Shaltiel-Karyo et al. 2012). Altogether, the wealth of 
benefits featured in D. melanogaster make it suitable for both large scale genetic screens and 
specific molecular-genetic interaction research. 
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Alongside the above traits, another useful feature used in D. melanogaster is the 
UAS/Gal4 mechanism taken from yeast (Saccharomyces cerevisiae). This is a bipartite 
system that can be controlled to drive expression of foreign DNA transcripts within a living 
fly (Brand and Perrimon 1993; Gao et al. 1999; Duffy 2002; St Johnston 2002). These 
transcripts can code for functional proteins, reporter proteins, missense RNA molecules, and 
more. Additionally, attaching the Gal4 DNA sequence to different genomic promoters can 
drive tissue specific expression allowing targeted research into localised genetic effects 
(Fischer et al.1988; St Johnston 2002). As the UAS/Gal4 system exists in 2 parts, the 
components are usually carried separately in two fly strains, whereupon crossing of an adult 
fly from each result in progeny with both parts of the system. Individually the UAS or Gal4 
regions tend to have no effect on the organism, and therefore stable stocks are possible even 
when driving expression of a known lethal protein (Duffy 2002). Additionally, there are 
constructs which can increase the expression of the UAS construct or even utilise external 
temperatures to selectively switch on or off the expression. While the UAS/Gal4 system is 
also used in cell cultures and select other organisms (Xenopus laevis and zebrafish), the fruit 
fly is the organism which requires the least time and resources to successfully culture. 
D. melanogaster can be cultured with relative ease on a food medium consisting of a 
mix of cornmeal, yeast, agar, and sugars in an incubator usually at a standard temperature of 
25°C. The flies are housed in a culture vial consisting of a base of food media and a cotton 
wool plug, enabling the adults to be moved to new vials as required. In these conditions, the 
fruit fly cultures can progress from egg fertilisation to new adult fly within 10-12 days (figure 
1.2). A significant amount of development happens within the first 24 hours, with the larva 
developing from a fertilised egg to hatching (Singh and Singh 1999; Linford et al. 2013). 
Over the following 5-7 days the larvae grow through 3 instar phases, living within the food 
media of the culture vial until they reach a size of up to approximately 5mm in length. At the 
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end of the 3rd instar stage, the larvae climb the sides of the culture vial and create a chrysalis 
which protects them while they undergo metamorphosis until around days 10-12 (Committee 
of developmental Toxicology 2000; St Johnston 2002). At this point, a new adult fly will 
eclose from the pupa and begin to reproduce in the following 8 hours (Committee of 
developmental Toxicology 2000). At the point where the fly metamorphoses into an adult, it 
undergoes a huge transformation in terms of general anatomy, neurological structure and 
physiology, and behaviour. The physiological changes to the central and peripheral nervous 
systems during pupation have been well studied, as this provides a new aspect to assess the 
effect of genes in neurological development through such a vital stage for the fly (Gao et al. 
1999; Singh and Singh 1999; St Johnston 2002).  
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Figure 1.2: The life cycle of Drosophila melanogaster. 
The life cycle of a fruit fly (Drosophila melanogaster) at 25°C (Committee of developmental Toxicology 2000). 
The fruit fly has a short life cycle of approximately two weeks. Following fertilization, the embryo develops and 
eventually hatches as a 1st instar larva after 24 hours. The larvae develop for the next 5 - 6 days through 2nd and 
3rd instar stages, before pupating. The adult flies eclose after approximately 10 days since fertilization. 
 
1.6.1.1 D. melanogaster genetics 
Humans and D. melanogaster differ hugely in appearance, but in terms of genetics the 
differences are not so extreme. The fruit fly genome consists of three chromosomes and an 
approximate length total of 180mb and only around 13600 genes (Adams et al. 2000). This 
makes the D. melanogaster genome much smaller than humans’, but they contain highly 
similar orthologous genes of around 77% of distinct human disease related genes (Reiter et 
al. 2001). In addition to this, when expressing the remaining human genes as a foreign 
insertion in the flies, they demonstrate similar phenotypical symptoms (St Johnston 2002). 
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Furthermore, D. melanogaster have hundreds of miRNA molecules within their genome 
(Ruby et al. 2007; Lu et al. 2008; Kozomara et al. 2014; Agarwal et al. 2018; Wessels et al. 
2019). To date, 466 individual miRNAs have been identified in flies which are predicted to 
regulate ~30% of genes (Kozomara et al. 2014; Agarwal et al. 2018; Wessels et al. 2019). 
This is a significantly smaller number than the 2588 miRNA in humans, however the 
expression and RNA-downregulation mechanisms are similar (Ruby et al. 2007; Lu et al. 
2008; Kim et al. 2009; Ha and Kim 2014; Agarwal et al. 2018; Wessels et al. 2019). Due to 
their usefulness as a genetic model, Drosophila have been the focus of many studies into the 
function of the conserved miRNA. Deletions of miRNA rarely cause lethal phenotypes or 
severe morphological changes in mammals as in Drosophila, where the effect is often more 
subtle and manifests when the organism is challenged (Wessels et al. 2019).  Examples of 
key miRNA, bantam and miR-14, were identified in drosophila to regulate apoptosis due to 
null genotypes that were developmentally lethal (Brenneke et al. 2003; Xu et al. 2003). miR-
8 was shown to finetune the translation of atrophin and prevent neurodegeneration, a function 
that is believed to be conserved in mammals (Karres et al. 2007). Since, miRNA molecules 
have been implicated in almost all biological pathways in flies ranging from embryogenesis 
to regulation of the circadian rhythm (Kim et al. 2009; Carthew et al 2017; Xue and Zhang 
2018). 
The fruit fly miR-137 gene holds an overall sequence identity of 68% with the human 
ortholog, while the most prevalent mature-3p miRNA sequence of 
“uauugcuugagaauacacguag” is 91% identical with only 2 differing residues. There are a 
limited number of studies into the effect of proper miR-137 regulation in D. melanogaster. 
One of the earlier studies, conducted by Chen et al. (2014), performed a screening of miRNA 
deficient flies and found that loss of endogenous miR-137 was accompanied by a significant 
decrease in climbing ability but no significant change in survival or lifespan. Later, in 2017, 
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Larval locomotion, specifically righting after being inverted, was not found to be impacted by 
miR-137 loss (Picao-Osorio et al. 2017). Regarding fly health, Atilano et al. reported that loss 
of miR-137 in flies resulted in increased susceptibility to infection of C. albicans and 
concluded that the miRNA played an important role in coordinating Drosophila immune 
response. miR-137 is increased 3-fold in Drosophila epithelial tumours, however reversing 
the expression did not suggest a role in tumorigenesis (Shu et al. 2017). Comparison of the 
predicted miR-137 targets show approximately 20% (278/1315) of human targets have an 
ortholog also regulated by miR-137 in the fly. Considering the miRNA is classed as highly 
evolutionarily conserved it might have been expected of a higher crossover between the two 
species, however the list of 283 genes include many from key pathways around neurological 
development, function, and maintenance. This includes calcium and potassium channels 
(CACNA1C/D/G/H/I, KCNAB3, KCNC1/2/3), transcription factors (TCF3/4), key genes 
previously mentioned in relation to psychiatric disorders (RORA, SCN2A), and more (full 
list of human genes and fly orthologs in supplementary material). This highly conserved gene 
identity and comparative regulation of key genes demonstrates miR-137 evolutionary 
importance. Furthermore, this reinforces the suitability of using D. melanogaster as a model 
to investigate this largely unknown miRNAs function further. 
 The use of fruit flies in scientific research has pioneered many advances since their 
introduction in the early 1900s. Studies have found that there are multiple features of the fly 
which allow for comparable traits to human behaviour or genetic counterparts, across a wide 
range of fields from cardiovascular maintenance to transcriptional regulation of cell 
specification in development (Duffy 2002; St Johnston 2002; Nichols et al.2012; Linford et 
al. 2013). The fruit fly has proven itself particularly useful as an organism to investigate the 
genetics behind maintenance and development of the brain and central nervous system, with 
studies using the model to better understand fundamental biological processes within the 
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brain like synaptic plasticity, axon pathfinding, and dendritic morphology (Zhong et al. 1992; 
Gao et al. 1999; St Johnston 2002; Venken et al. 2011; Jakubowski et al. 2012). Fruit flies 
have also been used to evaluate the genetic components of memory and learning, with many 
established protocols for evaluating these behaviours individually (Venken et al. 2011; 
Nichols et al. 2012; Baggio et al. 2013). The fly brain is estimated to have one tenth of the 
neurons of a human brain, with a total of approximately 90000 neurons (Venken et al. 2011). 
Other differences between the flies and the humans CNS also include a significantly reduced 
count of synapses per neuron in the fly, and the primary transmitter in flies is glutamate 
unlike vertebrates (Venken et al. 2011). However, the fly brain exhibits a similar complexity 
regarding multiple neuron types and brain sub regions working in sync (Bullock 1978), which 
gives reason to suggest that research into D. melanogaster will yield results with relevant 
insight to the mechanisms underlying vertebrate neurology. 
 Often, as genes are linked to human illnesses, the D. melanogaster ortholog is 
investigated for a phenotypical effect. Altered expression of the human Alzheimer’s disease 
risk gene Glycogen synthase kinase-3 (GSK-3) ortholog in flies induces progressive 
locomotor impairment in larval stages, a hallmark symptom of many neurodegenerative 
diseases (Jakubowski et al. 2012). Expressing human genes not normally in the fly genome is 
another approach available for neurological research. The fruit fly has a documented 
“Parkinson’s disease” model that expresses a foreign DNA insertion containing the human α-
synuclein gene. This model develops symptoms synonymous with Parkinson’s disease such 
as; loss of dopaminergic neurons, α-synuclein aggregates, and age-dependent locomotor 
defects (Shaltiel-Karyo et al. 2012). 
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1.7 Sleep 
Sleep is a process which is defined as a consolidated period of rest and inactivity 
coupled with reduced response to external stimuli (Cirelli et al. 2005; Cirelli 2009; Bushey et 
al. 2010; Crocker and Sehgal 2010). Sleep or sleep-like behaviour is a recurring state in many 
organisms and is a unique behavioural trait that contradicts the basis of survival, temporarily 
reducing awareness and putting muscles in a state of inactivity. While in such a state, the 
organism is vulnerable to risks such as predation and therefore to be prevalent in such a 
diverse set of species sleep must serve an important purpose 
 
1.7.1 Sleep Regulation 
It is known that sleep is governed by genetics, though environmental factors can have 
an impact on the quality of a sleep episode (Cirelli 2009; Sehgal and Mignot 2011). 
Discovery of hereditable sleep traits led to investigating suitable model organisms for sleep 
research, from which some of the molecular mechanisms behind sleep have been uncovered 
(Cirelli 2009, Sehgal and Mignot 2011). Sleep is regulated by two independent mechanisms, 
circadian and homeostasis. Circadian rhythm dictates the cycle of sleep within a 24-hour 
period, restricting the behaviour to times that are ecologically suitable (Cirelli 2009; Crocker 
and Sehgal 2010). The homeostatic mechanism is reflected in the perceived increase of 
pressure to sleep throughout the waking period, which is reset when having slept (Crocker 
and Sehgal 2010; Donlea et al. 2013). Both mechanisms have a set of genes already 
associated with them, some of which overlap. Circadian genes interact and determine 
circadian rhythmicity, mutations of which result in phenotypes such as abnormal sleep 
duration but no difference in sleep pattern following deprivation (Cirelli 2009).  
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Some genes’ level of expression changes in the brain between sleep and waking states, 
lending further evidence to a molecular function of sleep (Cirelli 2009). This molecular 
function is likely to be conserved across many organisms, as has been proven with other 
genetic pathways. Sleep-like behaviour has been documented in widely used model 
organisms such as mice, zebrafish, D. melanogaster, and even worms (Crocker and Sehgal 
2010; Bidaki et al.  2011; Sehgal and Mignot 2011). In mammalian and avian species, sleep 
can be recognised through criteria detected on an electroencephalogram (EEG) which cannot 
easily be done for many other species (Crocker and Sehgal 2010). Many sleep disorders, such 
as insomnia and narcolepsy, have had some underlying genetic mechanisms exposed through 
genome analysis and model organism research (Bidaki et al. 2011; Sehgal and Mignot 2011). 
Some disorders are also found to be caused by singular gene mutations such as chronic 
primary insomnia and sleep-phase syndrome. Many neurological disorders also have sleep 
variations reported as a symptom (Lane et al. 2017). While individual genes have been 
statistically or experimentally linked to the onset of sleep disorders, not all have had the 
molecular mechanisms behind their involvement exposed. 
The underlying process of sleep being governed by genetics but heavily influenced by 
external factors implies that the purpose of sleep is simply to recover from a bout of activity 
and prolonged consciousness. However, the exact purpose is unclear. 
Genetically and chemically, sleep and the abundance of certain chemicals or gene 
expression can be correlated. Furthermore, there are sleep promoting drugs which act as 
sedatives and other substances which act as stimulants that temporarily help reduce sleep 
pressure. 
There are several medical disorders which have sleep dysfunction as either a cause or 
symptom. Many psychiatric disorders such as SZ and BD exhibit differences in sleep 
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behaviour than would be expected of “normal” sleep. Alongside differences in sleep/wake 
cycle, symptoms such as catatonia are comparable to being sleepy and fatigued. It is also 
possible that dysfunctional sleep can lead to the deterioration of proper neurological 
functions, potentially describing a cause of the neurological disorders rather than symptom. 
Sleep dysregulation can cause a multitude of problems for the function of the body. 
Simply delaying sleep results in immediate negative impacts on performance and health 
(Bidaki et al. 2011), followed with a rebound effect of increased sleep duration in the next 
sleep period. Sleep issues have been linked to poor memory retention (Tomita et al. 2015), 
and abnormal total sleep amount has been linked to a reduced lifespan (Bushey et al. 2010). 
Disordered sleep may also play an important role in the aetiology and maintenance of 
physical and mental health (Lane et al. 2017). Links between fractured or curtailed sleep 
behaviour and type 2 diabetes are demonstrated by a rise in blood-glucose levels in 
individuals chronically deprived of sleep (Spiegel et al. 2005; Knutson and Cauter 2008). 
Sleep curtailment has also been linked to dysregulation of appetite, higher body mass, and a 
decrease in energy expenditure (Spiegel et al.  2005; Knutson and Caulter 2008). Chronic 
sleep deprivation has even been statistically correlated with increased suicide ideation in 
teenagers (Whitmore and Smith 2018). 
 
1.7.2 Sleep in Drosophila melanogaster 
While physiologically very different to humans, the fruit fly has a sleep state which 
demonstrates some clear parallels to human sleep. In flies, the documented sleep state is 
classified as a period of quiescence for 5 minutes or longer (Cirelli et al. 2005; Cirelli 2009; 
Bushey et al. 2010). Numerous studies have identified similarities between the human and D. 
melanogaster sleep states, including both behavioural features like increased arousal 
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thresholds and molecular mechanisms like Dopamine signalling (Shaw et al. 2000; Bushey et 
al. 2010; Tomita et al.  2015). If deprived of sleep through continuous stimuli, D. 
melanogaster exhibit decreased vigilance and upon being allowed to rest, display a sleep-
rebound effect of a longer and less fragmented sleep following sleep deprivation (Shaw et al. 
2000; Bushey et al. 2010). Another similarity with humans is that fruit flies are also 
predominantly diurnal, with most of the rest periods being consolidated in the night/lights off 
period (Bushey et al. 2010; Liu et al. 2015). 
Circadian rhythms and the regulating clock neurons which dictate the daily oscillations 
of most physiological and behavioural processes have been widely researched in the D. 
melanogaster model. The circadian rhythm or biological clock enables an organism to 
anticipate changes in environmental factors such as lights on or sunrise (Renn et al. 1999). 
The standard activity graph for flies in controlled conditions over a 24-hour period includes 
clear pre-emptive behaviour of increased activity before the programmed lights on or lights 
off timing (Cirelli et al. 2005; Cirelli 2009; Bushey et al. 2010). In mammals, the pacemaker 
for daily activity cycles is in the hypothalamus while the fly neurons regulating this cycle are 
associated with the brain’s visual centres (Renn et al. 1999). The fly brain contains 
approximately 150 dedicated clock neurons, divided into distinct subsets by function and 
anatomical location (Cavanaugh et al. 2014). Of these, the small lateroventral neurons appear 
to be one of the most dominant regulators of the sleep/wake cycle as loss of these neurons 
result in arrhythmic behaviour patterns in constant dark conditions, yet ablation of all but 
these neurons can allow a robust activity pattern even in total darkness (Renn et al. 1999; 
Cavanaugh et al. 2014). The neuropeptide pigment-dispersing factor (pdf) is expressed within 
most of the lateroventral neurons, and is implicated as the principal circadian transmitter, 
with flies deficient in this gene expression showing entrainment to the light/dark cycle but 
losing regular patterns in constant darkness (Renn et al. 1999). The requirement of rho for 
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sleep is localized to the pars intercerebralis part of the fly brain that is developmentally and 
functionally analogous to the hypothalamus in vertebrates (foltenyi k 2007; Cavanaugh et al. 
2014). This region is also proven to be responsible for the D. melanogaster ortholog of 
human corticotrophin releasing factor regulation of proper sleep/wake cycles, dysfunction of 
which results in arrhythmicity (Cavanaugh et al. 2014). 
The alternative, and less understood, component of sleep regulation is the sleep 
homeostat. This is responsible for creating an increased need to sleep in response to stimuli or 
prolonged periods of wakefulness, and the cause for the sleep rebound effect seen after sleep-
deprivation (Donlea et al. 2014). This function in D. melanogaster has been linked to fan-
body region of the brain, which is similar in function to the mammalian hypothalamic 
ventrolateral preoptic nuclei (Donlea et al. 2014). The fan-body is modulated by 
dopaminergic neurons, and artificial stimulation induces sleep on command (Lui et al. 2012). 
Sleep in both fruit flies and humans has been linked to longevity, with numerous 
genetic mutations in D. melanogaster affecting sleep amount often having a negative effect 
on average lifespan (Bushey et al. 2010).  
 
1.8 Hypotheses, Aims and Objectives 
The studies contained within this thesis investigated the functional role of miR-137 in 
the Drosophila melanogaster nervous system and used bioinformatic analyses of publicly 
available human genomic data to suggest the influence this micro-RNA might play in 
contributing to an increased risk of developing SZ. The miR-137 gene was selected for this 
study based upon an earlier GWAS by Ripke et al. (2013) that identified micro-RNA as 
statistically associated (p= 1.6 x10-11) in a sample size of (n SZ= 9,394, n controls = 12,642). 
Given that GWAS have no a priori hypothesis, any gene found to be statistically associated 
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must be validated through a biological experiment. miR-137 was selected as the candidate 
gene of choice for this investigation because it was 1) statistically associated in a GWAS, 2) 
biologically plausible and 3) central to cellular regulation. Although there is only a limited 
number of published psychiatric genetic studies involving D. melanogaster, the fruit fly was 
chosen as the model organism because miR-137 has an evolutionary conserved ortholog with 
92% mature sequence homology, a rapid-life cycle, cheap-to-run experiments and acts as a 
solid ‘first-pass’ compared to stem cell studies (e.g. Hill et al. 2014).  
Initially, a knockout strain of miR-137 was sourced and tested to measure phenotypes 
comparable with schizophrenia. Subsequently, a bioinformatics approach was used to 
determine putative molecular pathways. 
 
Aim: 
The aim of this work was to better understand the role of miR-137 in regulating vital 
processes for development using Drosophila melanogaster as a model organism and relate 
this to phenotypic and putative molecular processes involved in schizophrenia pathogenesis.  
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Objective A:  
Establish the likely importance of a loss of function of miR-137 on the development 
and health in Drosophila melanogaster (See Chapter 4). 
Hypothesis 1: 
Due to the published importance of miR-137 in development and neurological function, 
loss of genomic expression will have a negative impact on average lifespan in Drosophila 
melanogaster. 
H0: Loss of genomic miR-137 expression does not negatively affect lifespan. 
H1: Loss of genomic miR-137 expression negatively affects lifespan. 
Hypothesis 2:  
Due to the published importance of miR-137 in development and neurological function, 
loss of genomic expression will slow development rate in Drosophila melanogaster. 
H0: Loss of genomic miR-137 expression does not slow development rate 
H1: Loss of genomic miR-137 expression slows development rate 
Hypothesis 3:  
Due to the published importance of miR-137 in development and neurological function, 
loss of genomic expression will increase development lethality in Drosophila melanogaster. 
H0: Loss of genomic miR-137 expression does not increase development lethality 
H1: Loss of genomic miR-137 expression increases development lethality 
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Objective B: 
Establish the likely importance of a loss of function of miR-137 on the behaviour and 
physical ability of Drosophila melanogaster (See Chapter 5). 
Hypothesis 1: 
Due to published neurological importance of miR-137 and the data from the locomotor 
screen by Chen et al. (2014), loss of genomic expression will decrease overall activity in 
Drosophila melanogaster. 
H0: Loss of miR-137 does not decrease overall activity. 
H1: Loss of miR-137 decreases overall activity. 
Hypothesis 2:  
Due to published neurological importance of miR-137 and the data from the locomotor 
screen by Chen et al. (2014), loss of genomic expression will decrease movement velocity in 
Drosophila melanogaster. 
H0: Loss of miR-137 does not decrease movement velocity. 
H1: Loss of miR-137 decreases movement velocity. 
Hypothesis 3:  
Due to published data by Chen et al. (2014), loss of genomic miR-137 expression will 
decrease locomotor ability in Drosophila melanogaster. 
H0: Loss of miR-137 does not decrease locomotor ability. 
H1: Loss of miR-137 decreases locomotor ability. 
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Hypothesis 4:  
Due to the published neurological importance of miR-137, loss of genomic expression 
will increase total sleep amount in Drosophila melanogaster. 
H0: Loss of miR-137 does not increase sleep amount. 
H1: Loss of miR-137 increases sleep amount. 
 
Objective C: 
Establish the ability to phenocopy the increased sleep phenotype of the miR-137KO 
Drosophila melanogaster strain (See Chapter 6). 
Hypothesis 1: 
Due to the sleep phenotype exhibited in the miR-137KO strain, knockout of miR-137 
expression through the heterozygous crossing of another miR-137 null strain and the miR-
137KO strain increases sleep amount in Drosophila melanogaster. 
H0: Heterozygous knockout of miR-137 does not increase sleep amount. 
H1: Heterozygous knockout of miR-137 increases sleep amount. 
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Hypothesis 2: 
Due to the published importance and expression location of miR-137, plus the 
phenotype exhibited in the miR-137KO strain, targeted genetic knockdown of miR-137 
expression in the central nervous system increases sleep amount in Drosophila melanogaster. 
H0: Knockdown of miR-137 in the central nervous system does not increase sleep 
amount. 
H1: Knockdown of miR-137 in the central nervous system increases sleep amount. 
Hypothesis 3: 
Due to the published importance and expression location of miR-137, plus the 
phenotype exhibited in the miR-137KO strain, targeted genetic knockdown of miR-137 
expression in the fan-shaped body (brain subregion) increases sleep amount in Drosophila 
melanogaster. 
H0: Knockdown of miR-137 in the fan-shaped body does not increase sleep amount. 
H1: Knockdown of miR-137 in the fan-shaped body increases sleep amount. 
Hypothesis 4: 
Due to the published importance and expression location of miR-137, plus the 
phenotype exhibited in the miR-137KO strain, targeted genetic knockdown of miR-137 
expression in the mushroom bodies (brain subregion) increases sleep amount in Drosophila 
melanogaster. 
H0: Knockdown of miR-137 in the mushroom bodies does not increase sleep amount. 
H1: Knockdown of miR-137 in the mushroom bodies increases sleep amount. 
 
57 
 
Objective D: 
Establish the ability to recover the increased sleep phenotype of the miR-137KO 
Drosophila melanogaster strain (See Chapter 7). 
Hypothesis 1: 
Due to the published importance and expression location of miR-137, targeted 
reintroduction of miR-137 expression in the central nervous system reduces sleep amount in 
miR-137KO Drosophila melanogaster. 
H0: Reintroduction of miR-137 in the central nervous system does not reduce sleep 
amount. 
H1: Reintroduction of miR-137 in the central nervous system reduces sleep amount 
Hypothesis 2: 
Due to the published importance and expression location of miR-137, targeted 
reintroduction of miR-137 expression in the fan-shaped body (brain subregion) reduces sleep 
amount in miR-137KO Drosophila melanogaster. 
H0: Reintroduction of miR-137 in the fan-shaped body does not reduce sleep amount. 
H1: Reintroduction of miR-137 in the fan-shaped body reduces sleep amount. 
Hypothesis 3: 
Due to the published sleep-disrupting effect of caffeine, chronic treatment reduces sleep 
amount in miR-137KO Drosophila melanogaster. 
H0: Treatment with caffeine does not reduce sleep amount. 
H1: Treatment with caffeine reduces sleep amount. 
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Hypothesis 4: 
Due to the likelihood of dopamine sensitivity from loss of miR-137 regulation and the 
use of 3-iodo-tyrosine to inhibit dopamine, treatment reduces sleep amount in miR-137KO 
Drosophila melanogaster. 
H0: Treatment with 3-iodo-tyrosine does not reduce sleep amount. 
H1: Treatment with 3-iodo-tyrosine reduces sleep amount. 
Hypothesis 5: 
Due to the extensive use of lithium chloride to treat schizophrenia and the miR-137 and 
sleep link to neurological disorders, treatment reduces sleep amount in miR-137KO 
Drosophila melanogaster. 
H0: Treatment with lithium chloride does not reduce sleep amount. 
H1: Treatment with lithium chloride reduces sleep amount. 
 
Objective E: 
Establish the miR-137KO exome change similarities between Drosophila melanogaster 
expression data and Homo sapiens expression data (See Chapter 8). 
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Hypothesis 1: 
Due to the published evolutionarily conserved status of the miR-137 gene sequence, 
there will be a high proportion of differentially expressed genes found in Drosophila 
melanogaster and in Homo sapiens. 
H0: There will not be a high proportion of matching differentially expressed genes. 
H1: There will be a high proportion of matching differentially expressed genes. 
 
Objective F: 
Establish the similarities between differentially expressed genes in Drosophila 
melanogaster miR-137KO exome and human genome wide association study results (See 
Chapter 8). 
Hypothesis 1: 
Due to the published evolutionarily conserved status of the miR-137 gene sequence and 
the phenotype exhibited by the miR-137KO strain, there will be a high proportion of 
differentially expressed genes found in Drosophila melanogaster and in human sleep related 
genome wide association studies from the UKBiobank. 
H0: There will not be a high proportion of matching differentially expressed genes. 
H1: There will be a high proportion of matching differentially expressed genes. 
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Hypothesis 2: 
Due to the published evolutionarily conserved status of the miR-137 gene sequence and 
the original genome wide association study link to schizophrenia (Ripke et al. 2013), there 
will be a high proportion of differentially expressed genes found in Drosophila melanogaster 
and in the human schizophrenia-related genome wide association study by Ripke et al. (2018) 
H0: There will not be a high proportion of matching differentially expressed genes. 
H1: There will be a high proportion of matching differentially expressed genes. 
Hypothesis 3: 
Due to the published evolutionarily conserved status of the miR-137 gene sequence and 
the phenotype exhibited by the miR-137KO strain, there will be a high proportion of 
differentially expressed genes found in Drosophila melanogaster and in the human major 
depressive disorder genome wide association study by Pardinas et al. (2016). 
H0: There will not be a high proportion of matching differentially expressed genes. 
H1: There will be a high proportion of matching differentially expressed genes 
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2 Methods 
2.1 Fly Stocks 
Drosophila melanogaster strains were ordered online from the Bloomington Drosophila 
stock centre (BDSC) or the Vienna Drosophila resource centre (VDRC). Stocks at these 
institutes are donated by researchers worldwide and maintained/distributed to scientists for 
research or teaching purposes. Some stocks were already held on site from previous research 
by Dr Paul Hartley (Bournemouth University).  
 
2.2 Fly rearing and cultivation 
Drosophila strains were typically raised on a yeast cornmeal food blend made as in 
section 2.1.1. Stocks that were not in current use were kept at 18°C; while working stocks, 
crosses and experiments were kept at 25°C. 
 Routine stock maintenance was performed by flipping flies onto fresh food when 
required (typically once every 2 weeks at 25°C, and once every 6-8 weeks at 18°C) and 
visually observing general health. In the event of a failing stock, fresh food was supplied 
along with additional live yeast which provided additional nutrients to help boost health and 
stock proliferation. If this failed and the stock was down to minimal numbers, they were 
moved to a food which contained a high concentration of molasses and additional live yeast 
within the 25°C incubator. 
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2.2.1 Fly food 
The food was made from a cornmeal, yeast, agar mix in batches made as described 
below. Each batch supplied approximately 200 vials, some of which was preserved in sealed 
glass bottles and reheated/poured when required. The vials were sealed with a cotton wool 
plug and stored in a plastic bag at room temperature until used for fly cultivation. 
1. Mix 100g sucrose, 12g agar, and 700mL of distilled water. Heat until dissolved. 
2. In a separate container, mix 35g active yeast, 102.2g cornmeal, and 14g soy flour. 
Add distilled water up to a total volume of 700mL. 
3. Combine the two mixtures and heat in a microwave for 5x2 minute periods, with 
stirring in between. 
4. Allow to cool slightly before adding 5mL propionic acid and 3.8g of Nipagin 
dissolved in 40mL ethanol.  
5. Dispense into vials of approximately 8mL or store in airtight containers until needed. 
 
2.2.2 Crosses 
Genetic crosses were carried out to create specific genotypes for experimentation, such 
as the UAS/GAL4 system and deficiency crosses. These utilised phenotypic markers to 
properly identify the correct offspring. In this study, most of the markers were curly wing 
(CyO), stubble (Sb), tubby (Tb), white/red eyes, and scutoid (Scu) (figure 2.1). Crosses were 
set up with a mix of males and females to provide the correct genotype in the f1 offspring and 
were moved to a new vial within 4/5 days to prevent parent and progeny adults mixing. 
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Figure 2.1: Frequently used Drosophila melanogaster genetic markers. 
1) w1118 control strain with double recessive w- mutation resulting in a white eye phenotype. 2) True “wild type” 
red eye phenotype, often used in w1118 background to show the presence of a mutation. 3) Scutoid: Hairs on the 
body are not present. 4) Stubble: Hairs on the body are shorter and thicker. 5) Curly: The tips of the wings curl 
upwards. 
 
The selection of female virgins must be done within a few hours of eclosion as the 
markers become more difficult to identify after a longer period. Virgins are selected with 
noticeably pale and soft bodies, furled wings, and the meconium present. This is the most 
important marker for virginity and is a black spot seen in the abdomen. The differentiation of 
male and female flies was done by observing the obvious genitalia differences at the end of 
the body. 
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2.3 DNA extraction 
To begin DNA analysis, the DNA must be removed from the organism. DNA is a fairly 
robust structure, and there are many available protocols for successful extraction. For this 
Drosophila work, a phenol-chloroform protocol was used to extract the DNA and separate it 
from proteins and other cell debris. The method outlined in http://www.protocol-
online.org/prot/Protocols/Isolation-of-micro-RNA--miRNA--3342.html was used. While 
there are several commercially available kits or reagents to easily extract DNA, this method 
was chosen as it was both able to separate small RNA molecules along with the DNA and 
cost effective. As the project orientates around microRNA (~22bp) the ability to effectively 
collect small RNA molecules was imperative. The protocol utilises the solubility of DNA in a 
polar solvent, and the protein denaturing action of phenol to separate and protect the nucleic 
acid. Upon introducing phenol-chloroform to a lysed (broken up) biological sample, the 
nucleic acid dissolves in the water component while the proteins are denatured and soluble 
within the phenol environment. Following a spin in the centrifuge, the two layers clearly 
separate with the nucleic acid in aqueous solution that can be carefully pipetted out. The 
nucleic acid solution is then added to pure ethanol or isopropanol which changes the solutions 
polarity and forces the DNA and RNA out of solution, this process can have better results if 
performed on ice or including a brief incubation period in -20C. 
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Protocol: 
1. Collect sample 
2. Homogenize sample in 100μl denaturing solution (4M Guanidine Isothiocyanate 
(GITC), 0.02M Sodium citrate, 0.5% sarcosyl) in a 200μl ependorf. 
3. Add 10μl D of 2 M sodium acetate. 
4. Add 100μl of phenol:chloroform:isoamyl alcohol (25:24:1). Cap and vortex 
thoroughly. 
5. Spin the sample in a microcentrifuge at 12500 rpm for 5 minutes 
6. Transfer top aqueous layer to a tube containing 100μl of isopropanol. Mix 1μl of 
glycogen with the nucleic acid solution before adding the isopropanol. Leave at -20C 
for 30 minutes. 
7. Spin the sample in a microcentrifuge at 12500 rpm for 5 minutes 
8. Remove supernatant completely 
9. Wash pellet in 2x 200μl of 75% ethanol–25% DEPC-treated water 
10. Remove supernatant completely 
11. Dry for 5 minutes under a fume hood 
12. Resuspend pellet in DEPC-treated water (volume dependent upon concentration 
required) 
 
Initially samples of whole flies were used and homogenised by crushing in denaturing 
solution within the Eppendorf. For PCR genotyping; samples of miR-137KO, w1118, and 
heterozygous (w1118/miR-137KO) were used to provide a complete result. In this setup it was 
predicted that primer sets for both miR-137 and w+mW.hs would bind and produce a result in 
the heterozygous knockout flies as they carried both DNA regions, while primer specificity 
could be tested by presence-absence of relevant primer sets in the homozygous stocks. 
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2.4 PCR Genotyping 
To ascertain the presence or absence of a specific gene, the region must be amplified 
and run through a gel to visualize the DNA. To do so, the DNA extracted needed to be 
quantified and then undergo polymerase Chain reaction in a thermocycler to exponentially 
amplify a desired region to the concentrations which can be visually shown on an 
electrophoresis gel. 
 
2.4.1 DNA quantification 
Following DNA extraction and purification, the quantity of nucleic acid was measured 
to ascertain the procedure was successful. Using a Thermofisher Nanodrop 2000 machine, the 
nucleic acid concentration and purity can be measured using 1μl of PCR product per 
measurement. The machine utilises spectrophotometer readings to calculate the absorbance of 
certain molecules, which is then used to ascertain concentration and a 260/280nm wavelength 
ratio useful for judging purity. The results from a Nanodrop reading is a 
wavelength/absorbance graph, alongside a results table for DNA concentration (ng/μl), 
260nm, and 280nm wavelength readings. A 260/280 ratio of ~1.8 is deemed as “pure” for 
DNA, while a measurement of ~2.0 is “pure” RNA. Ratios of significant difference usually 
indicates that contaminants such as phenol or proteins are present, and additional steps taken 
to purify if contaminants will affect downstream procedures. 
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2.4.2 Primer Design 
To provide evidence of the genetic substitution, PCR genotyping through selected DNA 
region multiplication and gel electrophoresis was used for presence and absence analysis. 
Several sets of primers were designed to bind to the extended gene region of the endogenous 
miR-137, and some were made to bind to parts of the expected insertion (figure 2.2). 
 
 
Figure 2.2: Regions of predicted DNA amplification with designed primer sets. 
Primers were designed for use in PCR to bind to regions of genomic miR-137 and the w+mW.hs insertion. 
 
Primers are small sequences of 18-22 nucleotides which are specifically designed to be 
complementary to parts of the forward and reverse strands of a DNA sequence. They work as 
part of the polymerase chain reaction (PCR) protocol for amplifying regions of DNA. During 
the PCR process, the primers bind to the specific target regions and are then used to kick start 
an extension process which creates a complementary strand of the target region between the 
primers.  
 
68 
 
Correct primer design also has other important factors, such as melting temperature and 
nucleotide frequency. The sequence for the extended gene region of D. melanogaster miR-
137 was taken from FlyBASE (Gene ID: FBgn0262446), while the sequence for the synthetic 
w+mW.hs insertion was obtained from Klemenz et al. (1987).  These sequences were then used 
to design the complementary primer sets. Initially 5 primer sets were made, 2 for the miR-137 
region, 2 for the w+mW.hs insert, and one that may have spanned the whole insertion (figure 
2.2). Primer pairs were designed to span regions of approximately 5-600 base pairs (bp) so 
the amplificated DNA sequences were not too long which also kept the PCR cycles shorter 
(table 2.1). The primers were selected to be 18-22 nucleotides in length while also having a 
suitable melting and annealing temperature. They were also designed to include more G or C 
nucleotides towards the help with annealing stability. Primers also had to be designed to run 
5’ to 3’ orientation, so the reverse pair had to be the reverse complement of the reported 
sequence. 
The Tm or melting temperature was predicted using an online programme available at:  
http://www6.appliedbiosystems.com/support/techtools/calc/. While the reverse complement 
was computed via http://reverse-complement.com/.  
 
Table 2.1: Primer pair sequences and expected amplicon length 
 
 
Primer 
 
 
Forward sequence 
 
 
Reverse sequence 
 
Amplicon 
length 
 
1 GCCACGTGTATGCTCGTAG TGGTTCAAACTACAACTGACAG 612bp 
2 TAACATAAGGTGGTCCCG TTCATTAAACAATGAACAGGAC 512bp 
3 TTATAGTGCAATTAATTCTGCG TTCCAGCGTAGAGCAAATG 577bp 
4 AGACGACCCTGCTGAATG CATCAGAAGGATCTTGTCAAAG 536bp 
5 TGTACAGTTATGGCAGCAGG ACAAATCTCGGTGAACTACG 526bp 
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2.4.3 PCR machine 
Once DNA has been extracted and the relevant primers have been designed, they are 
used within a PCR machine. The machine is a thermocycler, which can be used to change the 
temperature of a solution throughout a programmed cycle. The programme is set up to mimic 
optimum conditions for the relevant reagents to work in cycles that ultimately result in an 
exponential amplification of the desired region (amplicon). Along with the DNA sample 
(template) and designed primers mentioned previously; Taq polymerase, buffers, free 
nucleotides (DNTPs), and magnesium chloride is added to a 200μl PCR tube (table 2.2).  
 
Table 2.2: Reagent and volume mix for PCR reaction mixture. 
Reagent Volume per 10μL reaction (μL) 
DNTPs (10mM) 0.2 
Taq Enzyme 0.1 
Taq Buffer (10x) 1 
MgCl2 (25mM) 0.6 
Reverse Primer 0.2 
Forward Primer 0.2 
DNA Template 1.5 
H20 6.1 
Total 10 
 
 
Taq polymerase is a thermostable DNA polymerase enzyme extracted from the bacteria 
Thermus aquaticus, that operates at relatively high temperatures of 72C. The enzyme binds 
to the primers following annealing and uses the free nucleotides to extend the complementary 
sequence, ultimately creating a complementary strand of the template. Following the 
extension period, the mixture heats up and the strands come apart allowing the next cycle of 
DNA amplification (table 2.3). The cycle was repeated 35x, which if successful can produce 
over a billion copies of the amplicon. 
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Table 2.3: PCR machine thermocycler programme 
Step Temperature (C) Time Purpose 
Start 94 2 min TAQ Polymerase activation 
Cycle i 94 15 sec Separation of DNA strands 
Cycle ii 56 15 sec Annealing of primers and enzyme 
Cycle iii 72 30 sec Extension of primers by enzyme 
Finish 72 5 min Final extension period 
 
 
2.4.4 Gel electrophoresis 
For electrophoresis, gels were made and tested at 1%, 1.5%, and 2% for best results. As 
the DNA fragments are quite short (~600bp) the 2% gel provided the best separation when 
run at 80 Volts for 60 minutes. For a 2% gel, 0.8gms of agarose was added to 40mL of 1x 
TAE buffer in a 100mL conical flask, and then heated in a microwave for approximately 2x 
30 seconds. SybrSafe was added at a concentration of 1uL per 10mL of gel, once the mix had 
cooled to approximately 50C. The gel was poured into an electrophoresis tray and a desired 
well-comb was put in, before letting it cool completely. While cooling, the PCR product has 
20% volume of 5x loading dye added. Once hardened, the gel is submersed in 1x TAE buffer 
and 5uL of sample/dye mix was added to each well. In the first well a 100bp ladder was used 
(100bp to 1kbp in 100bp increments). Following an hour electrophoresis, the gel was 
removed and put on a UV light viewing plate and photographed. In later experiments the gel 
was imaged using a Bio-Rad Chemidoc MP Imager. 
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2.5 Gene Expression 
Gene expression amount can be assessed through the concentration of RNA found 
within a sample. Following RNA extraction, the RNA must be protected by converting into a 
cDNA via Reverse transcription (RT). Once the RNA is stabilised, its comparative expression 
amount can be measured utilising the specific Taqman microRNA expression assays by 
Applied Biosystems in a qPCR machine. 
 
2.5.1 Reverse Transcription 
For gene expression analysis, fluorescent quantitative polymerase-chain-reaction 
(qPCR) techniques are used to assess the level of target messenger RNA (mRNA) present in 
the template sample. Before the expression can be measured, extraction of total RNA and 
conversion into double stranded complimentary-DNA (cDNA) through reverse transcription 
(RT). These cDNA molecules are more resilient and degrade slower which makes them better 
for storing while all samples are accumulated for a qPCR run. RT requires a suitable reverse-
transcriptase, a purified RNA sample, and a three-step programme in a thermocycler (tables 
2.4 and 2.5). The initial incubation at 16C enables the binding and annealing of the RNA, 
enzyme, and primers. The 42C incubation period is the working temperature for reverse 
transcription enzyme to extend the primer tail and make cDNA, following this phase a short 
time at a high temperature to deactivate the enzyme. Following RT, the samples are stored at 
-20C until ready to be used. To protect sample integrity, these were usually stored for a 
maximum of 2 weeks.  
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For miRNA molecules, the small size of around 20bp complicates the procedures and 
prevents conventional primers from converting and/or amplifying the target. For standard 
mRNA reverse transcription, a primer that binds to the poly-A tail of mRNA is used to 
convert all available mRNA into a cDNA library. However, miRNA do not have poly-A tails, 
therefore Stem-loop RT primers must be used to circumvent these problems and enable 
successful qPCR. The stem-loop RT primers contain a complimentary region to the target 
mature miRNA at the end region, attached to a synthetic stem-loop construct. The 5’ 6nt of 
the primer construct binds to the 3’ 6nt of the mature miRNA and the RT enzyme during the 
incubation period. Then in the extension phase the RT enzyme extends the primer tail with 
nucleotides complimentary to the mature miRNA sequence, resulting in a double stranded 
cDNA molecule that can be used as normal in qPCR (figure 2.3). 
 
Figure 2.3: MiRNA Stem loop primer reverse transcription. 
The mature miRNA molecule is 18-25 nucleotides in length, and therefore a standard primer cannot be used. To 
combat this, the stem loop primer has a ‘sticky end’ which binds to the last few nucleotides and then a reverse 
transcription enzyme completes the strand resulting in a hairpin loop integrating the miRNA molecule. 
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For this experiment, RT was done by splitting the same biological sample into two. One 
set used the hairpin-loop primers for converting miR-137, and another was used to make a 
total cDNA library with Poly-A primers for rps17 analysis. 
 
Table 2.4: Reverse Transcription thermocycler programme. 
Step Temperature (C) Time (Min) 
1 16 30 
2 42 30 
3 85 5 
 
Table 2.5: Reagent mixture used for reverse transcription 
Reagent for miR-137 for RPS17 
DNTPs (10mM) 0.15 0.15 
Taq Enzyme 1 1 
Taq Buffer (10x) 1.5 1.5 
Primer 3 1.5 
Template max within 5µL 
H2O To 15µL total 
 
 
2.5.2 Comparative QPCR 
Following RT, samples are loaded into a qPCR machine (Applied Biosystems Step-
One) with specific primer sets and fluorescent probes and quenchers (table 2.6). The qPCR 
machine amplifies the desired cDNA regions exponentially for 30-40 cycles, and as the 
sequences are multiplied more fluorescence is given off by the binding and release of 
fluorescent markers (table 2.7, figure 2.4). This increase in fluorescence is detected by the 
machine for each sample well and calculated against a standard curve for a comparative value 
of target mRNA expression. The standard curve is made using a known dilution factor and a 
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mixture of all samples or an mRNA with a known starting concentration. Within each qPCR 
run, samples are run with duplicate or triplicates for test mRNA expression and a control 
mRNA expression. The control mRNA is usually a housekeeping gene which is unlikely to 
have changed in expression across the different samples and is used to normalize test mRNA 
measurements in case of accidental differences in starting template cDNA concentrations. 
 
Table 2.6: Qualitative polymerase chain reaction reagent mix 
Reagent Volume (μL) 
RT Product 2 
Master Mix (2x) 10 
Taqman Assay (20x) 1 
H2O 7 
Total 20 
 
 
To analyse the expression of miR-137 within D. melanogaster heads, ribosomal protein 
rps17 was used as a control gene. Included on each qPCR plate were blanks for each primer 
set to check for of contamination and background fluorescence. Tests were run in duplicate, 
with 5 different genotypes in 48-well plates set up as shown in figure 2.5. The standard 
curves were made using an equal mixture of all genotypes in the experiment, and then diluted 
with a factor of 1:2 for 6 points. Genotype samples were all diluted 1:5 prior to being used in 
the qPCR mix, ensuring they were within the middle region of the standard curve and 
providing sufficient dilution to minimise contaminants. 
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Table 2.7: Quantitative PCR thermocycler programme steps 
Step Temperature (C) Time 
1 95 10 min 
2 95 15 seconds 
3 60 60 seconds 
 
 
 
Figure 2.4: MiRNA quantitative PCR process. 
The cDNA created from using a hairpin-loop primer with mature miRNA molecule uncurls as part of the 
melting part of the PCR cycle. In the annealing phase, a probe and a primer will bind to the single strand of 
cDNA. During the extension phase, RT will extend the primer tails and displace the probe, releasing a 
fluorescent marker that is measured by the PCR machine. 
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Figure 2.5: qPCR 48-well plate map. 
Comparative qPCR of five genotype samples (blue “U”) were run in duplicate and included assays for miR-137 
and for rps17, a housekeeping gene. Two control blanks for each gene assay were included (grey “N”) to check 
for background fluorescence. A standard curve for each gene was made using a mix of all genotype samples in 
the experiment, diluted for 6 points with a consecutive dilution ratio of 1:2 (orange “S”).  
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2.6 General Health of miR-137KO Drosophila  
To begin investigation of the function of miR-137 a set of general health assays were 
conducted to identify any obvious phenotype effect as a result of miR-137 LOF. 
 
2.6.1 Lifespan 
The lifespan assay recorded the number of male and female flies at the moment of 
eclosion and note when the flies died. To start the experiment, flies that had eclosed. The flies 
were moved to new vials every 4-6 days to prevent new offspring mixing into the adults. The 
results were recorded and analysed using Microsoft Excel. 
 
2.6.2 Development lethality and timing 
To easily count individuals, flies were set up in culture pots on a fruit juice agar plate 
(see section 2.6.2.1). Culture pots were inverted stock bottles, with enough small holes 
punched into it to enable air flow. 14 females and 10 males were added to each culture pot, 
and placed on a grape agar plate at 25°C. In addition to the agar plate, the flies were fed a 
yeast paste made from a roughly 7:9 ratio of yeast to distilled water. Initially the cultures 
were left to feed and acclimatise for 3 days, and then fresh plates and yeast paste were used. 
To collect eggs, the plates were left for 2 hours before being changed again. Once eggs had 
been laid on the agar, they were counted and transferred to another agar plate. Then they were 
viewed each day to count the number of individuals which progressed to the next stage and 
when. The next stage was often transferred to a new plate and supplied fresh yeast paste to 
enable easier counting. 
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Instars were differentiated by key features. First instars were present approximately 24 
hours after the eggs were laid and can be separated from second instars by analysing the 
mouthparts. In second instars the mouthparts have developed to look much more like hooks, 
whereas in the first instars the mouthparts appear to be 3 dark spots. Second instars are 
usually at 48 hours, and third instars are at approximately 72 hours. Third instars can be 
deduced by the fanning structure at the end of the trachea and the presence of dark orange 
rings around the spiracles. Once the larvae reached 3rd instar they were transferred to normal 
Bloomington food vials and watched until pupation occurred. The number of pupae and then 
the final number of adult flies were recorded. 
 
2.6.2.1 Agar plates 
To easily view and count individuals, flies were allowed to lay eggs on grape juice agar 
plates. The plates were made using a protocol mentioned in Featherstone et al. (2009). 70mL 
of distilled water was added to 3gms of agar in a 250ml conical flask and microwaved until 
boiling. In a 100mL conical flask, 30mL of grape juice was added to 3gms of sucrose and 
microwaved until boiling. The juice-sugar mix was added into the agar solution, and then 
0.05gms of methyl-4-hydroxybenzoate was added and the solution was swirled until well 
mixed. Approximately 5mL of the mix was poured into 35mmx10mm petri-dishes and 
allowed to cool and set. Once set, the plates were stored at 4°C upside down until used. 
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2.7 Drosophila Activity Monitoring System  
The Drosophila activity monitoring system (DAMS) by Trikinetics is a machine which 
is used to indirectly measure activity of individual flies housed in clear tubes. The machine 
communicates with a computer which is used to continuously record activity counts across 
periods of multiple days. 
 
2.7.1 Set-up and use 
Drosophila strains were put through DAMS analysis to assess circadian rhythm, sleep-
wake activity, and motor ability. The system functions by sending an infra-red beam through 
a plastic tube, and houses 32 individual plastic tubes per tray (figures 2.5 and 2.6). The 
system records the number of beam crosses performed by the fly in a set time frame, along 
with the time and date. 
 
 
Figure 2.6: Drosophila activity monitoring system (DAMS) function.  
The flies are individually housed in clear plastic tubes that have an infra-red light passing across the middle. The 
number of times the beam is broken is reported to a computer which records the data along with time and date 
stamp. This number can then be used to calculate activity or lack of activity of the individual flies across several 
days. 
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The DAMS tubes are 65mm in length, and with a 5mm outer diameter and 3mm inner 
diameter. They are set up to contain approximately 10mm of Bloomington Diet food at one 
end, sealed with parafilm, and a cotton wool stopper at the other. The distance of which is 
remained open for the fly to move around is controlled and kept even across all tubes in the 
experiment. Once the flies are introduced to the vials, they are loaded into the DAMS tray in 
alternating genotypes to ensure fair controls against environmental factors such as shading or 
heat gradient (figure 2.6). 
 
 
Figure 2.7: A complete DAMS array set-up. 
The DAMS tray is set up with 32 individual tubes housing 32 individual flies. Each tube has a cotton plug at one 
end and a small volume of yeast-cornmeal based food sealed with parafilm at the other. 
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For sleep-wake behaviour and activity analysis, the DAMS tray was set up and put in 
25C. The first readings including at least one full day (7am to 7pm) was omitted from 
subsequent analysis as it was the acclimatisation period, a during which the environment 
change may affect behaviour.  For circadian rhythm analysis, the DAMS monitor was set up 
in a box which could be shut to block out light. The flies were left to acclimatise for a full 
day, and then at the lights out of the incubator cycle the box was shut and left. The flies 
inside the box were subjected to no lights for 7 days. 
 
2.7.2 Data analysis 
The DAMS system produces a lot of raw data in the form of beam counts per 5-minute 
period per fly for an average run of 5-7 days. Depending upon how the data is converted it 
can be used to look at activity or sleep. 
Raw data from the DAMS was copied into Microsoft Excel sheets that were pre-
programmed to manipulate the data to provide activity or sleep-like behaviour results. 
Programming the cells to calculate each step enabled a “copy and paste” approach to 
analysing new DAMS data each time an experiment was run. 
The activity excel sheet calculated the average activity counts for half hour periods that 
was then plotted as an actogram, showing the activity pattern across a 24-hour period. 
The sleep excel sheet was programmed to turn the periods of inactivity into ascending 
counts of 1, and as a result was able to compute parameters such as: sleep bout length, total 
sleep amount, number of sleep bouts, and max sleep bout length. The data was also 
accumulated into an average sleep amount per 30 minutes to provide a sleep profiles across a 
24-hour period. 
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2.8 Video Tracking 
Due to some limitations of the DAMS system, additional verification of fly movement 
was undertaken to better understand behaviour. Direct video recording of D. melanogaster 
was taken and analysed to compare to the DAMS findings. 
 
2.8.1 Video Set Up 
Flies in DAMS vials were taken from the DAMS and placed on a transparent plastic 
tray atop a light box. The tray is necessary to prevent the flies overheating from prolonged 
direct contact with the light box. A video camera was set up on a quad-pod above the vials 
pointing down (figure 2.7). A recording was taken for approximately 50 minutes. 
 
 
Figure 2.8: Video recording set up for tracking. 
Video and subsequent computer analysis was used to directly monitor the fly’s activity over an approximate 50-
minute period. The backdrop of the light box gave a clear contrast which enabled the video camera to pick up 
the individual flies. The flies were taken directly from a DAMS set up and kept in the same vials. 
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2.8.2 Video analysis 
Following recording, the video was converted into 1 frame per second and then 
imported into ImageJ, where the image stack was cropped and converted into simplistic black 
and white images (figure 2.8). Then measure mass was used to get a y-plot for the median fly 
location (simplified to black dot) across all slices of the image stack.  
 
2.8.3 Data analysis 
The y-plot data was then put into Microsoft Excel and normalised into 0-1 
representative with 1 being cotton plug end and 0 being the food end. This was then 
converted into approximate mm measurements and each measurement was subtracted from 
the previous one to calculate the distance moved (mm), and subsequently velocity (mm/s). 
 
Figure 2.9: Simplified image frame from video recording. 
Flies were recorded in DAMS vials, and then the video was edited into 1 frame per second stacks and converted 
into a simplistic black/white image for tracking in ImageJ software. Due to the contrast editing, the sides of the 
tubes are not seen, however it is possible to pick out the food (large black dots at bottom of picture), the cotton 
wool (large black dots at top of picture), and the fly (small black dot) of each vial. 
 
Fly 
Food 
Plug 
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2.9 Negative Geotaxis 
Flies of 1-2 days since eclosion were separated under CO2, and cohorts of 10 male 
adults were stored in vials containing food until 5 to 7 days old. They were then transferred to 
an empty vial without using CO2. A second tube was inverted and secured to the top with 
tape. The double vials were stood up against a light box and horizontal ascending lines with 
20mm intervals, marking sections numbered 1 to 10.  A camera was set up at a controlled 
distance and levelled to approximately midway up the tubes. Once set up, a video recording 
was started, and the vials were inverted and tapped sharply three times to ensure all the flies 
were on the base. The video was taken for 20 seconds to capture all fly movement during the 
assay and after each round of recording, the flies were left untouched for 1 minute before 
repeating. Two vials of 10 males were used for each genotype (miR-137KO and w1118) and 
each was repeated 5 times. Once the videos were all collected, it was reviewed and stopped at 
a climbing time of 5 seconds and the numbered section achieved by each individual fly was 
recorded in excel. 
 
2.10 Statistics 
Due to the simple nature of the experiments, t-tests were conducted to calculate the 
significance between two variables at a time to reinforce the results and discussions. The 
experiments were set up to directly associate a change in behaviour differing from the 
“norm”, and as such compared one test genotype against the w1118 control at a time. To draw 
further comparisons, some tests (such as the recovery or phenocopying chapters 6 and 7) also 
included a significance test to assess the success of each experiment. To use a t-test, it 
assumes equal variances and a normal distribution of the data sets. For larger datasets the 
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distribution was assumed as normal in line with the Central Limit theorem, but for smaller 
datasets (n < 30) the distribution was checked as follows. 
 
2.10.1 Testing for equal variance and normal distribution 
Prior to any significance testing, the samples were put through f-test calculations using 
the prebuilt function in Microsoft Excel. The F-tests enable a measure of equal or unequal 
variance in the samples which can then be used to select the correct significance tests.  
An F-test of variances assumes a normal distribution of the datasets. To test the 
distribution, you can use the Shapiro-Wilks formula which calculates the distribution and if 
found significant (p-value <0.05) then the null hypothesis of a normal distribution is rejected. 
There are several online calculators that will calculate the p-value from your dataset, or it can 
be done manually using Shapiro-Wilks coefficient tables. The Central Limit Theorem 
generally applies to samples numbering over 30 and dictates that it is acceptable to assume 
normal distribution for such sample sizes and larger. In this study, sample sizes of under 30 
were subjected to the Shapiro-Wilks test for normality before significance testing. 
 
2.10.2 Testing for significant differences 
To test for significant differences between two datasets, a simple t-test was conducted 
utilising the prebuilt function in Microsoft Excel. The test chosen was either for equal or 
unequal variances dependent upon the result of the F-test. If the resulting p-value was smaller 
than 0.05, the null hypothesis of no significant differences between the samples was rejected 
and the two samples were deemed statistically significant until further correcting for false 
discovery rates. 
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2.10.3 Post-Hoc testing for false results 
Due to repeatedly conducting t-tests, the likelihood of false positives (Type I errors) is 
amplified. Finding a result that is significant to a 5% level will happen by chance 5 times out 
of every 100 tests and to reduce the likelihood of producing errors by chance, p-values can be 
corrected using one of several measures. One of the simplest, but most conservative, of which 
is the single-step Bonferroni correction method (Bonferroni 1936), which divides the 
significant p-value by the number of t-tests conducted within a “family” of experiments to 
give a new significance threshold. This correction for family-wise error rate (FWER) reduces 
false positives but, in the event of a high number of tests, can increase false negatives (Type 
II error) therefore reducing statistical power. Studies of several thousand significance tests 
such as genomic microarrays, often use a method for controlling the False Discovery rate 
(FDR) known as the Benjamini-Hochberg test (Benjamini and Hochberg 1995). This allows 
for a degree of error and produces candidate results that can be further validated in follow-up 
studies. 
In this thesis, a “family” of experiments were grouped in accordance to dataset 
regardless of how reported or grouped in graphs. As this study is not a large-scale screen and 
even the project-wide t-test count is under 1000, the Bonferroni method was used to calculate 
excessively conservative thresholds that were used as discussion points to evaluate if the 
result is likely truly significant. Only one test was conducted for lifespan, activity, and 
negative geotaxis so these needed no correcting. For the other experiments, the number of 
tests and most conservative calculated p-values used for discussion are as follows: 
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• Developmental rate: 
- Tests conducted = 3 
- Corrected 5% significance p-value = 0.0167 (3sf) 
• Video tracking velocity: 
- Tests conducted = 3 
- Corrected 5% significance p-value = 0.0167 (3sf) 
• DAMS sleep behaviour: 
- Tests conducted = 63 
- Corrected 5% significance p-value = 0.000794 (3sf) 
• Pharmacological treatments (individually): 
- Tests conducted = 6 
- Corrected 5% significance p-value = 0.00833 (3sf) 
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3 Verification of genomic miR-137 knockout 
Fly stock #58893 was ordered from Bloomington Drosophila Stock Centre which was 
reported to have a homologous arm substitution that replaced the endogenous miR-137 
coding region with an insertion which contained a w+mW.hs sequence. The stock was on a 
white-eyed (w1118) background and the result of the exogenous sequence was a red eyed 
phenotype. To be sure the stock was supplied as reported, experiments were needed to check 
for the presence of the insertion and lack of the original miR-137 gene. 
 
3.1 Gel electrophoresis 
Assuming successful amplification, the amplicons make up a significant portion of the 
PCR product. A loading dye can be added, and then the solution is put into a well along the 
top edge of an electrophoresis gel. The gel is made of a mixture of tris base, acetic acid, and 
ethylenediaminetetraacetic acid (TAE) buffer, agarose, and a DNA binding marker like 
Sybersafe. Once fully loaded, the gel is submersed in more TAE buffer and has an electrical 
current passed through it from a negative to positive electrode. As DNA is negatively 
charged, it will begin to travel through the gel towards the positive electrode. The gel 
impedes the DNA movement, and this separates the DNA in relation to size with the shortest 
sequences travelling faster than longer amplicons. The Sybersafe binds to the DNA as it 
travels and labels it with a fluorescent marker that can be seen under UV light. The result of a 
gel electrophoresis is a series of fluorescent bands that are separated in terms of size, 
allowing the identification of (or lack of) each amplicon.  
The function of the loading dye is trifold; it weighs down the sample to prevent it 
floating into the buffer, it also colours the sample for ease of locating, and the two visible dye 
components travel both faster and slower than the DNA sample to easily ascertain the 
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location the bands. Alongside the PCR product, the first well on the gel is usually a DNA 
ladder, which are pre-made solutions of a mixture of known DNA sequence lengths and can 
be used as a reference for the length of an amplicon. 
 
Table 3.1: Electrophoresis gel layout and expected DNA bands. 
Well number 
(left to right) 
Primer Genotype Expected band 
1 Ladder Ladder Ladder 
2 1 w1118 Y 
3 1 miR-137KO N 
4 1 Heterozygous knockout Y 
5 2 w1118 N 
6 2 miR-137KO Y 
7 2 Heterozygous knockout Y 
8 3 w1118 Y 
9 3 miR-137KO Y 
10 Ladder Ladder Ladder 
11 3 Heterozygous knockout Y 
12 4 w1118 N 
13 4 miR-137KO Y 
14 4 Heterozygous knockout Y 
15 5 w1118 Y 
16 5 miR-137KO N 
17 5 Heterozygous knockout Y 
 
 
The set-up of the first gels were the 5 primer sets used on each of the genotype samples 
(knockout, control, and heterozygous knockout) as laid out in table 3.1. Five primer sets were 
created to be able to select the most successful for amplification and subsequent sequencing, 
with methods described in chapter 2.4.2.  
Initially there were issues with the results demonstrated on the gels, with some of the 
expected bands missing (figure 3.1). PCR factors such as annealing temperature, extension 
time, and number of cycles can be modified to produce clearer results in the gel. Also, any 
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contamination during or carried from the extraction or purification process can also impair 
the amplification. Therefore, an absence of bands within the first few attempts could not 
simply be put down to ineffective primers. Several repeats of the DNA extraction process and 
subsequent electrophoresis gels were conducted, with emphasis on the reagents used and 
dilution of the DNA template to prevent carry over of any ethanol. 
 
 
Figure 3.1: Electrophoresis gel result of PCR genotyping. 
Clearly seen on the left-hand side of each is the molecular ladder and its increments used for sizing of the 
amplified bands. The bands are all in the lower region of the ladder (100 and 500bp were the smallest bands 
shown as the lowest marks in the “L” row). 
 
After several failed attempts, new primers and reagents were used to eliminate 
contamination. The extracted DNA template was also diluted further before introduction to 
the PCR reagents to minimise the carry-over of toxic products from DNA extraction, and 
Actin primers were ordered from DSRC to amplify ~200bp regions of Actin-5c and Actin-
57b. Genes from the Actin family are highly expressed across all cell types, and the primers 
acted as a positive control for presence of genomic DNA. 
100bp 
500bp 
L    1     2     3     4     5     6    7    8            L    9   10   11   12 
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Following the troubleshooting, the results demonstrated that primer sets 1 and 2 were 
most effective at amplifying the correct target gene regions, miR-137 and w+mW.hs 
respectively. Primer 4 designed to bind to w+mW.hs was also picked up in the w1118 control 
flies. The w1118 flies contain an allele that is a partial deletion of what would be a wild-type 
white gene. True wild-type flies have a red eye phenotype, which is not present in the w1118 
control flies who have the recessive white eye phenotype. The w+mW.hs insertion is a mini 
version of the white gene which recovers the red eye phenotype in a w- background.  
 
 
Figure 3.2: Electrophoresis gel result of PCR genotyping sent for sequencing. 
Clearly seen on the left-hand side is the molecular ladder and its increments used for sizing of the amplified 
bands (row “L”, with bands of 50, 100, 200 etc.). The next 4 bands (rows 1-4) are the amplified region from 
primer 1, a section of the genomic miR-137 sequence. The last 4 (rows 5-8) are the amplified regions from 
primer 2, part of the w+mW.hs sequence. 
 
 
100bp 
50bp 
200bp 
L      1         2        3        4         5        6        7       8  
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3.2 Amplicon Sequencing 
To verify the amplified regions of these primers, several individual PCR runs were 
collected for both selected primers (1 and 2) and checked for successful amplification (figure 
3.2), then sent to Beckman Coulter Genomics for sequencing. The amplicons were 
sequenced, and results were returned as a nucleotide sequence list and nucleotide read graph 
for each (figures 3.3 and 3.4).  
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Figure 3.3: Sequencing result of primer set #1 amplicon (miR-137). 
Primers were designed to bind to a selected region of miR-137, and then put through PCR amplification before being sent for sequencing. 
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Figure 3.4: Sequencing result of primer set #2 amplicon (w+mW.hs).  
Primers were designed to bind to a selected region of w+mW.hs, and then put through PCR amplification before being sent for sequencing. 
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3.3 Amplicon comparison to expected sequences 
The sequencing results were then compared to the predicted amplified sequence to 
check for high homology. Using the sequences and online programmes such as LALIGN 
(available from: https://embnet.vital-it.ch/software/LALIGN_form.html), the homology of 
the sequences can be assessed. The comparison shows a very high homology between the 
expected sequences and the amplified sequences (figures 3.5 and 3.6). Unfortunately, the 
primers were not designed to assess the mature miR-137 homology specifically and due to its 
proximity to the primer binding site (41 – 63 base pairs in figure 3.5, identified with the blue 
bar) it’s not possible to determine its identity. Similarly, the coding sequence of miR-137 (<0 
– 88 base pairs in figure 3.5, identified with the orange bar) cannot be fully seen, though there 
appears to be some discrepancies towards the end of the coding strand. While it is not clear 
what effects these differences could have, they are not part of the mature sequence and 
therefore not the area involved with RNA-regulation. 
 
 
 
 
96 
 
 
Figure 3.5: Alignment of miR-137 DNA sequences. 
Using Lalign, the amplified miR-137 region by primer set 1 and the sequence from Flybase was compared for 
sequence homology. The red letters highlight identical nucleotides and therefore demonstrate the very high 
similarities between the two. The mature miR-137 sequence responsible for the RNA-downregulation function is 
shown from base pairs 41-63 (blue bar), and the coding sequence for miR-137 is shown from base pairs <0 -88 
(orange bar). 
 
 
 
 
Figure 3.6: Alignment of wmW.hs DNA sequences. 
 Using Lalign, the amplified wmW.hs region by primer set 2 and the sequence from Flybase was compared for 
sequence homology. The red letters highlight identical nucleotides and therefore demonstrate the very high 
similarities between the two. 
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3.4 Conclusion 
Overall, the primers are proven to successfully bind and promote the amplification of 
the region they were designed around. Furthermore, the amplicons are clearly the expected 
regions as proved by the high sequence homology between reported literature sequence and 
the sequence of the amplicon. Through presence-absence analysis, the PCR genotyping 
clearly shows lack of genomic miR-137 DNA within the miR-137KO stock. Not only this but, 
in the same knockout stock, there is the addition of a w+mW.hs sequence as reported by 
Bloomington. 
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4 miR-137KO effect on D. melanogaster health 
With all genetic manipulation of DNA in vivo, the resulting genotype can be 
detrimental to overall health or living capabilities of the organism. With the loss of a 
microRNA, and subsequent introduction of a larger construct, the knockout stock was 
measured for any major defects within parameters such as longevity, development, and other 
general behaviours. Observation of the viable stock did not give obvious reason to evaluate 
behaviours such as feeding, overall size, or ability to reproduce. The flies were capable of 
propagating, reproducing and living as would be expected of a non-mutant stock. However, 
lifespan and development lethality/rate are harder to determine from simple observation and 
were therefore investigated to see if loss of miR-137 has implications for these factors. 
 
4.1 Lifespan 
A lifespan assay was conducted as Drosophila lifespan is reported to have been 
affected by many genetic manipulations previously. The test was conducted as described in 
Chapter 2.6. 
 
4.1.1 Results 
The lifespan assay shows that on average, both the w1118 and miR-137KO strain had a 
similar mean lifespan of circa 51 and 49 days respectively (figure 4.1). The average lifespan 
is not statistically different when using a t-test (p-value > 0.05).  
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Figure 4.1: Mean lifespan of w1118 and miR-137KO. 
The w1118 flies did not show a significant difference to the miR-137KO (51.1 days, n = 68 and 48.5 days, n = 101 
respectively). Error bars are standard deviation. (t-test p-value > 0.05). 
 
There is a clear drop in survival rate of the miR-137KO strain once they reach about 42 
days old (figure 4.2). This is shown with a dramatic increase in percentage death from ages 
31-45 days old and then 45-59 days old, with an additional ~25% death at each stage in the 
knockout strain compared to controls (figure 4.3).  
 
 
 
0
10
20
30
40
50
60
70
w1118                       mirko
A
ve
ra
ge
 L
if
es
p
an
 (
d
ay
s)
100 
 
 
Figure 4.2: Survival rate of w1118 (n=68) and miR-137KO (n=101) adults across age. 
There was an apparent drop in survival rate of the miR-137KO (n=101) at ~day 42 compared to w1118 (n=68). 
 
 
 
Figure 4.3: Mortality rate of w1118 and miR-137KO by age range.  
Percentage mortality for age ranges 0-31 days, 31-45 days, and 45-60 days for w1118 (n=68) and miR-137KO 
(n=101). In the early stage both genotypes have a similar death percentage, whereas in the older stages the miR-
137KO strain has an increased death rate of 24% and 28% in 31-45 and 45-60 respectively. 
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4.2 Developmental rate and lethality 
The rate at which an organism develops is governed by a multitude of factors from both 
environment and genetic roots. In controlled environments D. melanogaster generally keep to 
a generation cycle of approximately 10 days at 25C, with new adults emerging from eggs 
laid by the previous generation. To assess if miR-137 LOF affects developmental rate or 
lethality, assays were conducted as described in Chapter 2.6. 
 
4.2.1 Results 
The rate of development shows a significant difference between the control strains 
w1118 and miR-137KO subjects (figure 4.4). The knockout strain reaches 3rd instar stage 
significantly earlier than controls (t-test p-value < 0.05) yet takes longer in 3rd instar and 
pupal stages to reach adulthood later than controls (t-test p-value < 0.01). 
 
 
Figure 4.4: Average development time of w1118 and miR-137KO. 
 The w1118 (n = 48) flies reach third instar significantly slower than the miR-137KO (n=48) strain. However, reach 
adulthood quicker and spend less time in pupation.  Non-corrected t-test results: ⁕ p-value < 0.01. ⁕⁕ p-value < 
0.05. ⁕⁕⁕ p-value < 0.01. Following post-hoc Bonferroni significance corrections, the time to 3rd instar no longer 
satisfied the significant threshold. 
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The developmental survival assay shows increased lethality in the miR-137KO strain, 
with 45.8% surviving from 1st instar to adulthood compared to 56.2% in w1118 controls (figure 
4.5). The survival at each stage shows a change in survival percentage between the 3rd instar 
and adult, with 4% death in the controls and 14% death in the knockout strain (figure 4.6). 
 
 
Figure 4.5: Survival rate from hatching to adulthood.  
The miR-137KO (45.8%) has a lower survival rate compared to w1118 controls (56.2%). 
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Figure 4.6: Survival rate across developmental stages. 
The miR-137KO strain (n=48) shows less overall survival to adulthood compared with w1118 controls (n= 48). The 
knockout flies also show an increase in mortality between 1st and 2nd instars. 
 
4.3 Discussion 
From the lifespan and developmental assays, there is little evidence of this stock having 
a severe longevity problem with genomic loss of the miR-137 gene. The mean average ages 
are not significantly different (p-value > 0.05), and correlate with documented lifespan from 
various studies. When cultivated on a sugar yeast diet, Linford et al. (2013) found that wild 
types had a mean age of 50 days, and a Sun et al. (2002) reported 46-52 days being within 
acceptable parameters of control D. melanogaster lifespan. While investigating differences in 
diet effect on lifespan, Bass et al. (2007) reported that mixed gender vials of canton-S 
(another widely used control strain) produced an average individual lifespan of around 49 
days when on standard laboratory food mix including maize, yeast, and sugar. In a screen for 
miRNA mutants, no significant change in lifespan was found for males or females with miR-
137 knockout (Chen et al. 2014). 
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As the flies age, there is a noticeable difference in the survival graph following ~41days 
old (figure 4.2). The miR-137KO strain survival rate drops much faster at this stage than the 
controls, though this does not appear to influence the mean age (figure 4.1, which has a t-test 
p-value > 0.05). The rate of survival decrease looks to be more severe in the controls at a later 
stage, which could then be masking the average life span across the population. This drop 
~41 days could infer a maintenance role for miR-137 that helps delay or manage the onset of 
age-related mechanisms. 
Developmentally, there appears to be a small change in the percentage of individuals 
which survive from imago hatching to post-eclosion adult (figure 4.5). The survival rate 
graph shows the expected overall trend for both, with less surviving individuals at each 
developmental stage.  There is an overall lower yield of adults in the miR-137KO strain, with 
46% survival compared to 56% in the w1118 controls where the biggest decrease difference 
was during the pupal stage between 3rd instar and adulthood. The knockout strain had a 14% 
decrease in survival compared to 4% in the controls, potentially implying a role for miR-137 
through the metamorphosis period. During this stage it is known that the organism undergoes 
huge changes in terms of biological anatomy and neural development (Technau and 
Heisenberg 1982: Singh and Singh 1999: Pauls et al. 2010), so genes responsible for CNS 
maintenance or proliferation would be important. This developmental lethality during 
pupation is contrasting to results by Chen et al. (2014) which did not find any significant 
difference in fly survival to adulthood. 
The rate at which miR-137KO flies reach development stage is has a slight but 
significant difference when compared w1118. This trend was reversed when looking at time to 
reach adulthood, where the controls were faster. This switch is because the knockout strain 
spends an increased amount of time in the 3rd instar and pupal stages, further inferring miR-
137 is required for an aspect of metamorphosis. When allowing for Bonferroni correction of 
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the t-test p-values, the significance cut-off value is changed to 0.0167. This new threshold 
means that the difference in the time taken for the flies to develop from egg to 3rd instar larva 
is no longer significant (non-corrected p-value of 0.0468). This however does not change the 
significance of time spent in pupation or overall time to adult fly. 
The knockout strain has had the miR-137 locus missing for a long period of time and 
with each generation it is more likely to have background mutations, which allow the stock to 
cope with the miRNA LOF. These modifiers could have a masking effect causing the flies to 
display a subdued phenotype. As longevity is widely research in D. melanogaster, there are 
many genes which are linked to a change in lifespan. For example, when overexpressing 
antioxidative enzymes, explicitly mitochondrial superoxide dismutase mnSOD, there is an 
increase in mean lifespan likely because of the increased enzyme expression reducing the 
accumulated effects of oxidative stress in an aging individual (Sun et al.2002). TOR 
signalling pathways are also widely believed to result in an increase in lifespan if reduced in 
adults, an effect linked to insulin signalling and dietary restriction (Stefana et al. 2017). 
 
4.4 Conclusion 
There is a noticeable change within some of the characteristics contributed to 
measuring drosophila health in the miR-137 deficient flies. Most apparent is a significant 
change within developmental survival and overall longevity particularly in the old aged flies. 
The severity of the phenotype resultant of losing a ~100bp non-coding gene demonstrates the 
biological importance of miR-137, further backed up with a high evolutionary conservation of 
the gene across a multitude of species. The lack of significant difference in average lifespan 
means that objective A hypothesis 1 must reject the alternate hypothesis and accept H0 
(Chapter 1.8). 
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Developmentally, the miR-137KO flies exhibit a developmental delay and an increased 
mortality rate within the 3rd instar and pupal stages when compared to controls, which means 
that null hypothesis from objective A hypotheses 2 and 3 can be rejected in favour of the 
alternate hypotheses (Chapter 1.8). The pupal stage is a natural phenomenon which puts 
excessive stress on the organism as it undergoes metamorphosis. It is likely vital for the 
correct expression of genes responsible for maintenance and proliferation of the CNS at this 
stage, and the loss of miR-137 could be affecting successful CNS development.  
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5 miR-137KO effect on D. melanogaster behaviour 
Drosophila have been widely used as a model organism to investigate genes for human 
relevance in diseases. The most obvious effects of gene expression manipulation are 
phenotypical changes, which can be anatomical, behavioural or both. To investigate any 
effect loss of genomic miR-137 may have, the stock was put through some behavioural tests. 
 
5.1 Drosophila activity monitoring system 
The Drosophila activity monitoring system (DAMS) is a well-used system that 
indirectly measures activity of individual flies across periods of time. The DAMS is an array 
which holds 32 flies in individual 75mm long plastic tubing and passes a perpendicular 
infrared beam through the centre. To measure activity, the number of beam crosses is collated 
across periods of time to provide average activity counts. The data was then manipulated in 
Microsoft excel as described in Chapter 2.7. 
 
5.1.1 Results 
The comparison of w1118 controls and miR-137KO flies show a drastic decrease in 
overall activity in the knockouts (figure 5.1). The circadian rhythm is apparent in both strains, 
with signature peaks at ZT 0 and ZT 12 plus a pre-emptive gradual increase in activity 
throughout the night phase and inverted parabola during the day. Wild types reach 9 and 7 
counts per 5 minutes for the morning and evening peaks respectively, whereas the miR-137 
knockout strain reaches only 3.3 and 4.2 counts per 5 minutes. 
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The bars represent average beam crosses in 5 minutes for each 30-minute slot, averaged from 5 days of monitoring in the Drosophila activity monitoring system (DAMS). ZT 
is Zeitgeber time, which is normalised to 0 for lights on and 12 for lights off. The light and dark bars represent day and night as appropriate. The activity of the w1118 flies 
(n=398) represent a normal circadian pattern of peaks at ZT 0 and ZT12, and a gradual increase in activity in the night period (ZT 16-24). The miR-137KO (n=114) strain 
shows a similar overall pattern but is severely stunted in terms of activity count across the whole 24-hour period. Error bars are standard error.
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Figure 5.1: Actograms of miR-137KO flies and controls across a 24-hour period. 
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Total average activity per day shows a significant difference between control and test 
subjects (figure 5.2). Average beam crosses for w1118 was 727.5 while miR-137KO flies had a 
significantly lower average of 251.1 beam crosses (t-test p-value < 0.01). 
 
Figure 5.2: Average number of beam crosses per 24-hour period. 
The bars represent total number of beam crosses per 24 hours activity count for w1118 (w1118, n=398) and miR-
137KO (mirko, n=114) strains. The data is obtained from 5 days monitoring in the Drosophila activity monitoring 
system (DAMS) by Trikinetics. The w1118 strain had a mean average of 727.5 while miR-137KO was 251.1, a 
significantly different value (T-test p-value < 0.01). Error bars are standard error. 
 
5.2 Video Tracking 
Due to the DAMS inability to determine lack of movement and lack of ability to move, 
the flies were subjected to periods of direct video recording and subsequent computer 
tracking in ImageJ as described in Chapter 2.8. By direct analysis of the fly movement a 
pattern of travel can be determined to verify the use of the beam-pass method of the DAMS. 
It can also be used to calculate velocity for each fly to assess locomotor ability, by calculating 
distance moved per second across the recording. This can then be used to create average 
velocity for each fly and the genotype. 
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5.2.1 Results 
The fly plots for each fly show that their movements frequently cross the mid-point and 
therefore validates the findings and future use of the DAMS array (figure 5.3). Furthermore, 
the knockout flies appear to have “flat” periods which demonstrate a pause or period of 
inactivity that may be indicative of a sleep-like episode. 
 
Figure 5.3: Fly tracking plots of w1118 and miR-137KO. 
The plots represent location for every second across a continuous period of 51 minutes (x-axis). The flies were 
placed in single tubes identical to the Drosophila activity monitoring system (DAMS) by Trikinetics. The vials 
had cornmeal, yeast, agar food at one end (base of plot) and a cotton wool plug at the other (top of plot). The 
dotted red line is representative of where the infra-red beam would pass through the vial and can be seen that 
almost all movement resulted in a crossing of the beam, validating the DAMS use for activity monitoring. As 
can be seen, the w1118 strains have a rhythmic and continuous up and down movement, while the miR-137KO 
strain also traverses the entire tube but has “resting” periods of little or no activity. Two plots for each genotype 
represent two different flies recorded for the same period of time and are included as two to indicate similarities 
and that they are indicative of the genotype as a whole. 
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Analysis of the imagestacks showed a significant velocity change between w1118 and 
miR-137KO strains in both the evening experiment and when both morning and evening 
results were combined (t-test p-values < 0.01) (figure 5.4). The morning results have a greater 
difference in the average velocities than the evening experiment, although there is quite a 
variance in the 7am w1118 velocities potentially explaining the lack of significance found (t-
test p-value > 0.05). The morning period was seen to have different velocities, with the w1118 
controls averaging 1.94mm/s and the miR-137 knockout strain only achieving 1.64mm/s. The 
evening experiment showed the w1118 controls and miR-137KO achieving average velocities of 
1.90 and 1.72 mm/s respectively. 
 
 
Figure 5.4: Mean velocity of w1118 and miR-137KO. 
The am period shows the controls and knockout strain averaging speeds of 1.94 and 1.64mm/s respectively, with 
no significance at 5% value (p-value > 0.05). When subjected to a t-test and subsequent Bonferroni corrections 
as described in Chapter 2.10, the pm period shows a significant difference with the controls and knockout strains 
averaging 1.90 and 1.72mm/s respectively (●: p-value < 0.01). Collectively the results are significant (●●: p-
value < 0.01) with the w1118 control strain achieving a higher velocity of 1.92mm/s compared to the knockout 
strain at 1.69. 
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5.3 Negative geotaxis 
Negative geotaxis is a test used to startle and assess locomotor response of D. 
melanogaster. The test is carried out as outlined in Chapter 2.9 and utilises an innate 
behaviour to run upwards (away from gravity) when prompted. While it is a simple assay, the 
results can be used to infer climbing or general locomotor ability.  
 
5.3.1 Results 
The miR-137KO line did not perform as well as the w1118 stock in the climbing assay. 
There was a clear difference on the percentage of flies reaching each height region, as can be 
seen in the exceedance graph (figure 5.5). In the knockout strain there is a steep decline at the 
start of the plot, indicating a high percentage (27.7%) remained within the starting section 
compared to 8% in the controls.  
 
Figure 5.5: Percentage exceedance of height achieved in a negative geotaxis assay. 
The miR-137KO (n=300) performs poorly compared to the w1118 (n= 295), with a noticeable drop at the start 
(27.7% compared to only 8% in controls). Just 1% of the knockout flies reached the top two sections of the test 
apparatus, compared to 3.4% in controls. 
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 The average climbing ability of the miR-137KO strain was significantly lower than that 
of the w1118 controls (figure 5.6) (t-test p-value < 0.01). The controls averaged 5.38, while 
knockouts reached 3.77. 
 
 
Figure 5.6: Mean height achieved in a negative geotaxis assay 
Average height achieved of w1118 (n=59, repeated x5) and miR-137KO (n=60, repeated x5) in a negative geotaxis 
assay. The assay was separated into 10 different ascending sections that were approximately 2cm wide. The 
control flies averaged 5.38 while the miR-137 knockout flies reached 3.77, which is a significant difference (t-
test p-value < 0.01). 
 
5.4 Sleep-like behaviour  
D. melanogaster is well known for having a sleep-like state comparable to human 
sleep. Like in humans, the fly sleep state is associated with an increased arousal threshold and 
less environment awareness (Cirelli et al. 2005). Another comparison to human sleep is the 
two separate regulatory systems, circadian rhythm and homeostatic regulation. Circadian 
pathways are relatively well understood and enables an organism to anticipate changes in 
environmental factors such as lights on or sunrise (Renn et al. 1999). The homeostatic system 
is less well known and is an area of current interest in scientific communities, responsible for 
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creating an increased need to sleep in response to stimuli or prolonged periods of 
wakefulness, and the cause for the sleep rebound effect seen after sleep-deprivation (Donlea 
et al. 2014). In literature, an inactive period of 5 minutes or more is associated with the above 
criteria and is therefore counted as a period of sleep-like behaviour (Cirelli et al. 2005; Cirelli 
2009; Bushey et al. 2010). The sleep behaviour was calculated using the data from the 
DAMS system, with inactive 5 minutes periods counting as 1 sleep count. The DAMS was 
set up as explained previously in Chapter 2.7. 
 
5.4.1 Results 
The miR-137KO flies have a sleep profile that shows high amounts of sleep throughout 
most of the 24-hour period when compared to controls (figure 5.7). At lights on and lights off 
(07:00 and 19:00 respectively) both the w1118 and miR-137KO strains demonstrate a standard 
circadian sleep profile with lower sleep at the light change times, an inverted parabola of 
sleep during the light phase (07:00 – 19:00), and high sleep and gradual awakening 
throughout the night phase (19:00-7:00). 
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Figure 5.7: 24-Hour sleep profile in w1118 and miR-137KO. 
w1118 (n=410) and miR-137KO (n=102). Sleep amount is shown for 30-minute bins across a 24-hour period, 
calculated using the Drosophila activity monitoring system (DAMS) by Trikinetics and Microsoft excel. The 
wild-type control flies can be seen to have a “standard” profile, with very low sleep amounts recorded at lights 
on and lights off (07:00 and 19:00 respectively), and an inverted parabola during daylight with high sleep 
gradually waking up towards the end of the night period. The knockout flies can be seen to have much higher 
sleep amounts throughout, with a much more stunted drop at the lights on and lights off times. Error bars are 
standard error. 
 
Throughout a 24-hour period, miR-137KO flies were shown to sleep for an average of 
1240.4 minutes, compared to w1118 controls sleeping 816.7 minutes (figure 5.8). This was 
mostly a result of a marked increase in daytime sleep in knockouts, with controls sleeping a 
total of 316.4 minutes and knockouts 602.9 minutes (t-test p-value < 0.01). The total sleep 
during the night period was less severe but still significant (t-test p-value < 0.01), with 
controls sleeping 500.4 minutes and knockouts sleeping 637.5 minutes. 
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Figure 5.8: Total sleep amount in w1118 and miR-137KO. 
w1118 (n=322) and miR-137KO flies (n=77) throughout a 24-hour period and separated day and night 12-hour 
periods. The data is obtained by using the Drosophila activity monitoring system (DAMS) by Trikinetics and 
analysed in Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded on the DAMS, 
and measurements are taken across 5 days and averaged. When subjected to a t-test and subsequent Bonferroni 
corrections as described in Chapter 2.10, the control strain sleeps significantly less in total than the knockout 
strain (●: t-test p-value < 0.01), which is mostly due to a very high sleep amount during the day period for the 
miR-137KO flies. The differences in total sleep is significantly different in both the day and night periods (●● 
and ●●●: t-test p-values < 0.01). Error bars are standard error. 
 
Sleep bout length is the measure of time between first recorded sleep behaviour and the 
next recorded activity in the DAMS system. This can vary from 5 minutes upwards. The 
control flies were found to have an average sleep bout length of 29.7 minutes for a 24-hour 
period, 19.4 minutes during the day, and 47.5 minutes during the night (figure 5.9). 
Comparatively the knockout strain was seen to have much longer sleep bout lengths of 95.6 
minutes over a 24-hour period, 95.6 minutes in the day, and 113.9 minutes at night. Both the 
total 24-hour period and individual day/night are significantly different to controls when 
subjected to a t-test. 
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Figure 5.9: Mean sleep bout length in w1118 and miR-137KO. 
w1118 (n=324) and miR-137KO flies (n=77) throughout a 24-hour period and separated day and night 12-hour 
periods. The data is obtained by using the Drosophila activity monitoring system (DAMS) by Trikinetics and 
analysed in Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded on the DAMS, 
with recordings taken across 5 consecutive days and averaged. One sleep bout is the amount of time between 
first sleep period and when activity was recorded again. When subjected to a t-test and subsequent Bonferroni 
corrections as described in Chapter 2.10, the control strain sleep for significantly shorter periods when compared 
to the knockout strain (●: t-test p-value < 0.01). The differences in sleep bout length is significantly different in 
both the day and night periods (●● and ●●●: t-test p-values < 0.01). Error bars are standard error. 
 
Alongside sleep bout length, the sleep bout number shows significant differences 
between control and knockout strains (figure 5.10). The knockouts have much lower number 
of sleep bouts across both periods of the day, particularly the day period with approximately 
50% the number recorded. The knockouts demonstrate 18.3, 8.8, and 9.5 average sleep bouts 
for 24-hour, day, and night periods respectively. In comparison to 29.8, 18.3, and 12.8 in 
controls which displays significantly higher values. 
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Figure 5.10: Mean sleep bout number in w1118 and miR-137KO. 
w1118 (n=324) and miR-137KO flies (n=77) throughout a 24-hour period and separated day and night 12-hour 
periods. The data is obtained by using the Drosophila activity monitoring system (DAMS) by Trikinetics and 
analysed in Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded in the DAMS, 
with recordings taken across 5 consecutive days and averaged. One sleep bout is the amount of time between 
first sleep period and when activity was recorded again. When subjected to a t-test and subsequent Bonferroni 
corrections as described in Chapter 2.10, the control strain sleep for significantly higher number of sleep bouts 
when compared to the knockout strain (*t-test p-value < 0.01). The differences in sleep bout number is 
significantly different in both the day and night periods (** and ***: t-test p-values < 0.01). Error bars are 
standard error. 
 
To assess the internal circadian clock of the knockout strain, the flies were kept in 24-
hour darkness for an extended period of time. The graphs show that there is a general 
confusion and diminished movement exhibited by both the control and knockout strains, but 
unfortunately no obvious trend seen due to the already minimal activity in the miR-137KO 
flies (figure 5.11). 
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Figure 5.11: Circadian rhythm under constant dark (DD) conditions. 
The lines represent average beam crosses in 5 minutes for each 30-minute slot measured in the Drosophila activity monitoring system (DAMS). A total of 16 males from each 
genotype were entrained to a normal LD rhythm with lights on and lights off at 6am and 6pm respectively.  The experiment measured 1 day in normal 12:12 hour light/dark 
(LD) and following 5 days of constant darkness (DD). The days have been duplicated and put next to previous day to better visualise data, separated by the dotted line and are 
numbered accordingly. Shading denotes light and dark conditions. 
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5.5 Discussion 
5.5.1 Activity 
The hypoactive phenotype is a severe behavioural trait that could provide an important 
aspect of miR-137 function. The 24-hour actograms clearly display minimal activity counts 
and the overall 24-hour activity change is circa 66% less in the miR-137KO strain than 
controls. This behavioural change signifies the importance of miR-137 regulation, as the 
impact is obvious. Despite the overall activity defect, the circadian rhythm is not impacted 
and shows the usual peaks appearing at ZT 0 and ZT 12. There is also the gradual increase 
over night, inverted parabola during the day, and pre-emptive activity before the peaks (Renn 
et al. 1999; Cirelli et al. 2005; Cirelli 2009; Bushey et al. 2010). The biggest difference in 
activity is during the morning peak, which in controls was the highest point and therefore 
most active period of the day. In the miR-137 knockout strain, the morning peak was stunted 
more so than the evening peak, implicating miR-137 in pathways responsible for arousal from 
sleep. 
The DAMS system is a quick and efficient set up that requires minimal researcher input 
and returns a wealth of data. This data can be used in different ways to measure multiple 
behaviours including sleep, circadian rhythm or sleep/wake pattern, and overall activity 
levels. It is also possible to look at specific periods of time, offering the ability to narrow 
down the results. The DAMS is, however, an indirect measure of activity which allows for 
some interpretation. A limitation of the DAMS system is the inability to separate sleep-like 
behaviour and locomotor behaviour, as defects within either or both will present similar data. 
To further define the contribution of sleep and locomotor behaviour to the phenotype, 
additional research is needed. 
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5.5.2 Location and Velocity 
 D. melanogaster have a well-documented circadian pattern with boosted activity at 
periods around light phase changes, resulting in actograms like the one produced by the 
DAMS. These periods offer the biggest comparative difference between the behaviour of 
w1118 and miR-137KO flies and were therefore the times chosen to record to investigate the 
phenotype further. 
Directly tracking fly location against time, as shown in the (figure 5.3), demonstrates an 
obvious difference between the two strains. The data from the DAMS can report a false 
hypoactive phenotype that is due to the DAMS array failing to detect the activity of flies not 
crossing the centre point of the tube. Less overall activity can also be indicative of reduced 
locomotor ability, with more time taken to traverse the length of the tube causing a decrease 
in the count of beam crosses. As can be seen from the video tracking graphs, the control w1118 
flies display a rhythmic behaviour of a continuous up and down pattern. In comparison, the 
miR-137KO flies have stationary periods and sporadic activity. However, despite the obvious 
difference in overall behaviour, neither strain demonstrates significant activity which do not 
cross the centre of the vial. This therefore validates the hypoactive phenotype and the use of 
the DAMS. 
Relating the DAMS and the video tracking is not a fair comparison because of the 
obvious differences between the video recording and DAMS setup. The DAMS were set up 
within a climate-controlled incubator, with a constant temperature of 25C and a fixed light 
source away from the vials. With the video recording, the external temperature was not 
controlled, and the light source was brighter and directly below the flies. There was also more 
background noise in the recordings as there was no protection like being within a closed 
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incubator. These are all factors which could have produced a change in the activity or 
behaviour of the flies between the two experiments. 
The resolution of the video and subsequent editing to a black and white image-stack, 
then analysis in ImageJ software leads to some interference on pixel colour and location. This 
is the reason for the clearly never truly stationary fly, which is an artefact of the subtle light 
changes and fly extremities giving a different black pixel count for each image slice. This is a 
parameter which would be better to control for, but as the fly plots work to adequately locate 
and follow the movement of the fly and is similar in all experiments it is suitable for this 
experiment. A cleaner graph could be achieved with better equipment or software; however 
this is outside the scope of this project and the results shown are sufficient for evaluating the 
severe phenotype change in the miR-137KO flies. 
 
5.5.3 Climbing 
 The negative geotaxis test is a simple but effective assay to assess a variety of 
behavioural factors through climbing ability. However, like the DAMS, the negative geotaxis 
assay is not able to differentiate between more complex behaviours. The miR-137KO are less 
capable of reaching a high section during the 5 second constraint of the test. The difference 
shown is significant when compared in a t-test, and the most obvious cause for achieving a 
lesser height is inability to climb or generally move as well as the controls, indicating a 
locomotor defect. There are other factors such as disordered climbing, lack of proper gravity 
sensing, or inability to cope with the initial stimulation of short but abrupt tapping/shaking. 
The decrease in climbing ability found in the miR-137KO stock was also reported by Chen et 
al. 2014 and taken with the results from video tracking there is a locomotor defect as a result 
of miR-137 LOF. 
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5.5.4 Sleep-like behaviour 
Sleep in D. melanogaster is a widely accepted and understood concept that has been the 
subject of extensive research due to its similarities with human sleep and the organisms ease 
of use as a model. In this project, there is a severe increase in the sleep-like state of the miR-
137KO flies throughout a 24-hour period, particularly noticeable within the day (figure 5.7). 
There are two mechanisms behind sleep, the homeostatic pathways and the circadian 
pathways. The circadian rhythm is the biological clock which dictates the day/night activity 
or sleep cycle within a 24-hour period. The homeostat is the pathway which drives the 
accumulating need to sleep and is responsible for increased tiredness following an interrupted 
sleep period. D. melanogaster have both these pathways just as in humans, with a rebound 
effect of increased sleep following prolonged wakefulness and pre-emptive behaviour 
patterns around the light changes. 
For flies, the circadian rhythm is well documented that in a 12:12 hour light-dark cycle, 
a “wild type” activity graph shows peaks at lights on and lights off, with a gradual build up 
before each. Dark period activity tends to decrease sharply after the evening peak and build 
gradually, whereas during the light period a uniform parabola shape dipping at ZT6 is most 
common (Renn et al. 1999; Cirelli et al. 2005; Cirelli 2009; Bushey et al. 2010). Any changes 
involving the circadian rhythm genes often result in a longer or shorter biological clock, 
altering the shape of the activity graph. While the miR-137KO strain has decreased activity, 
they show the two characteristic peaks of activity when kept to a 12-hour light-dark cycle. To 
investigate possible circadian changes, miR-137KO and w1118 flies were put into 24-hour 
darkness (DD) following entrainment to the standard 12:12 hour light-dark cycle. The low 
activity levels in the miR-137KO strain means it is difficult to perceive the rhythm, but under 
DD conditions there does not appear to be any obvious circadian problem. This visual 
assessment points to the homeostatic sleep regulation pathways as the reason behind the 
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increased sleep amount and not issues within the circadian rhythm. However, further 
investigation is needed to validate such a conclusion. 
 Total sleep in this experiment set is an inverse measure of activity, which can be 
influenced by several factors that are not necessarily sleep-like behaviour. However, the total 
sleep data shown here has an extreme difference across both total 24-hour and daytime 
amount, with a lesser but still significant difference within the night period. The lesser 
difference at night-time is explained with a natural increase in sleep-like behaviour for 
controls during the night phase, as the organisms are diurnal. This increase brings the control 
total sleep amount closer to the threshold of 720 minutes (number of minutes in 12-hour 
period) and therefore dilutes the differences. However, the substantial difference within the 
daytime is a significant feature of miR-137KO behaviour and with such a severe phenotype it 
is unlikely to be caused by other influences. The scale of the phenotype displayed in the 
knockout strain is severe even in comparison to screens performed in previous studies (Cirelli 
et al 2005). 
Sleep bout length is the measure of amount of time spent asleep in each sleep period. 
This is a parameter less easily influenced by behavioural differences as it is more specific 
than simply a measurement of inactivity. The sleep bout length values show a similar trend to 
that of the total sleep amount, where all values are significantly higher in the miR-137KO 
strain compared to the w1118 controls. The difference however is severe in both the 24-hour 
period and the day/night separated data, indicating that the sleep exhibited by the knockout 
strain is because of drastically increased sleep bout lengths. From this data alone, it is unclear 
whether this is due to an increased pressure to stay asleep or an issue within the arousal 
pathways consequently having issues waking up from a sleep period. 
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Average sleep bout number is not such a useful parameter by itself but can be used to 
deepen the understanding gained from total sleep and sleep bout length. Alongside these 
values the increased total sleep shown in the miR-137KO is consolidated and much longer 
bouts of sleep accumulating to the high total sleep value. Furthermore, in controls the sleep is 
much more broken up (lots of short bouts), while the knockout strain displays a very similar 
pattern to the night period with a few long sleep bouts. Long periods of consolidated sleep 
reinforce the lack of waking ability or increase pressure to sleep hypothesized from the other 
graphs. 
 
5.6 Conclusion 
The loss of miR-137 appears to have both a locomotor defect and a severe hyper-sleep 
effect on general fly behaviour. The most obvious result is a severe activity deficit within the 
miR-137KO strain that, when compared to control flies within the same environment, gives a 
very high significance value and visually clear actogram. This outcome enables the rejection 
of the null hypothesis in objective B hypothesis 1 (Chapter 1.8). Initially the phenotype 
needed verification and dissection into different classes of behaviour, and through carefully 
selected experiments with the equipment available to this project the behaviour was 
determined to be both a locomotor defect and sleep-like behaviour issue. 
The verification of the DAMS system via the video recording of peak activity times, 
performed a two-part function where the tracking of the fly within the vial verified the 
DAMS ability to read activity while also providing an ability to effectively measure average 
velocity for both test and control genotypes. With a further experiment of a simple but 
effective negative geotaxis test, the locomotor issue was well defined as a decrease in 
velocity shown by physical recording and lessened climbing ability within a short timeframe. 
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These results enable the rejection of the null hypotheses in objective B hypotheses 2 and 3 
(Chapter 1.8). 
The further investigation of sleep-like behaviour by inversely analysing the activity for 
sleep bouts, stated previously in literature as 5 minutes of inactivity. The result of which 
shows a drastic increase within overall sleep amount as well as average sleep bout length, 
both differences with high statistical significance. This outcome enables the rejection of the 
null hypothesis in objective B hypothesis 4 (Chapter 1.8). The video recording also displays 
that within the knockout flies there were several periods of quiescence where the flies 
appeared to stay still for short periods of time, despite the recordings being taken within the 
“most active” times of the day. This pause is likely a bout of sleep-like behaviour, further 
emphasising the effect of miR-137 on sleep behaviour. 
miR-137 is known to be enriched in the brain of an organism, potentially localising at 
synapse junctions. Many of the targets (both predicted and proven) are major players in brain 
neuron proliferation and maintenance, or vesicle release/signalling pathways. As such, lack of 
finetuning by the microRNA molecule appears to lead to issues that ultimately manifest as 
behavioural phenotypes that could potentially be explained with deficiencies within the 
neuron maintenance and synapse transmission regulation. Further investigation into the 
pathways that are governed by miR-137 would be useful to better decipher the reasons behind 
the phenotype exhibited by the miR-137KO strain. 
It is worth noting that, mainly due to limitations with the DAMS, these experiments 
were conducted solely on male Drosophila and further work to confirm the phenotype in 
females still needs to be completed. 
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6 Phenocopying genomic loss of miR-137  
Further investigation of the effect of miR-137 comes from trying to create the same 
phenotype in a different way. Phenocopying in this way can be a useful tool to further 
diagnose a behaviour and its cause. This study utilised both deficiency stocks from 
Bloomington, and the well published UAS/Gal4 system to attempt to reproduce the hyper-
sleep phenotype to further understand the proper function of the miR-137 gene.  
 
6.1  miR-137 knockout via deficiency strain 
The original miR-137KO stock featured a substitution of the miR-137 gene for a wmW.hs 
insertion. The result of which meant there was no genomic expression of miR-137 at all, and 
the hyper-sleep and hypoactive phenotypes were displayed (chapter 5). As the stock was used 
straight from Bloomington, there was a chance that the results were false positives and a 
result of background mutations which exist within the culture. Normal protocols are to 
homogenise the DNA with the controls by backcrossing so that the DNA sequence except the 
region of interest is highly similar. In this project, many attempts at back crossing proved 
unsuccessful as the red eye marker did not behave normally and proved problematic and time 
consuming. In most other cases, copies of the red eye phenotype exhibit a darker colour in 
homozygous flies that can be easily identified and separated from the lighter eye colour of 
heterozygous individuals. During the repeated attempts to backcross, either no homozygous 
flies emerged due to homozygous miR-137 fatality or the eye phenotype was 
indistinguishable between the two. 
Therefore, to combat the likelihood of false results, the use of a deficiency cross by 
Bloomington was used to provide heterozygous and homozygous knockouts in cooperation 
with the original knockout line. The deficiency genotype was a partial deletion of several 
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genes which included the miR-137 locus and surrounding areas. This would serve as a 
comparison to the original knockout line behaviour, while also being able to provide flies 
which have no miR-137 expression due to heterozygous combinations of both strains. As 
such this provides a method through which to separate the likelihood of background 
mutations causing the sleep behaviour and further investigate homozygous and heterozygous 
knockout of the miR-137 gene. 
The DF(2R)ED2457 D. melanogaster strain was ordered directly from Bloomington 
(stock number: 8915). The stock exhibits a partial deletion on the 2R chromosome arm, that 
removes the coding regions of 25 genes including miR-137 (table 6.1). While not a perfect 
substitution for backcrossing due to other gene implications, presence or absence of the 
hyper-sleep phenotype would indicate that loss of miR-137 is the cause of such behaviour 
change or if the mutations required to enable surviving miR-137 LOF are the cause. 
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Table 6.1: D. melanogaster deficiency stock DF(2r)ED2457 affected genes. 
DF(2R)ED2457 affected genes 
Gene symbol Gene name 
Asph Aspartyl β-hydroxylase 
ATPCL ATP citrate lyase 
casp caspar 
CG30095 - 
CG8370 - 
CG8386 Ubiquitin-fold modifier conjugating enzyme 1 
CG8388 - 
CG8389 - 
CG8397 - 
CG8399 - 
CG8401 - 
CG8405 - 
CG8414 - 
CR43415 long-noncoding RNA 
Dg Dystroglycan 
Jhe Juvenile hormone esterase 
Jhedup Juvenile hormone esterase duplication 
miR-137 microRNA-137 
mRpL34 mitochondrial ribosomal protein L34 
Prosbeta1 Proteasome β1 subunit 
Rho1 - 
Ric Ras-related protein interacting with calmodulin 
Rrp42 - 
SP2353 - 
spin spinster 
 
 
6.1.1 Method 
Stocks that exhibited different combinations of miR-137 knockouts were put into the 
DAMS system as described in Chapter 2.7. The genotypes used were controls, original 
knockout stock, heterozygous knockout stock and deficiency cross, and heterozygous 
deficiency control cross (table 6.2). 
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Table 6.2: Genotypes used in deficiency strain knockout experiment. 
Strain Full genotype Expected miR-137 expression 
wild type w1118; +; + normal ~100% 
mirko w1118; miR-137KO; + none ~0% 
hets w1118; miR-137 KO /+; + ~50% 
df/ko w1118; miR-137 KO /DF(2R)ED2457; + none ~0% 
df/+ w1118; DF(2R)ED2457/+; + ~50% 
 
6.1.2 Results 
Comparison of the two full knockout strains, miR-137KO and DF(2R)ED2457/miR-
137KO, show no significant difference across either the day or night period (table 6.3, figure 
6.1). Both strains exhibit a severe hyper-sleep phenotype (over 1200 minutes per day) that is 
most obvious in the day period compared to w1118 controls. The heterozygous knockouts, 
miR-137KO/w1118 and DF(2R)ED2457/w1118, showed a similarly increased sleep amount total 
at approximately half the increase shown by full knockouts over the 24-hour period. 
However, they separate in behaviour with the DF/+ strain having a significantly higher sleep 
amount during the day (t-test p-value < 0.01) and significantly lower at night (t-test p-value < 
0.01). Full statistics can be found in supplementary information. 
 
Table 6.3: Total sleep amount from deficiency strain knockout experiment. 
 Total sleep amount (min [2dp]) 
Strain 24-hour Day Night 
w
1118
 816.72 316.36 500.36 
hets 966.25 413.75 552.50 
mirko 1240.40 602.91 637.49 
df/+ 996.33 482.61 513.72 
df/ko 1214.74 595.32 619.42 
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Figure 6.1: Total sleep amount in deficiency knockout experiment. 
Average total sleep amount in minutes for w1118 (controls, n=324), miR-137KO flies (mirko, n=77), miR-
137KO/w1118 (hets, n=32), DF(2R)ED2457/w1118 (df/+, n=18), and DF(2R)ED2457/miR-137KO (df/ko, n=31) 
throughout a 24-hour period and separated day and night 12-hour periods. The data is obtained by using the 
Drosophila activity monitoring system (DAMS) by Trikinetics and analysed in Microsoft Excel. One sleep 
period is counted as 5 minutes of no activity recorded in the DAMS, with recordings taken across 5 consecutive 
days and averaged. Genotypes with a sample size of less than 30 were subjected to the Shapiro-Wilk test for 
normal distribution, then all genotypes were compared to the w1118 strain individually using equal or unequal 
variance t-tests, with significant differences (p-value <0.05) signified by ●. The heterozygous knockouts (hets 
and df/+) were compared with a significant difference found in the day and night period separately, signified by 
⁕, though these differences were not significant following Bonferroni corrections as described in Chapter 2.10. 
Full knockouts were also compared but were not significantly different during any period. Error bars are 
standard error. 
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6.1.3 Discussion 
The sleep phenotype shown in the miR-137KO strain is of such a high severity that it 
was unlikely to have been caused by any random background modifier, but without 
backcrossing it still required verification. The results from original knockout stock and 
deficiency strain cross showed that with full loss of genomic miR-137 there is a heightened 
sleep amount. Comparatively, the heterozygous knockouts show an increase that is half as 
severe as the full knockouts. When combining these results, it is not feasible for a 
background mutation to cause the phenotype as it would not be in both stocks. If the effect 
was solely due to a background mutation then the heterozygous knockouts and the full 
knockout/deficiency would be equivalent, each with one copy of the apparent background 
modifier. Instead the full knockout deficiency cross is comparable to the original 
homozygous miR-137KO results, backing up the loss of miR-137 as the cause. Following 
Bonferroni corrections as described in Chapter 2.10, the corrected p-value becomes 
0.000794. All comparisons previously reported as significant meet this new threshold except 
the comparisons of the two heterozygous genotypes in the separated day and night. This loss 
of significance reinforces the similarities between the genotype behaviours. 
The deficiency cross is not a perfect cover for lack of backcrossing, as there are 
multiple genes involved with the deletion. As such, not only is there a lack of miR-137 
expression in these stocks but there are also other genes missing. Some of the genes deleted 
with the deficiency strain have had links to behaviours such as hyperactivity and implicated 
within neural development.  
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6.2 RNA-sponge downregulation of miR-137 
Drosophila melanogaster are a useful model organism for many reasons. One of which 
is the UAS/Gal4 system which has been widely used to manipulate genetic expression in vivo 
for research. The system is explained fully in Chapter 1, but essentially it is a bipartite system 
which composes of a promotor and a coding sequence of choice that are inserted separately 
into the genome of D. melanogaster at embryotic stages. These flies develop and can be 
cultured without much difficulty as the individual components of the system rarely have any 
effect. Upon crossing of the two parent flies, the offspring will have both parts of the system 
and will therefore have the inserted UAS sequence expressed as part of their genomic 
expression. This system can be used to express a copy of a genomic gene sequence or express 
a complementary section of a gene for RNA-interference downregulation. Marker genes such 
as fluorescence proteins or phenotype changes can also be included to validate the success of 
the UAS/Gal4 system. 
For miRNA research, copies of the mature sequence can be inserted as the UAS 
sequence but, due to the small size and function of the miRNA, an RNAi approach is not 
possible. Therefore, to downregulate miRNA expression the UAS insertion encodes a sponge 
construct that binds and captures miRNA molecules, preventing them from functioning as 
normal. The sponge constructs are specific to individual miRNA molecules and can be 
expressed alongside other markers such as fluorescent proteins. 
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6.2.1 Elav-Gal4 
Elav-Gal4 is a Gal4 promotor sequence attached to the genomic embryonic lethal 
abnormal vision gene (elav) gene, which is heavily expressed in the larval and adult CNS. If 
this construct is used alongside the UAS-miR-137-sponge insertion, it will drive the 
expression of the sponge construct alongside elav and downregulate miR-137 expression in 
these areas. Genotypes used in the experiment are shown in table 6.4. 
To help verify the success of the elav-Gal4/UAS-miR-137-sponge system in 
downregulation of miR-137, samples of dissected D. melanogaster brains were subjected to 
DNA extraction and subsequent comparative qPCR to measure miR-137 expression. The 
procedure for extraction, quantification, reverse-transcription, and qPCR was carried out as 
described in Chapter 2.3-4. 
 
Table 6.4: Genotypes used in elav driven knockdown experiment. 
Strain Full genotype Description 
w1118 w1118; +; + ‘Wild type’ control flies 
mirko w1118; miR-137KO; + miR-137 knockout flies 
Elav/sponge w*; +; elav-Gal4 / UAS-miR-137-sponge 
miR-137 downregulation 
within the CNS 
Elav/+ w*; +; elav-Gal4 / + Gal4 heterozygous control 
Sponge/+ w*; +; UAS-miR-137-sponge / + UAS heterozygous control 
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6.2.2 Brain regions 
Utilising different genes to attach the Gal4 construct enables a better targeted 
expression of the sponge construct and therefore more precise area of miR-137 knockdown. 
D. melanogaster have a brain region known as the mushroom body that has been compared to 
the mammalian cerebral cortex and been linked to sleep regulation (Sitaraman et al. 2015). 
Another region of the D. melanogaster brain is the fan-shaped body, which is close in 
proximity to the mushroom body and similarly has been linked to sleep regulation in flies 
(Liu et al. 2012). Because of miR-137 LOF on sleep behaviour and known high brain 
expression, two different Gal4 promotors were used to evaluate precise miR-137 knockdown 
within these regions. Genotypes used in the experiment are shown in table 6.5. 
The stocks used were GMR23E10-Gal4 (#49032) and R13F02-Gal4 (#69908) from 
Bloomington donated by Janelia farms. GMR23E10 causes expression near AstA-R1 which 
is highly localised to the fan-shaped body and nearby dopaminergic neurons, while R13F02-
Gal4 expresses strongly within the mushroom bodies (Jenett et al. 2012). 
 
Table 6.5: Genotypes used in brain region knockdown experiment. 
Strain Full genotype Description 
w1118 w1118; +; + ‘Wild type’ control flies 
mirko w1118; miR-137KO; + miR-137 knockout flies 
MB/sponge 
w*; +; R13F02-Gal4 / UAS-miR-137-
sponge 
miR-137 downregulation within 
the mushroom body 
FB/sponge 
w*; +; GMR23E10-Gal4 / UAS-miR-
137-sponge 
miR-137 downregulation within 
the fan-shaped body 
MB/+ w*; +; R13F02-Gal4 / + Gal4 heterozygous control 
FB/+ w*; +; GMR23E10-Gal4 / + Gal4 heterozygous control 
Sponge/+ w*; +; UAS-miR-137-sponge / + UAS heterozygous control 
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6.2.3 Results 
Comparative qPCR of brain samples was conducted as described in Ch2.5, with the 
samples run in duplicate on a 48-well plate to measure comparative expression values of miR-
137 and housekeeping gene rps17. In total there were 3 separate qPCR attempts with the 
same methodology, and the results repeatedly demonstrated that no expression levels of 
mature miR-137-3p were detected in the miR-137KO sample. The standard curve and 
calculations for PCR efficiency, R2 value, and slope gradient were automatically calculated 
by the Applied Biosystems Step-one software V2.3 (table 6.6). The calculated values for 
these parameters were not within applied biosystems recommended ranges and therefore the 
validity of the comparative gene expressions is questionable (table 6.6). The step-one 
software does allow for manual inclusion or exclusion of data points which can then be 
recalculated and offer better values for efficiency, R2 and slope; however, as the samples 
were run in duplicates only this was not deemed suitable to provide clear results. Unaltered 
(fully included) gene expression graphs and standard curves are included in supplementary 
information (Chapter 12). 
 
Table 6.6: Comparative qPCR efficiency, R2, and slope results 
qPCR Experiment Number Standard Curve Slope R2 Value PCR efficiency 
Recommended values -3.3 > 0.99 100% 
1: miR-137 -3.59 0.92 91.66% 
1: rps17 -4.25 0.97 71.91% 
2: miR-137 -5.02 0.85 58.15% 
2: rps17 -4.33 0.97 70.17% 
3: miR-137 -3.70 0.90 86.99% 
3: rps17 -3.59 0.98 92.42% 
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Flies with the sponge construct expressed under elav control demonstrate a hyper-sleep 
phenotype that is like that of the miR-137KO flies (table 6.7; figure 6.2), but still significantly 
lower over the 24-hour period and during the day (p-values of 0.00017 and 3.57517E-07 
respectively). The control strains elav/+ and sponge/+ were largely comparable to the w1118 
flies, with a small decrease in 24-hour elav/+ sleep (p-value = 0.046). Full t-test results can 
be found in the supplementary section. 
 
Table 6.7: Total sleep amount from elav driven knockdown experiment. 
 Total sleep amount (minutes [2dp]) 
Strain 24-hour Strain 24-hour 
w1118 816.72 316.36 500.36 
mirko 1240.40 602.1 637.49 
elav/sp 1151.53 516.80 634.73 
elav/+ 762.07 356.53 405.53 
sponge/+ 811.56 344.19 467.38 
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Figure 6.2: Total sleep amount in elav downregulation experiment. 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=324), miR-137KO (n=77), elav/sponge (n= 45), sponge/+ (n = 16), and elav/+ (n= 15) flies were put into a 
Drosophila activity monitoring system (DAMS) by Trikinetics and the data was analysed in Microsoft Excel. 
One sleep period is counted as 5 minutes of no activity recorded in the DAMS, with recordings taken across 5 
consecutive days and averaged. Genotypes with sample sizes of less than 30 were subjected to the Shapiro-Wilk 
test for normality, and then all genotypes were compared to the w1118 strain individually using equal or unequal 
variance t-tests, with significant differences (p-value <0.05) signified by ●. The elav/sponge strain was 
compared to the miR-137KO strain in the same manner and significant differences are signified by ◊. Following 
Bonferroni corrections as described in Chapter 2.10, the difference shown across the 24-hour period between the 
elav/+ control and the w1118 strain does not meet the new threshold. Error bars are standard error. 
 
Expression of the UAS-sponge construct within the specific subregions of the brain 
produced similar effects on the total sleep, with an overall increase in sleep amount per 24 
hours (figure 6.3; table 6.8). The amount of sleep is around halfway between the w1118 flies 
and the miR-137KO flies across all periods. The heterozygous control strains are comparable 
to the w1118 control flies, with any significant differences being a reduction in total sleep 
amount. Full t-test results can be found in the supplementary information. 
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Figure 6.3: Total sleep amount in brain region downregulation experiments. 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=324), miR-137KO (n=77), mb/sponge (n= 15), fb/sponge (n= 16), sponge/+ (n = 16), mb/+ (n = 16), and fb/+ 
(n= 16) flies were put into a Drosophila activity monitoring system (DAMS) by Trikinetics and the data was 
analysed in Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded in the DAMS, 
with recordings taken across 5 consecutive days and averaged. Genotypes with sample sizes of less than 30 were 
subjected to the Shapiro-Wilk test for normal distribution, and then all genotypes were compared to the w1118 
strain individually using equal or unequal variance t-tests, with significant differences (p-value <0.05) signified 
by ●. The fb/sponge and mb/sponge strains were compared to the miR-137KO strain in the same manner and 
significant differences are signified by ◊. Error bars are standard error. 
 
Table 6.8: Total sleep amount from brain region knockdown experiments. 
 Total sleep amount (minutes [2dp]) 
Strain 24-hour Day Night 
w1118 816.72 316.36 500.36 
mirko 1240.40 602.91 637.49 
sponge/+ 811.56 344.19 467.38 
fb/sp 1037.00 441.13 595.88 
fb/+ 811.44 319.50 491.94 
mb/sp 1035.07 470.00 565.07 
mb/+ 725.06 286.06 439.00 
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6.2.4 Discussion 
The comparative qPCR results repeatedly demonstrated a complete loss of miR-137 
expression within the knockout strain, reinforcing the work done in chapter 3. However, the 
other data collected did not meet the recommended requirements (efficiency, R2, and standard 
curve slope) and should not be considered. Additionally, results had large standard deviations 
and expected outcomes were not found, such as the heterozygous KO which should have 
shown approximately half the expression of miR-137 as the controls further reducing 
confidence in the results. The method for the expression analysis was conducted as explained 
in chapter 5.2 and was designed to enable an investigative approach for several genotypes. 
The number of genotypes put onto one 48-well plate meant that duplicate samples were used 
instead of triplicates so they could all fit into one run. Further areas for complications include 
the intricate process for microRNA extraction using phenol-chloroform and separate 
procedures for amplification of the housekeeping gene (poly-adenosine primers for total 
cDNA) and the specialised microRNA amplification kits. There is also the potential for 
genomic differences across individual flies, with sponge or overexpression constructs having 
differing levels of effectiveness. Lack of robust results ultimately meant that the Oregon 
control strain and miR-137 overexpression strain were not investigated further as it was 
impossible to evaluate the expression levels. The overexpression strain was put through a 
pilot test for altered behaviour patterns and did not appear to display any phenotype, so there 
was no reason to believe the constructs caused an expression change. This effect was not 
mimicked in the sponge regulated knockdown as there was a phenotype difference when 
compared to the w1118 wild-type and the heterozygous construct controls. An obvious 
improvement to the qPCR method would be to drop the additional phenotypes and focus on 
using triplicates to increase validity before further trouble shooting. There was also no 
randomisation of sample location within the plate, which could have allowed machine errors 
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to occur across all runs without knowing. Utilising a different method of microRNA 
extraction, such as commercially available silica-based bind-wash-elute columns, may also 
increase the effectivity of extraction and reduce contaminants being taken through to the 
reverse transcription and amplification process. Should the comparative expression approach 
be discarded, it is also possible to purchase known quantity solutions that can be used as the 
compared sample to produce actual values of the expression in each sample which may have 
produced more finite results. 
The miR-137KO strain was donated to BDSC in 2014 by Stephen Cohen (A*STAR 
institute of molecular and cell biology). Since this time, the stocks will have been self-
propagating under the care of the BDSC with a new generation approximately every 2 weeks. 
With a phenotype of this severity (Chapter 5), there is a possibility that background modifiers 
will have occurred that help the organism cope with miR-137 LOF. This could be a random 
mutation within a gene that alleviates the strain on the individual’s biology. If this partially 
rectified any of the health phenotypes found in Chapter 4, then these flies were more likely to 
reproduce and after several generations most of the stock would contain this modifier. If 
these modifiers were the cause of the sleep phenotype then miR-137 is not likely to be 
directly responsible, and therefore additional checking was needed to validate the importance 
of miR-137. 
The experiments had varying degrees of success in replicating the phenotype of miR-
137KO strain. The use of heterozygous controls successfully validates the phenotype seen is as 
a result of the combined UAS/Gal4 construct, as no controls were significantly higher that 
would look to cause a false representation. When taking into consideration that the miR-
137KO strain has a complete genomic loss of miR-137, the sleep amount seen when the 
sponge construct downregulates the miRNA in any of the experiments is impressive. The 
highest amount of sleep per 24-hour period was in the elav-Gal4 flies. Expressing the miR-
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137-sponge in just the FB and MB also demonstrated a significantly higher sleep per 24-
hours. Since these experiments targeted specific regions, this infers these brain regions are 
part of the mechanism through which miR-137 regulates proper sleep function. Following 
post-hoc Bonferroni corrections, all significance tests meet the new conservative p-value with 
the exception of the elav/+ control and the wild-type across the 24-hour period. This benefits 
the experiment by removing the significant difference between controls, further reinforcing 
the effect shown by the combined UAS and Gal4 constructs. 
 
6.3 Conclusion 
The excessive sleep phenotype was also demonstrated in a heterozygous cross of the 
original knockout stock and another deficiency strain, which reaffirms that miR-137 LOF is 
the cause of the behaviour. This outcome enables the rejection of the null hypothesis in 
objective C hypothesis 1 (Chapter 1.8). 
Downregulation of the miRNA through the UAS/Gal4 construct implicates the function 
of miR-137 as within the CNS, and even more specifically related to the homeostatic sleep 
control by the FB and MB brain regions. These are regions of interest related to many higher 
cognitive functions like learning and memory in flies, and speech in humans. These results 
enable the rejection of the null hypotheses in objective C hypotheses 2, 3, and 4 (Chapter 
1.8). Altogether, these results provide a putative mechanism and brain region for the sleep 
phenotype in the miR-137KO strain. 
Unfortunately, the qPCR was not successful in producing robust gene expression data, 
though it consistently confirmed the lack of miR-137 expression in the original knockout 
strain. Further investigation of methods is needed. Ultimately qPCR data would have been 
useful to establish the quantitative effect of the sponge knockdown, however the use of 
143 
 
heterozygous construct controls and phenotype changes validates that the sponge system 
causes a behavioural change through miR-137.  
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7 Recovery of normal sleep in miR-137KO 
To better evaluate the mechanisms behind the loss of miR-137 leading to the phenotype 
exhibited by the flies, attempts to rectify the underlying cause of the behaviour were 
undertaken. By attempting to reintroduce miR-137 expression, in specific regions of the CNS 
or utilising pharmaceuticals to cure the symptoms this chapter aims to provide additional 
information through which to hypothesise on the mechanisms linking miR-137 to sleep and 
locomotor defects. 
 
7.1  Reintroduction of miR-137 expression 
The genomic excision of the miR-137 gene led to a complete loss of the gene 
throughout the flies, which were then shown to have sleep and locomotor defects (Chapter 5). 
To further investigate this, reintroduction of miR-137 gene expression through use of the 
UAS/Gal4 system to the miR-137KO stock was conducted. As the normal expression pattern 
for miR-137 was in the brain, one experiment aimed to reintroduce expression within the 
CNS in a hope to reverse the phenotype. As the main phenotype expressed was a severe sleep 
defect, another set of experiments were to reintroduce expression within the fan-shaped body, 
a specific sub region of the brain related to sleep regulation (Donlea et al. 2011; Liu et al. 
2012; Pimental et al. 2016).  
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7.1.1.1 CNS expression 
Utilising elav-GAL4 driven UAS-miR-137, an attempt to reintroduce miR-137 
expression to the CNS of D. melanogaster with miR-137KO genotype. The embryonic lethal 
abnormal vision gene (elav) is heavily expressed in the larval and adult CNS, and with it will 
also express the UAS insertion of the coding sequence for miR-137. Data available from 
FlyAtlas (available online: http://flyatlas.gla.ac.uk/) shows the Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM) value of the gene expression and the enrichment 
score. The enrichment is a measure of the abundance of a gene in a particular tissue relative 
to that in the whole fly and can be used to determine whether the expression of a particular 
gene is tissue-specific or not. The highlighted figures are the highest enrichment levels which 
show a particularly specific elav expression across the CNS, head, eye, and Thoracico-
abdominal ganglion (table 7.1). 
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Table 7.1: Elav gene expression location and enrichment. 
Gene: elav Adult Male Larval 
Tissue FPKM SD Enrichment FPKM SD Enrichment 
Whole body 5.62 0.38 1 2.15 0.36 1 
Head 21.5 1.49 3.83 - - - 
Eye 14.2 3.22 2.53 - - - 
Brain / CNS 25.48 0.86 4.53 42.54 9.92 19.79 
Thoracico-
abdominal ganglion 
14.36 2.35 2.56 - - - 
Crop 4.87 0.09 0.87 - - - 
Midgut 2.34 0.09 0.42 0.86 0.23 0.4 
Hindgut 3.91 0.41 0.7 1.21 0.24 0.56 
Malpighian Tubules 2.35 0.4 0.42 1.31 0.36 0.61 
Fat body 1.81 0.52 0.32 2.1 0.35 0.98 
Salivary gland 2.46 0.27 0.44 0.71 0.17 0.33 
Heart 
   
- - - 
Trachea - - - 1.98 0.25 0.92 
Ovary - - - - - - 
Virgin Spermatheca - - - - - - 
Mated Spermatheca - - - - - - 
Testis 0.76 0.31 0.14 - - - 
Accessory glands 2.11 0.35 0.38 - - - 
Carcass 2.66 0.52 0.47 3.62 0.51 1.68 
Rectal pad 2.66 0.34 0.47 - - - 
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7.1.1.2 Fan-shaped body brain expression 
The stock used was GMR23E10-Gal4 (#49032) from the BDRC donated by Janelia 
farms. GMR23E10 causes expression near astA-R1 proteins which are highly localised to the 
fan-shaped body and nearby dopaminergic neurons (Jenett et al. 2012). Data available from 
FlyAtlas (available online: http://flyatlas.gla.ac.uk/) highlights the highest enrichment levels, 
which show a particularly specific astA-R1 expression across the CNS, head, eye, and 
Thoracico-abdominal ganglion (table 7.2). Reports from Janelia demonstrate, through 
expression of a fluorescence protein, that the Gal4 construct drives expression specifically in 
the fan-shaped body and some projecting neurons (figure 7.1). 
 
 
Figure 7.1: Expression of GMR23E10-Gal4 in the D. melanogaster brain. 
Image obtained from Janelia research centre online reports (available from: https://www.janelia.org/). Image 
shows the results of a fluorescence protein UAS insertion driven by GMR-23E10-Gal4 construct. The brain is 
shown in magenta, and the fan-shaped body and projecting neurons in green (Jenett et al. 2012). 
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Table 7.2: AstA-R1 gene expression location and enrichment. 
Gene: astA-R1 Adult Male Larval 
Tissue FPKM SD Enrichment FPKM SD Enrichment 
Whole body 1.45 0.26 -1 0.09 0.04 -1 
Head 8.58 0.86 4.29 - - - 
Eye 8.61 1.43 4.3 - - - 
Brain / CNS 9.99 1.53 5 2.26 0.26 1.13 
Thoracico-
abdominal ganglion 
5.16 0.05 2.58 - - - 
Crop 0.08 0.04 -1 - - - 
Midgut 0.07 0.03 -1 0.01 0.02 -1 
Hindgut 0.02 0.03 -1 0.01 0.02 -1 
Malpighian Tubules 0.05 0.06 -1 0 0 -1 
Fat body 0 0 -1 0.13 0.13 -1 
Salivary gland 0.12 0.09 -1 0.05 0.07 -1 
Heart 
   
- - - 
Trachea - - - 0.07 0.05 -1 
Ovary - - - - - - 
Virgin Spermatheca - - - - - - 
Mated Spermatheca - - - - - - 
Testis 0.04 0.06 -1 - - - 
Accessory glands 0.02 0.03 -1 - - - 
Carcass 0.55 0.23 -1 0.34 0.15 -1 
Rectal pad 0.02 0.02 -1 - - - 
 
7.1.2 Method 
Two stocks of heterozygous miR-137KO with either UAS or Gal4 construct were 
crossed and the offspring were selected against genetic balancers to identify flies which have 
both endogenous miR-137 knockout and both parts of the UAS/Gal4 system. These flies 
should therefore have the inserted copy of miR-137 expressed in the regions driven by the 
gene with Gal4 attached to it. Control strains with heterozygous copies of all insertions 
individually were also assessed in case any phenotype shown is a result of the insertion not 
the expression of the construct (table 7.3). Once these adults were collected, they were put 
through the DAMS system and the data was analysed as described in Chapter 2.7.  
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Table 7.3: Genotypes used in genetic recovery experiment. 
Genotype Description 
w1118 Control strain 
Mir-137KO miR-137 knock out strain 
elav Expressed Elav-Gal4 driven expression of UAS-miR-137 in the CNS 
FB Expressed GMR23E10-Gal4 driven expression of UAS-miR-137 in the 
fan-shaped body and projected neurons 
FB/+ Heterozygous GMR23E10-Gal4 control strain 
elav/+ Heterozygous elav-Gal4 control strain 
UAS-miR-137/+ Heterozygous UAS-miR-137 control strain 
 
 
7.1.3 Results 
The total amount of sleep (minutes) across a full 24-hour period show a slight decrease 
in both recovery attempts (figure 7.2, table 7.4), but only the FB expressed is significantly 
different from the miR-137KO strain (p-value < 0.05). All controls are similar to the control 
w1118 strain, with the exception of elav/+ which is significantly lower (p-value < 0.01). 
During the 12-hour day period, neither of the recoveries show a significant difference to the 
miR-137KO stock but the controls elav/+ and UAS-miR-137/+ are different from the w1118 
strain (p-values of < 0.01 and < 0.05 respectively). During the night phase, both recovery 
strains slept for significantly less time compared to the miR-137KO (p-values of < 0.01). 
However, they were not significantly different from the control w1118 flies. The full statistics 
can be found in the supplementary information. 
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Figure 7.2: Total sleep amount in miR-137 recovery experiments. 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=324), miR-137KO (n=77), elav expressed (n= 4), FB expressed (n = 5), elav/+ (n= 15), FB/+ (n = 16), and 
UAS-miR-137/+ (n = 16) flies were put into a Drosophila activity monitoring system (DAMS) by Trikinetics 
and the data was analysed in Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded 
in the DAMS, with recordings taken across 5 consecutive days and averaged. Genotypes with sample sizes of 
less than 30 were subjected to the Shapiro-Wilk test for normality, and then all genotypes were compared to the 
w1118 strain individually using equal or unequal variance t-tests, with significant differences (p-value < 0.05) 
signified by ●. Both recovery strains were compared to the miR-137KO strain in the same manner and significant 
differences are signified by ◊. Post-Hoc Bonferroni corrections reduced the critical threshold p-value to 
0.000794, and several comparisons did not meet this new value. These were: the FBrecov strain compared to the 
KO strain across 24 hours and the night period, the elavrecov strain compared to the KO in the night period, the 
uasmir137/+ control against the wildtype across the day and night periods, the elav/+ and mb/+ controls against 
the wildtype across the 24 hours period. Error bars are standard error. 
 
Table 7.4: Total sleep amount from miR-137 recovery experiments. 
Genotype 24hr sleep (min) Day sleep (min) Night sleep (min) 
w1118 816.7205 316.3602 500.3602 
Mir-137KO 1240.403 602.9091 637.4935 
elav Expressed 1133.25 594.5 538.75 
FB Expressed 1097.2 553.4 543.8 
FB/+ 811.4375 319.5 491.9375 
elav/+ 762.0667 356.5333 405.5333 
UAS-miR-137/+ 817.625 284.375 533.25 
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7.1.4 Discussion 
Assumed reintroduction of miR-137 expression within the CNS (elav recovery) appears 
to have little effect recovering the hyper-sleep phenotype demonstrated in the miR-137KO 
strain (figure 7.2). However, expression in the fan-shaped body shows a significant decrease 
in the total sleep amount exhibited in 24-hour period (p-value < 0.05). Furthermore, this was 
due to a slight decrease during the daytime total sleep and a significant decrease in the night 
period, which was not significantly different to night-time sleep in the w1118 controls. The 
most exaggerated phenotype change in the knockout flies is an increase in sleep during the 
day phase. This could be due to a saturation effect at night, where there is a finite number of 
minutes available in the timeframe, so it is not possible to physically sleep more at this time. 
In this experiment, the daytime sleep for both recovery strains were not significantly different 
from the knockout strain indicating that either the recovery was not successful or that 
reintroduction of the miRNA into just these regions is insufficient for normal behaviour. 
There was an effect in the night phase exhibited by both recovery strains, with significant 
decreases compared to the knockout flies and no significant difference when compared to the 
controls. 
The fan-body is a region of the D. melanogaster brain, which is linked to sleep 
regulation, specifically that of the homeostatic control (Donlea et al. 2011; Liu et al. 2012; 
Pimental et al. 2016). Activation of the region induces a “need to sleep” and is signalled by 
the lack of dopamine expression (Liu et al. 2012). Interestingly, the method of activation 
involves function of potassium voltage gated channel shaker, and subunits hyperkinetic and 
shab in the fly, orthologs of human KCNA/B protein channels. These channels are well 
documented to have implications in signal transduction and development of neurological 
symptoms (Somers et al. 2010; Askland et al. 2012; Imbrici et al. 2013). In addition, several 
of the shaker related genes are predicted binding targets for miR-137 (Agarwal et al. 2015). 
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Hyperactivation of the fan-body, utilising the same GMR23E10-Gal4 construct to drive 
increased expression of the depolarizing Na+ channels, resulted in an exaggerated hyper-
sleep phenotype (Ni et al. 2019), like that displayed by the miR-137KO strain. Cumulatively, 
these results provide a potential hypothesis for the relevance of miR-137 regulation of sleep 
and the onset of neurological disorders. 
Correction using the post-hoc Bonferroni method (described in Chapter 2.10) produced 
a corrected p-value of 0.000794 which meant several comparisons were no longer significant. 
Reinforcing the project results was loss of significant differences between several of the 
control strains and the wildtype flies: elav/+ and mb/+ across the 24-hour period, and 
uasmir137/+ across both day and night periods. The new threshold also meant that FB-
recovery during the 24-hour period and the night period, and the elav-recovery during the 
night period are not significantly different from the KO strain. This outcome removes the 
success of the recovery attempts, though as discussed in Chapter 2.10, the Bonferroni 
correction method is highly conservative. Visual representation demonstrates a difference 
between the original KO strain and these recovery attempts (figure 7.2), presenting an 
argument for further evaluation into false negatives (Type II errors) at such a stringent level. 
Furthermore, due to the random chance of offspring having the right genetic insertions 
(identified through visual lack of phenotype markers), the numbers of offspring available for 
the DAMS at the correct time was very limited. This does provide a degree of error when 
assessing phenotype behaviour as this can be a very flexible measure. Additionally, the 
expression level of the insertion is unknown due to lack of ability to perform the tests in these 
areas. The inclusion of heterozygous controls, as well as the original knockout and control 
strains, work well to evaluate the likelihood of the phenotype changes being as a result of the 
combined UAS/Gal4 constructs. 
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7.2  Pharmacological treatment 
In humans, sleep abnormalities are usually treated through pharmacological chemicals 
that influence parts of the brain. These medicines treat only the symptom, such as too much 
or too little sleepiness, and not the underlying cause. As the miR-137KO strain exhibits a hyper 
sleep phenotype, experiments using some pharmacological chemicals were conducted to see 
if the symptom of miR-137 loss can be treated in D. melanogaster. Furthermore, relatable 
phenotype changes due to the treatment can help identify abnormal pathway functionality. 
 
7.2.1 Caffeine 
Caffeine is an example of a widely used substance which is taken to alleviate feelings 
of tiredness and energise the individual. Commonly taken as coffee or within energy drinks 
for its stimulating effect, the compound acts on the CNS competing with adenosine molecules 
(Wu et al. 2009). Adenosine binding in the brain results in a depressive effect and subsequent 
drowsiness or fatigue. In the presence of caffeine molecules, the binding sites for adenosine 
are inhabited by caffeine compounds with an effect that ultimately leads to a stimulating 
effect (Lehnig et al. 1992; Wu et al. 2009). Caffeine has been linked to hyperactivity, 
sleeplessness, and over time chronic administration can cause an increase in adenosine 
receptors (Lehnig et al. 1992).  
As miR-137KO flies exhibited a hyper-sleep phenotype, an experiment of adding 
caffeine to their food was conducted to evaluate the recovery of normal behaviour. Initially 
the dose of caffeine was 0.5mg/mL, as was done in a previous study (Wu et al. 2009). 
However, this concentration produced little to no effect and after further investigation the 
study used a different food type that flies tend to eat in larger volumes and therefore the 
concentration was doubled to 1mg/mL. 
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7.2.1.1 Method 
Caffeine was administered for 5-7 days to 8 w1118 and 8 miR-137KO adult flies before 
being put into the DAMS system alongside 8 controls for each genotype. Pupa were removed 
from a normal food vial and moved into a vial containing food containing either caffeine 
dosed at 1mg/mL. After the flies eclosed and reached the correct age, they were added to the 
DAMS with drugged food. The DAMS and subsequent analysis were conducted as described 
in Chapter 2.7. 
 
7.2.1.2 Results 
Addition of 1mg/mL caffeine to food of the flies caused a significant decrease in total 
sleep amount for the w1118 strain compared to controls across the 24-hour period (p-value < 
0.05), which is the combination of no day time effect (p-value > 0.05) and a significant 
decrease in the night period (p-value < 0.01). The miR-137KO strain exhibited contradictory 
results of a significant increase during the day phase (p-value < 0.05). Like the w1118, the 
knockout strain displayed a significant reduction of sleep in the night period (p-value < 0.05), 
however the overall change was an insignificant slight increase across the 24-hour period 
(table 7.5; figure 7.3). 
 
Table 7.5: Total sleep amount from chronic caffeine recovery experiment 
 Average sleep amount (minutes [1dp]) 
Experiment 24-hour Day period Night period 
Normal: W1118 784.1 251.0 533.1 
Normal: miR-137KO 1257.6 588.0 669.6 
Caffeine: W1118 593.3 215.1 378.1 
Caffeine: miR-137KO 1286.3 643.3 643.0 
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Figure 7.3: The effect of chronic caffeine treatment on total sleep amount 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=8), miR-137KO (n=8), w1118 with caffeine (n=8), and miR-137KO with caffeine (n=8) flies were put into a 
Drosophila activity monitoring system (DAMS) by Trikinetics and the data was analysed in Microsoft Excel. 
One sleep period is counted as 5 minutes of no activity recorded in the DAMS, with recordings taken across 5 
consecutive days and averaged. Experiments were compared between the treated and non-treated flies 
individually using t-tests. In the 24-hour period the w1118 flies showed a significant decrease in total sleep (●1: 
p-value < 0.05), while the miR-137KO flies showed a significant increase during the day period (◊1: p-value < 
0.05. Both genotypes showed a significant decrease in total night-time sleep amount (●2: p-value < 0.01, ◊2 p-
value < 0.05). Following post-hoc correcting for Type I errors using the Bonferroni method as described in 
chapter 2.10, the caffeine difference exhibited in the wildtype flies across the 24-hour period and the difference 
in the KO strain during the day and night periods did not meet the corrected p-value of 0.00833. Error bars are 
standard error. 
 
7.2.1.3 Discussion 
The use of caffeine as a stimulant to promote wakefulness is a normal occurrence in 
human daily life, and as such the mechanism of its effect is largely understood. The control 
flies demonstrated an overall decrease in sleep amount, particularly within the night phase 
when there is more average sleep volume to be disrupted. This data reinforces numerous 
other studies which show caffeine intake has an immediate sleep deprivation effect in 
Drosophila melanogaster controls. Potdar et al. (2018) fed caffeine to control strain w1118 in 
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the day or night exclusively at concentrations of 0.5mg/ml and 1mg/ml as was in this study, 
however only for acute periods of time. They reported an immediate decrease in average 
sleep amount by ~50% in response to 0.5mg/ml treatment, and ~20% in response to 1mg/ml 
treatment which they explained as likely due to less food consumption because of the high 
caffeine content. In 2016, Nall et al. chronically treated flies with a range of caffeine 
concentrations; 0.2mg/mL, 0.5mg/mL, and 1mg/mL mixed into sucrose-agar food. They 
discovered that the increasing concentrations positively correlated with a decrease in night-
time sleep, with the highest concentration reducing sleep amount by 30% which is 
comparable to this study.  The increase of sleep deprivation correlating with the increase of 
caffeine concentration was also shown in a study by Andretic et al. (2008). The sleep 
depriving effect of caffeine was not displayed in the miR-137KO strain, which showed an 
overall decrease that is the reverse effect shown in the control genotype. It is important to 
note that this experiment used solely male flies, and the effect of chronic caffeine treatment 
on females remains to be confirmed. 
Using caffeine to treat flies with excessive sleep amounts has provided an interesting 
outcome in flies lacking miR-137, which subsequently creates a putative hypothesis of 
adenosine pathway dysfunction or downstream mechanisms regulating requirement. The 
expected decrease in sleep in the night period, while not reversing the knockout phenotype 
completely, does suggest that the caffeine may be having the expected effect. However, this 
is offset by an increase within the day period that is in contradiction to what should happen 
upon introduction of a stimulant and infers a potential overpowering sleep drive under the 
homeostatic control. This sleep-rebound effect was exhibited by flies in the Potdar et al. 
(2018) study, where removal of caffeine stimulation by moving to non-drugged food 
produced increased daytime sleep. Correcting for Type I errors produced by multiple t-tests 
meant that the effect exhibited by the KO strain in the presence of caffeine did not meet the 
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new threshold level calculated using the Bonferroni method as described in Chapter 2.10. 
Nonetheless, this result still demonstrates that chronic caffeine dosage did not cause the 
expected recovery of the KO sleep phenotype. Similarly, the overall 24-hour effect of 
caffeine on the wildtype flies does not meet the new 0.00833 significance cut-off, though the 
night period effect remains significant even after such conservative corrections. 
 
7.2.2 3-iodo-tyrosine and lithium chloride 
Dopamine is a neurotransmitter responsible for promoting wakefulness and is 
responsible for the morning peak of activity exhibited in D. melanogaster (Kume et al. 2005). 
The phenotype displayed by the miR-137KO strain exhibits a somewhat stunted morning peak 
compared to controls (Chapter 5.1), along with the excessive sleep and decrease motility, 
these are symptoms synonymous with Drosophila research into dopamine deficiencies 
(Reimensperger et al. 2011). 3-iodo-tyrosine (3IY) is an inhibitor of dopamine synthesis and 
has been found in fruit flies to promote sleep by lowering dopamine levels (Catterson et al. 
2010). While counterproductive in reversing the hyper-sleep phenotype, an initial hypothesis 
for the action of miR-137 knockout promoting sleep is the desensitization of the dopamine 
signalling pathway due to increases in miR-137 predicted targets such as dopamine receptors 
(Dop1r1, Dop1r2, d2r), and tyrosine hydroxylase ortholog pale (ple) (Jia et al. 2016; 
Agarwal et al. 2018). An increase in these genes could increase the amount of dopamine 
synthesized and the number of receptors to pick up the molecules, resulting in overexcited 
neurons and a resulting desensitization as the larvae develop. To test this hypothesis, 3IY was 
given to flies throughout development to try and prevent this overload. A chosen dosage of 
0.5mg/mL was used as this concentration proved effective in a study by Catterson et al. 
(2010). 
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Lithium is well known for its use as a treatment for psychological issues in earlier 
times. It was administered as pure tablets, but also eventually as lithium chloride (LiCl) salts 
or lithium carbonate for treatment of acute mania and BD. It has toxic effects on the body in 
high concentrations which results in renal failure and several other issues. While the exact 
mechanism of the neuroprotective effects of lithium is not understood, the chemical is known 
to interact with glycogen-synthase-kinase-3 (GSK3) which is a component of several 
neuroprotective genetic pathways (Klein et al. 1996; Jia et al. 2013). miR-137 has a risk allele 
associated with SZ and several of its predicted targets are risk genes for many psychiatric 
disorders such as CACNA1C and TCF4. Furthermore, GSK3 itself is a predicted target of 
miR-137 downregulation (Agarwal et al. 2018). LiCl was introduced to the food of D. 
melanogaster to investigate if this medication could reduce the phenotype caused by miR-137 
LOF. A dosage of 15mM was chosen as this successfully induced an effect in a study by Jia 
et al. (2013). 
 
7.2.2.1 Method 
For chronic treatment, LiCl or 3IY were administered for 5-7 days to adult flies before 
being put into the DAMS system. Pupa were removed from a normal food vial and moved 
into a vial containing food containing either LiCl dosed at 15mM or 3IY mg/mL. After the 
flies eclosed and reached the correct age, they were added to the DAMS with drugged food. 
The DAMS and subsequent analysis were conducted as described in Chapter 2.7. 
For acute treatment, 16 w1118 and 16 miR-137KO male flies were raised normally and put 
into the DAMS as described in Chapter 2.7. At circa 7am on the 4th day in the DAMS, half 
of each genotype was moved to new vials containing drugged food containing either LiCl 
dosed at 15mM or 3IY at 5mg/mL, and the other half was transferred to fresh normal food. 
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Data was collected and analysed in Microsoft Excel, producing total sleep amount per 24-
hours of the 3 days before and 4 days after exposure to the drugged food. The 4th day was 
excluded to allow the flies to reacclimatise to the vials after disturbance. 
 
7.2.2.2 Chronic treatment results 
Chronic exposure of flies with 3IY produced an overall decrease in total sleep amount 
across a 24-hour period for the miR-137KO strain (p-value < 0.05), but not a significant 
change in the w1118 controls (p-value > 0.05) (figure 7.4; table 7.6). Most of the change in the 
knockout flies was a significant decrease of sleep amount during the day period (p-value < 
0.01) and a small but not statistically relevant decrease in the night period (p-value > 0.05). 
No change within any period was statistically significant (p-value < 0.05) for the w1118 flies. 
The full statistics can be found in the supplementary information. 
 
Table 7.6: Total sleep amount from chronic 3IY recovery experiment 
 Average sleep amount (minutes [1dp]) 
Experiment 24-hour Day period Night period 
Normal: W1118 841.5 321.5 520.0 
Normal: miR-137KO 1239.6 647.0 592.8 
3IY: W1118 821.6 308.4 513.3 
3IY: miR-137KO 1105.0 544.4 560.6 
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Figure 7.4: The effect of chronic 3IY treatment on total sleep amount 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=8), miR-137KO (n=8), w1118 with 3IY (n=8), and miR-137KO with 3IY (n=5) flies were put into a Drosophila 
activity monitoring system (DAMS) by Trikinetics and the data was analysed in Microsoft Excel. One sleep 
period is counted as 5 minutes of no activity recorded in the DAMS, with recordings taken across 5 consecutive 
days and averaged. Experiments were compared between the treated and non-treated flies individually using t-
tests. In the 24-hour period and the day period the miR-137KO showed a significant decrease in total sleep (◊1: p-
value < 0.05, ◊2: p-value < 0.01). The w1118 strain shows no significant difference between treated and non-
treated groups. Correcting for Type I error using the Bonferroni method (described in ch2.10) resulted in the 
3IY effect in the KO strain for the 24-hour period is no longer significant. Error bars are standard error. 
 
Treatment with 15 mM LiCl did not produce any significant changes in total sleep 
between the treated and non-treated miR-137KO flies (figure 7.5; table 7.7), however the 
controls demonstrated a significant decrease in total sleep across the 24-hour period and both 
the day and night phases separately (P-values < 0.01). 
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Figure 7.5: The effect of chronic LiCl treatment on total sleep amount 
The graph shows both the total 24-hour period, and the separation of the two 12-hour day/night phases. w1118 
(n=7), miR-137KO (n=8), w1118 with 3IY (n=8), and miR-137KO with 3IY (n=8) flies were put into a Drosophila 
activity monitoring system (DAMS) by Trikinetics and the data was analysed in Microsoft Excel. One sleep 
period is counted as 5 minutes of no activity recorded in the DAMS, with recordings taken across 5 consecutive 
days and averaged. Experiments were compared between the treated and non-treated flies individually using t-
tests. The w1118 showed a significant decrease in total sleep across both periods and in total (●1: p-value < 0.01, 
●2: p-value < 0.01, ●3: p-value < 0.01). The miR-137KO strain shows no significant difference between treated 
and non-treated groups. Error bars are standard error. 
 
Table 7.7: Total sleep amount from chronic LiCl recovery experiment 
 Average sleep amount (minutes [1dp]) 
Experiment 24-hour Day period Night period 
Normal: W1118 944.8571 365.8571 579 
Normal: miR-137KO 1314.375 658 656.375 
LiCl: W1118 792.875 304 488.875 
LiCl: miR-137KO 1279.25 638.75 640.5 
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7.2.2.3 Acute treatment results 
Treatment of 3IY shows an obvious increase in total sleep amount per 24 hours upon 
introduction of the drug in w1118 flies compared to those not treated (figure 7.6, table 7.8). 
There is no change in miR-137KO flies compared to non-treated controls. 
 
 
Figure 7.6: The effect of acute 3IY treatment on total sleep amount 
The graph shows the 3 days on normal food, followed by a period of acclimatisation following switching of 
food. w1118 (NW, n=8), miR-137KO (NK, n=8), w1118 with 3IY (3W, n=7), and miR-137KO with 3IY (3K, n=8) 
flies were put into a Drosophila activity monitoring system (DAMS) by Trikinetics and the data was analysed in 
Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded in the DAMS, with recordings 
for all flies averaged. The w1118 strain shows an obvious increase in total sleep amount following exposure to 
3IY, while the miR-137KO flies show no difference between treated and non-treated groups. 
 
Table 7.8: Total sleep amount from acute 3IY recovery experiment 
 Average sleep amount (minutes/24 hours[1dp]) 
Experiment Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
Normal 
W1118 
820.6 785.6 830.6 - 876.9 906.25 896.25 925.0 
Normal 
miR-137KO 
1340.6 1347.5 1335.0 - 1340.6 1341.2 1345.6 1365.6 
3IY 
W1118 
946.4 877.1 887.9 - 1210.0 1187.1 1172.1 1172.1 
3IY 
miR-137KO 
1347.5 1318.8 1308.8 - 1295.0 1313.1 1324.3 1305.6 
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Treatment of LiCl shows no change in either w1118 or miR-137KO flies compared to non-
treated controls (figure 7.7; table 7.9). 
 
 
Figure 7.7 The effect of acute LiCl treatment on total sleep amount 
The graph shows the 3 days on normal food, followed by a period of acclimatisation following switching of 
food. w1118 (NW, n=8), miR-137KO (NK, n=8), w1118 with LiCl (LW, n=7), and miR-137KO with LiCl (LK, n=8) 
flies were put into a Drosophila activity monitoring system (DAMS) by Trikinetics and the data was analysed in 
Microsoft Excel. One sleep period is counted as 5 minutes of no activity recorded in the DAMS, with recordings 
for all flies averaged. Both the w1118 strain and the miR-137KO flies show no obvious difference between treated 
and non-treated groups. 
 
 
Table 7.9: Total sleep amount from acute LiCl recovery experiment 
 Average sleep amount (minutes/24 hours[1dp]) 
Experiment Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
Normal 
W1118 
866.4 822.9 854.2 - 886.4 877.1 897.1 920.0 
Normal 
miR-137KO 
1288.8 1266.9 1272.5 - 1253.8 1291.3 1273.8 1270.0 
LiCl 
W1118 
885.6 851.9 875.0 - 800.0 863.8 938.1 925.6 
LiCl 
miR-137KO 
1333.1 1308.8 1306.3 - 1173.1 1256.3 1232.5 1265.6 
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7.2.2.4 Discussion 
Chronic treatment of 3IY affected the two genotypes differently. The w1118 strain 
showed no real change in sleep amount comparing treated to untreated flies, but the miR-
137KO flies exhibited a contradictory effect of reduced sleep across the 24-hour period. 3IY is 
a molecule which inhibits the production of dopamine by limiting the tyrosine hydroxylase 
(ple in D. melanogaster), therefore promoting sleep (Catterson et al. 2010; Reimensperger et 
al. 2011). Catterson et al. (2010) reported a 4.5-fold increase in average sleep bout length, 
while Tomita et al. (2015) demonstrated an increase of circa 20%. These studies used 
differing food mediums and drug concentrations but produced an increase in control sleep. 
Furthermore, a higher dose of 10mg/mL 3IY administered for 48 hours produced a tenfold 
decrease in dopamine levels and had no effect on locomotor climbing ability in male flies 
(Bainton et al. 2000). This dosage was lethal when given for extended periods of time or 
during larval development. Initially, the data from the chronic treatment was thought to be 
erroneous because of improperly prepared food/drug concentrations, but acute exposure to 
the same 3IY food produced the expected increased sleep behaviour within the w1118 strain. 
Potentially the prolonged exposure to 3IY has allowed for some sort of tolerance which 
prevents the 5-day average sleep value being different in the control flies, but these results 
reinforce the dopamine desensitisation hypothesis of increased dopamine receptor activation 
in the absence of miR-137 creating a tolerance throughout development of these flies. When 
the Bonferroni method was used to correct for Type I errors, the corrected significance 
threshold meant that the effect of 3IY on the KO strain across the 24-hour period was no 
longer deemed significant. Nonetheless, even with the conservative corrected p-value of 
0.00833, the difference exhibited by the KO strain in the day was still significant and 
therefore contradictory to the lack of effect seen in the wildtype controls. 
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Lithium chloride is known to produce therapeutic effects in D. melanogaster models of 
Huntington’s disease and Alzheimer’s disease (Berger et al. 2005; Sofola et al. 2010), 
thought to be due to inhibition of GSK3B and subsequently preventing the toxic aggregation 
of proteins characteristic of these diseases (Jia et al. 2013). Furthermore, an MDD model in 
flies (induced by repeated and unavoidable stressors) showed a locomotor deficit which was 
then reversed upon LiCl treatment (Ries et al. 2017). With LiCl’s use as an effective 
neurological treatment, it was hypothesized that LiCl may alleviate some of the sleep 
symptom exhibited within miR-137 deficient flies, however no such study appears to have 
been done previously. Acute exposure to lithium produced little results for either strain, 
however chronic treatment severely decreased the sleep in w1118 flies across both periods of 
the day. With many medications prescribed for psychological symptoms there is a period 
required before the level of the drug within the body is enough to produce the therapeutic 
effect, and the body can adapt to it. This is a potential explanation as to why the acute 
treatment did not seem to cause any change in any of the flies, but the concentration of 15mM 
also does not restore the normal sleep phenotype in miR-137KO flies. There is a small 
decrease across both periods, but nothing calculated as significant (p-value < 0.05). 
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7.3 Conclusion 
Genetically, the statistically significant decrease in sleep amount shown in the FB-
recovery, along with the comparison of this region to the mammalian hypothalamic 
ventrolateral preoptic nuclei, offers promising options as to the mechanism resulting in 
exaggerated sleep and links to psychiatric disorders. The Bonferroni corrected p-values 
ultimately resulted in no significance found with reintroduction of miR-137 to the CNS as a 
whole or the fan-shaped body by itself. This ultimately means that the null hypotheses in 
objective D hypotheses 1 and 2 cannot be rejected (Chapter 1.8). 
Exposure to pharmaceuticals produced some confounding results that could infer 
further neurological abnormalities. The lack of behavioural change when treated with anti-
psychotic medicine LiCl, both chronically and acutely, in the knockout flies demonstrates 
another potential molecular anomaly that has links to psychiatric diseases. The decrease in 
sleep when chronically exposed to 3IY, but no effect upon acute treatment lends further 
evidence to the desensitisation to dopamine hypothesis explained in Chapter 7.2.2. The 
significant effect of 3IY across the day period allows for rejection of the null hypothesis 4 in 
objective D (Chapter 1.8). The increase of daytime sleep within the knockout flies upon 
exposure to caffeine and loss of some night-time sleep implicates miR-137 with the sleep 
homeostat as was also concluded in Chapter 5. Following Bonferroni corrections, the lack of 
significant effect overall from caffeine and LiCl treatment means that the null hypotheses for 
objective D hypotheses 3 and 4 cannot be rejected (Chapter 1.8). 
It is worth mentioning that these pilot experiments were conducted on numbers that 
while enough for comparison, could be amplified for greater experimental validity. Further 
work could also use a range of drug concentrations and assess food ingestion rates as proof of 
drug intake. Furthermore, mainly due to limitations with the DAMS and experimental 
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continuity, these experiments were conducted solely on male Drosophila and further work to 
confirm the effect in females still needs to be completed. 
In conclusion, none of the recovery attempts produced results that could be deemed as a 
full recovery of the phenotype behaviour shown in the miR-137KO flies. However, all 
experiments provided a novel vantage point and research direction for miR-137 dysfunction 
that can be assessed in the future. Of interest is the hypothesis of dopamine desensitisation, 
which is evidenced with the results from the 3IY chronically treatment flies and the dopamine 
driven fan-body region recovery. 
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8 Bioinformatics 
The experimental results presented in the previous chapters, showed that miR-137 is 
important for proper locomotor and sleep behaviours in flies. These results obviously 
represent the phenotypic effects of sequestering that gene in Drosophila melanogaster. 
However, this project began with a statistical association of human MIR-137 in a SZ GWAS; 
a different phenotype. The crossover between many documented psychiatric symptoms and 
the phenotypes displayed by the miR-137KO strain implied potential effects of human MIR137 
in psychiatric disorders and the severe sleep phenotype is also a symptom of many 
neurological diseases. Therefore, this phenotype appears to be broad based. Unfortunately, 
the miR-137KO phenotype alone does not offer an explanation as to the mechanism with 
which the microRNA creates this effect, or the many hypothesised genes downstream in the 
pathways. A complete transcriptome of the fly stock with miR-137 gene removed could be 
used to identify any genes where the expression was significantly different compared to 
control strains. This data could also then be compared with bioinformatic analysis to try and 
identify genetic pathways where there are multiple expression changes as a result of miR-137 
loss. Additionally, published data from a study of miR-137 inhibition in progenitor neural 
stem cells (Hill et al. 2014), provided the opportunity to investigate if similar genetic 
expression changes matched the D. melanogaster data. Furthermore, analysis of other human 
GWAS data could provide links to differentially expressed genes and other psychiatric or 
neurological disorders. Ideally pooling all data together might provide synergies between 
gene sets leading to hypotheses of tangible mechanisms through which the altered expression 
of miR-137 acts, resulting in the phenotypes displayed. 
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8.1 Introduction 
Bioinformatics is the modern practice of computer aided analysis and interpretation of 
complex biological data such as that from gene expression, GWAS, proteomic and in vivo 
experiments. Historically, as research results contained numerous genes or SNPs, researchers 
would have to methodically accumulate information on each component and then assess and 
hypothesise pathways and interactions based upon literature. With advances in technology 
and the wealth of open sourced publicly deposited data, there has been a huge number of 
bioinformatic programmes developed to help non-bioinformatic skilled researchers quickly 
access and interpret gene lists for pathways, expression data, sample enrichment, genome-
wide significance and more. As these resources have become increasingly used by non-
specialists, many online programmes now adopt very simple interfaces to enable accessibility 
to a greater number of researchers.  
This section details my efforts to establish a selection of evidence based and 
biologically plausible genes affected by miR-137 dysregulation. Utilising a service for 
Drosophila transcriptomics offered by Cambridge University (FlyChip), the expression of all 
genes was compared between adult control strain flies and the flies with genomic miR-137 
removed. Using these results alongside other published ‘wet-lab’ experimental data, I show 
how I assess cross-species links and produce a select group of matched genes. In addition, I 
then used publicly available bioinformatic tools and datasets (DAVID, UKbiobank, Neale 
Lab data, FUMA CTG lab), as well as data received from Dr Richard Anney of Cardiff 
University to evaluate the ontology and potential links to sleep and locomotion behavioural 
phenotypes. 
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8.2 Drosophila Transcriptome 
To assess the effect of miR-137 ablation on a genetic level in the fruit fly, a FlyChip 
gene expression chip was conducted utilising a service at Cambridge University. The service 
performed a full transcriptome analysis using a custom long oligonucleotide probe array to 
measure comparative expression values between a test and a control sample, then performed 
simple statistical analysis to evaluate the significance of the expression differences. The 
results would give comparative gene expression changes of all identified genes in the miR-
137KO strain against the control w1118 flies, which would then be useful for assessing 
pathways and biological mechanisms affected by miR-137 dysfunction. 
 
8.2.1 Preparation of FlyChip samples 
Samples of homogenised Drosophila heads in Trizol solution (Thermofisher) were 
collected and delivered to Cambridge University in dry ice for FlyChip analysis. The FlyChip 
utilised two biological samples to produce two readings of the comparative expression 
amount of test sample against control sample. Cambridge University also applied use of the 
Bioconductor Linear Models for Microarray Data (LIMMA) programme to perform statistical 
analysis producing a standardised p-value and log2 change factor. The log2 factor represents 
a fold change between test and control (eg: log2 of 2 signifies a doubling of expression). 
Adult flies aged 4 – 7 days post eclosion were put into -20°C for approximately 30 
minutes before being transferred to a dissection plate. A total of 50 Drosophila of each w1118 
and miR-137KO were dissected under a microscope in Phosphate-buffered Saline solution. 
The heads were collected whole and put directly into a 1.5mL ependorf containing 300uL of 
Trizol solution. While the samples were being collected the ependorf was stored on ice, and 
once the full amount was transferred, they were then homogenised using a sterile micropestle. 
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Following homogenisation, the samples were stored at -80°C before being transported in dry 
ice. Once delivered, Cambridge University performed RNA extraction then a Chip-style 
expression array. The time between sample collection and RNA extraction was kept to under 
36 hours to minimise RNA degradation as much as possible. The sample size and trizol 
volume used were suggested amounts by Cambridge University. 
 
8.2.2 Differentially expressed genes (DEG) 
The pre-analysed results from Cambridge University indicated that in the miR-137KO 
strain there were a total of 7450 genes with a decrease of expression compared to controls, 
and 6990 genes which were increased compared to controls. Of these, only 30 gene 
expression changes were significant to a p-value of less than 0.05 (tables 8.1 and 8.2).  
 
Table 8.1: Significantly upregulated genes in the FlyChip. 
Gene Symbol Gene Name Log2 Change (3dp) P-Value (3dp) 
FBgn0033631 Sod3 4.232 0.002 
FBgn0003996 W 3.830 0.002 
FBgn0260793 2mit 2.970 0.009 
FBgn0031228 ND-15 2.573 0.009 
FBgn0010473 Tutl 2.589 0.013 
FBgn0001217 Hsc70-2 2.300 0.013 
FBgn0027584 CG4757 2.281 0.014 
FBgn0051157 CG31157 2.277 0.017 
FBgn0031560 CG16713 2.038 0.018 
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Table 8.2: Significantly downregulated genes in the FlyChip. 
Gene Symbol Gene Name Log2 Change (3dp) P-Value (3dp) 
FBgn0040074 Retinin -3.753 0.002 
FBgn0033065 Cyp6w1 -3.377 0.005 
FBgn0023171 rnh1 -2.632 0.009 
FBgn0034330 CG18107 -2.610 0.009 
FBgn0261477 Slim -2.357 0.013 
FBgn0038237 Pde6 -2.521 0.017 
FBgn0086348 Se -2.190 0.017 
FBgn0069973 CG40485 -2.090 0.017 
FBgn0038343 Trissin -2.066 0.018 
FBgn0028371 Jbug -2.070 0.019 
FBgn0039459 IntS12 -2.042 0.019 
FBgn0034860 CG9812 -1.951 0.021 
FBgn0040256 Ugt86Dd -2.016 0.031 
FBgn0035676 ssp6 -1.826 0.031 
FBgn0050456 CG30456 -2.492 0.041 
FBgn0267435 Chp -1.852 0.042 
FBgn0036183 CG6083 -1.788 0.042 
FBgn0260746 Ect3 -1.774 0.043 
FBgn0011693 Pdh -2.023 0.046 
FBgn0259229 CG42329 -1.814 0.046 
FBgn0043534 Obp57b -1.876 0.047 
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8.2.2.1 Discussion 
The 30 Drosophila melanogaster genes listed (P<0.05) consist of nine over-expressed 
and 21 under-expressed (Tables 8.1 and 8.2) genes. According to Flybase (available at: 
www.flybase.org), these genes are involved in the following: 
Sod3 is a Superoxide dismutase 3 and encodes an extra-cellular copper-zinc 
superoxide dismutase that can be produced as secreted and membrane bound forms. It 
converts oxygen free radicals to hydrogen peroxide and is involved in free radical defence 
and redox balance. 
White (w) encodes a member of the ABCG2 class of transporters, transporting 
molecules such as cyclic GMP, biogenic amines and pigments. This is an expected change 
within the transcriptome as the genetic marker used to differentiate between miR-137KO flies 
and control was a recessive allele of a truncated version of the w gene causing 
white/colourless eyes in the controls. 
2mit encodes a putative leucine-rich repeat transmembrane protein that is mainly 
expressed in the developing central nervous system. In the adult, it has a role in short-term 
memory and learned courtship behaviour (Baggio et al. 2013). 
ND-15 NADH dehydrogenase (ubiquinone) is likely to be involved with 
mitochondrial electron transport, and downregulation of the gene causes body size defects 
and swollen mitochondria in third instar larva (Zhou et al. 2019). 
Turtle (tutl) encodes an Ig-superfamily transmembrane protein. Its roles include 
axonal tiling, dendrite self-avoidance, axonal pathfinding and coordinated motor control. 
Loss of function in flies causes locomotor and behavioural defects, plus partial lethality 
during pupation (Bodily et al. 2001).  
174 
 
Heat shock protein cognate 2 (Hsc70-2) encodes a member of the heat shock protein 
family. It functions as a chaperone to promote proper post-transcriptional folding of proteins. 
In flies with RNAi driven knockdown of hsc70-2 through development, the larva develops 
anatomically smaller and feature fragmented mitochondria (Zhou et al. 2019). 
Retinin is a structural component of the eye, expressed in the extracellular space and 
around pigment cells. This is likely to be related to the white eye phenotype mentioned under 
the white gene. 
Cyp6w1 is predicted to be part of the cytochrome P450 family. It is likely to have 
heme-binding and oxidoreductase properties and has a peak expression level observed in 
third instar stages and in adult males. 
Rnh1 ribonuclease H1 (rnh1) encodes an RNA-DNA hybrid ribonuclease. Partial 
deletion of the genomic sequence causes developmental defects including a delay in 
developmental time, pre-pupal and pupal developmental lethality, and melanotic tumours 
(Filippov et al. 2001). 
CG18107 is also known as Bomanin Short 4, part of the Bomanin family. Bomanins 
are small secreted immune-response peptides induced by Toll signalling, likely responsible 
for bacterial or infection resistance. 
Slim is called ‘scruin like at the midline’ and is involved in the stress-activated MAPK 
signalling cascade. RNAi driven downregulation in the CNS causes sleep dysfunction in both 
males and females, and anatomical muscle defects in the larval wall (Schnorrer et al. 2010; 
Lobell et al. 2017). 
Pde6 is a 3',5'-cyclic-GMP phosphodiesterase, which is expressed in the adult eyes 
and its product is involved in drosopterin (red eye pigment) synthesis. This is another likely 
genetic change likely caused by the white gene change. 
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Sepia (se) is a Glutathione dehydrogenase/transferase, which produces a product used 
in eye cell pigments. This change is likely as a result of the white gene modification. 
CG40485 is predicted to be a steroid dehydrogenase, which are NAD or NADP 
dependent oxidoreductases with steroid as a substrate. RNAi downregulation causes early 
larval lethality and neuroanatomy defects with less daughter cell neuroblasts (Schnorrer et al. 
2010; Neumuller et al. 2011). 
Jitterbug (jbug) encodes a Filamin-type protein. Filamins are actin crosslinkers that 
organize actin filaments into networks and connect them to membrane receptors. The product 
of jbug is required in photoreceptor cells for axon targeting and in tendon cells to maintain its 
shape during muscle-tendon interaction. 
Integrator S12 is predicted to localise with the integrator complex and have 
involvement with the processing of small nucleolar RNA molecules. RNAi mediated 
downregulation causes early larval lethality and neuroanatomy defects with smaller 
neuroblasts (Schnorrer et al. 2010; Neumuller et al. 2011). 
Ugt86Dd is “UDP-glycosyltransferase family 35 member C1”, part of the 
glycosyltransferase family that plays a major role in detoxification of substrates, formation of 
pigments, and olfaction. 
Chaoptin (chp) is involved in rhabdomere and microvilli organisation and anchoring 
to the plasma membrane adhesion molecules. Loss of function results in irregular 
photoreceptor and eye morphology (Pollock et al. 1990; Gurudev et al. 2014). 
CG6083 is involved in Alcohol dehydrogenase (NADP (+)) and Aldehyde reductase. 
Expression of an RNA-inhibition molecule in Drosophila mushroom bodies demonstrated 
significant neuroanatomical defects, characterised by lobe fusion in approximately 35% of 
cases (Koboyashi et al. 2006).  
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 Ect3 is predicted to have beta-galactosidase activity catalysing the hydrolysis of β-D-
galactosyl residues in the presence of water to galactose and alcohol. This forms part of the 
larger carbohydrate metabolic process. 
Photoreceptor dehydrogenase (Pdh) encodes a retinal pigment cell dehydrogenase 
involved in retinol metabolism. Loss of function in flies results in progressive degeneration of 
the rhabdomeres in normal light/dark cycle, and RNAi downregulation in neuroblasts result 
in higher lethality rate compared to controls when placed in higher temperatures (Neely et al. 
2010; Wang et al. 2010) 
Genes CG42329, Obp57b, ssp6, CG30456, Trissin, CG4757, CG31157, CG9812, and 
CG16713 are of unknown function with little or no information available to assess 
involvement with the rest of the gene set. 
Genes 2mit and pde6 are predicted direct targets of miR-137 on Targetscan, however 
2mit is upregulated in the miR-137KO strain which is contradictive of the predicted 
downregulatory effect. The pde6 gene does not have a lot of information regarding its 
function or effect however, the available information implies the change is likely exasperated 
by the differing eye phenotypes as mentioned previously. In addition to this, none of the 
human orthologs of these genes calculated by DIOPT are predicted targets in humans and 
therefore unlikely to be of direct relevance. 
Overall, the list includes several photoreceptor/eye morphology related genes which 
are likely to be due to the truncated white gene marker used extensively across D. 
melanogaster studies for its recessive and easily observable phenotype. Despite this, one of 
these genes (pde6) is a putative direct target of miR-137 which may be worth investigating in 
the future. Several genes are implicated within metabolism and energy transfer. There are 
also a few genes linked to neuroanatomy, be it brain regions, axon guidance, or signalling 
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between the CNS and muscle. Of interest is gene CG8063, which has experimental links to 
mushroom body development when downregulated. In the FlyChip assay this had a Log2 
change of -1.788 (3dp), a significant decrease in expression. This region of the fly brain has 
been functionally compared to the mammalian cerebral cortex, which is subsequently one of 
the key regions related to psychiatric disorders in humans (Nesvag et al. 2007; Iritani 2013; 
Sitara 2015). There is also a gene linked to sleep dysfunction, slim, which may prove to be a 
link to the severe phenotype displayed in the flies (Chapter 5.4). The sleep dysfunction 
phenotype was exhibited in flies with RNAi mediated downregulation of the gene, and this 
matches the FlyChip data which had a Log2 factor of -2.357 (3dp). There are many genes 
which do not have any or much information available to assess function or potential 
phenotypical importance within this project, as the understanding of these genes develops, 
they may become of more importance. 
 
8.2.3 Significant gene ontology 
As identification of significantly expressed genes above shows, using Flybase does not 
provide adequate indication of what pathways they are likely to be involved with collectively. 
To investigate this, the online platform DAVID was used to calculate molecular interactions 
and pathways. DAVID is the “database for annotation, visualization, and integrated 
discovery” (accessible from: david.ncifcrf.gov/), a publicly available web interface for 
assessing gene lists for enrichment, disease relevance, and biological categories amongst 
other features. The database is run and updated constantly by the Laboratory of Human 
Retrovirology and Immunoinformatics. The output calculates enrichment p-values for easy 
identification of enrichment within the gene set for further analysis. 
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Visualised pathways were also produced utilising online resource “Gene Mania” 
(accessible from genemania.org). The online platform has a user-friendly interface and the 
results are useful for generating hypotheses about gene function, analysing gene lists and 
prioritising future workload. The algorithm extends the list with functionally similar genes 
that it identifies using available genomics and proteomics data (Warde-Farley et al. 2010). 
The visual network features lines of different weights indicative of the predicted value of 
each selected data set for the query. Gene Mania relies upon data sources including; 
GeneMANIA relies on the following data sources: GEO, BioGRID, EMBL-EBI, Pfam, 
Ensembl, NCBI, MGI, I2D, InParanoid, Pathway Commons, and also smaller data sets. 
 
8.2.3.1 Method 
The 30 genes were inputted to the online resource DAVID to look for gene ontology 
and pathway enrichment using the preloaded algorithms and databases. The significant genes 
from the FlyChip were put as FlyBase IDs with the D. melanogaster background selected. 
Any results from DAVID analysis were to be assessed for relevant key terms within both 
functional clusters or individual functional terms, the degree of enrichment, and 
automatically calculated p-value. This was then used as a basis for further reading to build 
information for potential methods of action of miR-137 manipulation on the phenotype. 
Additionally, the significant orthologs were created by putting the fly genes into the 
online DIOPT programme (accessible from: www.flyrnai.org/diopt). These orthologs were 
then put into the online programme Gene Mania, which created a visual network map of 
proven or predicted interactions via similar protein regions and localization. To do this, the 
human ortholog list was copied into the Gene Mania search bar, and the organism type was 
changed to Homo sapiens before selecting the search button. 
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8.2.3.2 Results 
DAVID database did not produce any significant results when the 30 significant D. 
melanogaster genes. 6.7% of the input gene list (2/30) were involved in the Galactose 
Metabolism pathway (p-value > 0,05). The two genes involved with the pathway were ect3 
and CG6083. 
 
Table 8.3: DAVID functional annotation of significant FlyChip genes. 
Database Pathway Gene Count 
Percent 
of input 
Enrichment 
P-value Gene Name 
KEGG_PATHWAY 
 
 
  
Galactose 
metabolism 
 
  
2 
 
 
  
6.7% 
 
 
  
0.095 
 
 
  
CG6083 
 
  
Ect3 
  
 
 
Gene Mania produced network maps clearly showing three main clusters around UGT, 
HSAP, and AKR1 protein families indicated by lots of linkage through “shared protein 
domains” (figure 8.1). The programme also identified additional links to genes outside of the 
significant list that was inputted. These include; KCNAB1, CCS, and ACHE which are linked 
to the gene set through direct protein interactions or shared protein domains.  
180 
 
 
Figure 8.1: Human ortholog gene network of the DEGs from the FlyChip. 
The 30 differentially expressed genes (p-value <0.05) were put into DIOPT to produce 119 human orthologs. 
The analysis and visualisation were created by Gene Mania (accessible from: genemania.org). Additional genes 
are in full black while inputted genes are in stripes. The colours of lines represent different links: Beige = 
Shared protein domains, Purple = co-localisation, Red = Physical interactions, Blue = Pathways, Green = Shared 
protein domains, Orange = Predicted interactions.  
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8.2.3.3 Discussion 
DAVID produced one association of the inputted gene list, with 2 genes implicated as 
part of the galactose metabolism pathway. While the association was not deemed a significant 
enrichment (P-value > 0.05), galactose metabolism is part of a larger carbohydrate 
metabolism process where dysfunction within can cause severe side effects ranging from 
lethargy to death in humans (Sehgal 1998). The gene CG6083 has been implicated in flies 
with proper mushroom-body brain development (Kobayashi et al. 2006), the fly brain region 
which shares functional similarities to the mammalian cerebral cortex (Sitara 2015). This 
region is linked to neurological and psychiatric disorders in humans.  
Of the additional genes identified by Gene Mania, KCNAB1 is of interest as it is part 
of the potassium voltage-gated channel family known to be involved with synaptic signal 
transmissions. It is an ortholog of D. melanogaster gene hyperkinetic (hk), which is a subunit 
of shaker channels responsible for action potentials in neurons and transmitter release. It 
specifically is responsible for activation of the fan-body brain region of the fruit fly which 
regulates sleep (Bushey et al. 2010; Pimental et al. 2016). Gene Mania links KCNAB1 via 
shared protein domains to AKR1A1, the human ortholog of fly gene CG6083. CG6083 is 
involved in Alcohol dehydrogenase (NADP (+)) and Aldehyde reductase pathways. CG6083 
is downregulated by a log2 factor of 1.8 in the FlyChip, and inhibition of CG6083 in D. 
melanogaster mushroom bodies caused neuroanatomical defects such as lobe fusion in 
approximately 35% of cases (Koboyashi et al. 2006).  
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8.3 Comparison to Human stem cell transcriptome 
The effect of miR-137 inhibition on the transcriptome of human progenitor human stem 
cells has been investigated by Hill et al. (2014). The published work identifies over 1000 
genes which had a difference in gene expression to a significance value of less than 5%. As 
there is clear evidence of evolutionary conservation in the miR-137 gene, it is plausible that 
the mechanisms through which the miRNA works being similar across species too. 
To test this hypothesis, the significant D. melanogaster genes from the FlyChip were 
compared with the genes identified in the results of the stem cell culture experiment.  
 
8.3.1 Method: DIOPT Orthologs 
To compare fruit fly genes with human genes, they must be converted into the human 
orthologs. The list of 30 significant Drosophila genes was put into the online platform 
DIOPT (DRSC Integrative Ortholog Prediction Tool) (accessible from 
www.flyrnai.org/diopt). This identified a list of 119 human genes (table 8.4). 
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Table 8.4: Human orthologs of the DEGs from the FlyChip 
Human orthologs of the Significantly changed Drosophila genes in the FlyChip Data 
ABCG1 CES4A GSTO2 LRRC3 PLEKHG4B UGT1A4 
ABCG2 CES5A HPGD LRRC4 PODN UGT1A5 
ABCG4 CYP3A4 HSPA12A LRRC4 PODNL1 UGT1A6 
ABCG5 CYP3A43 HSPA12B LRRC4B RNASEH1 UGT1A7 
ABCG8 CYP3A5 HSPA14 LRRC4B RTN4R UGT1A8 
AKR1A1 CYP3A7 HSPA1A LRRC4C SCRIB UGT1A9 
AKR1B1 CYP3A7-CYP3A51P HSPA1B LRRC4C SHOC2 UGT2A2 
AKR1B10 CYTIP HSPA1L LRRC53 SLC26A10 UGT2A3 
AKR1B15 DHRS11 HSPA2 LRRC7 SOD1 UGT2B10 
AKR1C1 EPPIN-WFDC6 HSPA5 MCF2 SOD3 UGT2B11 
AKR1C2 ERBIN HSPA6 MCF2L SPINT2 UGT2B15 
AKR1C3 FLNA HSPA8 NDUFS5 TBXAS1 UGT2B17 
AKR1C4 FLNB IGSF9 NLGN1 TFPI UGT2B28 
AKR1D1 FLNC IGSF9B NLGN2 TFPI2 UGT2B4 
AKR1E2 GLB1 INTS12 NLGN3 TMEM135 UGT2B7 
ARHGEF40 GLB1L KLHDC10 NLGN4X TMEM38A UGT3A1 
CEL GLB1L2 LGR4 NLGN4Y TMEM38B UGT3A2 
CES1 GLB1L3 LGR5 PDE11A UGT1A1 UGT8 
CES2 GRASP LGR6 PDE5A UGT1A10 WFDC6 
CES3 GSTO1 LRRC1 PLEKHG4 UGT1A3 ------------ 
 
 
8.3.2 Method: Matched gene expression change direction 
Hill et al. 2014 published a list of 1025 genes which were found to be differentially 
expressed in human neuro stem cells (CTXOE03) when MIR-137 was inhibited using a 
Mirvarna Mir-inhibitor. Comparison of the FlyChip DIOPT-calculated orthologs and the Hill 
data produced a list of genes which had different expression levels in both flies and human 
cells when miR-137 function is decreased. Additionally, this list was further filtered for genes 
who had matching expression change direction, up or down, to keep only genes which 
behaved in the same manner across both organisms. All comparisons and conversions were 
performed in Microsoft Excel. Two lists were created, one of the Fly orthologs and one of the 
results from Hill et al. and then the MATCH function was used to check if the same gene 
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name could be found in both data sets. The matches were then separated into another list and 
the expression change values were associated with the gene names using VLOOKUP 
function to search for the right cell in the original data table. Using the IF function, another 
list was created if both values for the gene (one from FlyChip and one from Hill et al.) were 
either positive or negative (figure 8.2). 
 
 
Figure 8.2: Method of creating matched-expression candidate gene set 
Representation of method behind the creation of the candidate gene set from both human cells and Drosophila 
melanogaster transcriptome data. Two data sets were compared using Microsoft Excel to produce a list of genes 
which displayed similar genetic expression change behaviour when miR-137 expression was lost, or function 
was inhibited. One data set was a total transcriptome comparison of flies with endogenous miR-137 region 
removed and controls, while the second data set was the transcriptome effects of miR-137 inhibition in 
CTXOE03 cells compared to controls (Hill et al. 2014). The genes from the FlyChip were first converted to 
human orthologs utilising the DIOPT (DRSC Integrative Ortholog Prediction Tool) to allow comparison with 
the CTXOE03 data. The resultant multi-organism matched gene set was then used as one of the lists in further 
bioinformatic analysis. 
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8.3.2.1 Results 
Comparing the total FlyChip orthologs with the significant genes from the Hill et al. 
(2014) results separated a list of 403 individual genes that behaved in the same manner across 
two organisms when in an environment lacking miR-137 (table 8.5).  
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Table 8.5: Genes directionally matched in FlyChip and CTXOE03 
 
flyCHIP-Hill genes
AACS CENTG2 EDEM1 HSGT1 MARK1 PSMA5 SFRP4 TRIM33
ABCB9 CFL2 EFEMP1 HSP90AA1 MAX PSMB8 SFRS15 TROVE2
ABHD7 CFLAR EIF4A1 HSP90AB1 MSI2 PTGR1 SGCE TRPM3
ACAD10 CHCHD9 ELP3 HSPA2 MYH9 PTGS1 SH3PXD2A TSC22D3
ACOT9 CIB1 EML1 HSPE1 MYNN PTPN3 SHC2 TSPAN1
ACSBG1 CLSTN1 ENO3 HTR1E N4BP2L1 PUS3 SHROOM2 TSPAN5
ADAT1 CMPK1 ENTPD6 IDS NACA PXDN SIGLEC6 TSPAN9
ADRA2B CMYA5 EPHB2 IFIT1 NANS RAB2A SLC15A4 TULP4
ADRM1 CNBP ETNK2 IGFBP3 NARS RAB33B SLC19A1 TXNL1
AGFG1 CNN2 EXOC2 INA NBPF14 RAB5C SLC25A11 UBE2F
AGK CNNM4 EXT1 ING4 NCSTN RAB7L1 SLC25A14 UBE3C
AIFM1 CNOT4 FAHD1 INTS4 NDUFB6 RAC1 SLC25A20 UBQLN1
AK2 COL11A1 FAM177A1 IQCB1 NDUFV1 RAD21 SLC25A22 UCK2
AKR1B1 CPSF4L FAM179B IRS1 NFS1 RAG1AP1 SLC25A25 UPF3A
AKT3 CPT1A FAM86B1 ITGA10 NHP2L1 RANBP6 SLC26A2 USF2
ALDH3A2 CPT1C FBXL12 ITGA2 NHS RANBP9 SLC26A7 USP14
ALDH9A1 CRIM1 FCGR3A JARID1D NKTR RASD1 SLC35A2 USP2
ALG14 CRKL FGF13 KBTBD7 NOP16 RBBP5 SLCO3A1 USP4
ALK CSNK1E FMNL1 KCNIP1 NOTCH2NL RBED1 SLCO4A1 VAV3
ANAPC4 CSNK1G1 FOXH1 KCNK1 NP RBM12 SLCO5A1 VPS25
ANKS1A CTCF FOXO3 KCNK3 NPC1 RBM28 SLK VPS37B
ANXA6 CTDSP2 FRRS1 KCNS1 NRD1 RBM45 SMAP1 WASF3
AP1S2 CTSB FRZB KIAA0528 NUP155 RDH11 SNRPA WNT7B
ARAP3 CTSC FTL KIAA0564 NUP54 RDH14 SNX32 XRN1
ARL5A CUL4A FTSJ1 KIF21A NUP62 REEP1 snx6 YBX1
ATP5G2 CUX1 FYN KIF3B NUP93 REEP5 SOCS3 YWHAB
ATP6V0A2 CYB561D2 FZD3 KIF5C NXF1 RFWD2 SOD2 ZDHHC24
ATP6V0E1 CYB5A GADD45A KLF11 OASL RGS17 SORL1 ZDHHC8
AUTS2 CYFIP1 GALNTL4 KPNA2 OGFOD1 RNASEH1 SPATA2L ZMYM5
B3GALNT1 CYTSA GGNBP2 KRAS OLFML2B RNF112 SPATA6 ZNF146
BBOX1 DACH1 GPHN KRT80 P4HA2 RNF114 SRPK2 ZNF197
BIRC3 DDB1 GPKOW KTELC1 PAICS RNF122 SRRM1 ZNF281
BIRC6 DDR2 GPR98 LAMA4 PATE1 RNF19A STK35 ZNF304
BRP44L DEAF1 GPT2 LAPTM4B PCNA ROCK2 STK38 ZNF33B
BTBD7 DHFR HADHB LGALS8 PCOLCE2 RPL18 STX5 ZNF343
BTG3 DMXL2 HBA2 LGALS9B PELI1 RPL19 SULF2 ZNF37A
C14orf118 DNAJC12 HERC6 LIPA PEPD RPL24 SURF4 ZNF397
C14orf143 DNAJC18 HES2 LOC100131530PHF6 RPS6 SV2A ZNF407
C1orf83 DNAJC7 HIP1 LOC641298 PIGF RPS7 SYF2 ZNF485
C1RL DNAL1 HISPPD2A LONP2 PIGN RPSA TACC1 ZNF512B
C21orf55 DNALI1 HIST1H4C LOX PKNOX1 RSU1 TAF1 ZNF626
C6orf162 DNM3 HIVEP1 LRBA PLAA RUNX1T1 TBC1D23 ZNF630
C8orf33 DPH2 HK1 LRRC8D PMS2L1 SDAD1 TEX10 ZNF674
CANX DPP3 HK2 LRRC8E POLA1 SDHC TJP2 ZNF75A
CAPRIN1 DSC2 HMGB1 LTBP3 POLR2D SEC11A TM2D1 ZNF768
CASKIN2 DUS4L HNRNPAB LTF POLR2L SEMA3C TM9SF1
CCDC127 DUSP4 HNRNPD LYL1 PPAPDC3 SEMA6C TMEM164
CCT2 DYM HNRNPL LYPD6B PPIC SENP3 TMEM185A
CD44 DYNC1H1 HNRNPUL2 MAGED1 PPIE SERINC3 TMEM19
CDC2L5 ECAT8 HNRPA2B1 MAP2 PRKAG2 SETDB2 TRAF7
CDKN2C ECE1 HSDL1 MAP3K2 PSMA3 SF3B14 TRIM25
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8.3.2.2 Discussion 
The number of matches found across the two datasets was extensive and prompted 
further assessment of the method going forward. In discussion with Dr Richard Anney from 
Cardiff University, it was noted that the process of comparing the entire genome of the fruit 
fly (around 14400 genes) to 1000 significant DEGs was very likely to produce matches due 
to sheer volume. Furthermore, filtering of upregulation or downregulation creates a statistical 
chance of a 50/50 for a positive match. Overall this is likely to present false positive results 
which could consequently lead to misrepresentation of the importance of certain genes. 
The DIOPT programme automatically calculates the orthologs of genes in an 
alternative organism. When converting from human to Drosophila, the list is likely to get 
smaller due to the overall genome size and likelihood of specific sub-genes in a simpler 
organism. In contrast, from Drosophila to humans produces multiple orthologs in the same 
family (eg: D. melanogaster gene CG6083 is an ortholog of genes AKR1A1, AKR1C1, 
AKR1C2, AKR1C3, AKR1C4, and AKR1E2). With the conversion of human to fly being a 
degenerative method, you might lose potential genes but alternatively the conversion of fly to 
human includes a wider range of genes which might not be indicative of the genetic function 
in the fly. 
 
8.3.3 Matched significant genes 
Following the production of the match expression direction list and encountering 
potential false positives, a more specific comparison of the two datasets was conducted. To 
identify higher value gene matches, only the significant differentially expressed genes from 
the FlyChip were matched to the data from Hill et al. (2014). 
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8.3.3.1 Method 
The top genes with a p-value of less than 0.05 were selected from the FlyChip 
orthologs from DIOPT. This list was then compared against the data from Hill et al. 2014 for 
matches in excel using the MATCH function to look for name matches in both lists. The 
genes identified from matching across the two organisms’ experiments were put into DAVID 
and Gene Mania as previously done in section 8.1.3 to assess any enriched pathways and 
ontology for information on how they might relate to the fly phenotype. 
 
8.3.3.2 Results 
Comparison of the FlyChip orthologs and the Hill et al. (2014) data identified 3 genes 
of interest which were differentially expressed in both data sets (table 8.6). 
 
Table 8.6: Significant DEGs in both FlyChip and CTXOE03 
Drosophila gene Human ortholog Information 
rnh1 RNASEH1  Both the fly gene and human gene were 
significantly downregulated, with p-values < 0.01 
hsc70-2 HSPA2  The fly gene was significantly upregulated while 
the human gene was significantly downregulated, 
with p-values < 0.05 respectively. 
CG6083 AKR1B1  Both the fly gene and human gene were 
significantly downregulated, with p-values < 0.05 
 
 
DAVID did not produce any enriched pathways from the 3 candidate genes; however, 
Gene Mania added several genes to the pathway including members of the TOR family. The 
network appears to be mostly separated into 3 distinct sections, indicating little overlap 
between the mechanisms of the 3 candidate genes (figure 8.3). 
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Figure 8.3: Genetic network of genes; HSPA2, AKR1B1, and RNASEH1 
Created by Gene Mania (accessed from: genemania.org/). Additional genes are in full black while inputted 
genes are in stripes. The colours of lines represent different links: Beige = Shared protein domains, Purple = co-
localisation, Red = Physical interactions, Blue = Pathways, Green = Shared protein domains, Orange = 
Predicted interactions. The weight of the lines is in proportion to biological process involvement with the 3 
inputted genes. 
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8.3.3.3 Discussion 
The comparison of two very different experiment results has shown a lack of crossover 
which is explained by substantial differences between the two studies. One of the more 
obvious differences is the species or tissue type used to evaluate miR-137 effect on the 
transcriptome. The Hill study utilised human neural stem cells in a culture, while the FlyChip 
was completed using whole D. melanogaster heads. Further differences are within the 
experimental approach to MIR-137 expression change. The CTXOE03 cells were cultured as 
normal and then exposed to a chemical miRNA inhibitor, preventing the expressed miRNA to 
function properly. In the flies, the genomic region containing the miR-137 gene was 
substituted for another gene. This causes complete loss of miRNA expression throughout 
development and adulthood. These differences create many incomparable factors like level of 
MIR-137 expression remaining and potentially biological coping mechanisms from lack of 
miRNA in development. 
AKR1B1 is the ortholog of Drosophila gene CG6083. Aldo-keto reductase family 1 
member B1, prevalent in the adrenal glands and responsible for glucose metabolism and 
osmoregulation (Shah et al. 1997). In humans, dysfunction within the gene has been 
implicated with increased risk of nephropathy, neuropathy, and retinopathy in insulin-
dependent diabetics. The gene encodes an enzyme responsible for the metabolism of glucose 
aldehydes to sorbitol which is then slowly broken down by sorbitol dehydrogenase. In 
hyperglycaemic conditions, there is a dramatic increase in sorbitol concentration which can 
cause additional cellular hyperosmotic stresses and subsequently may increase damage 
caused by diabetes (Chung and Lamendola 1989). Expression of an RNA-inhibition molecule 
in Drosophila mushroom bodies demonstrated significant neuroanatomical defects, 
characterised by lobe fusion in approximately 35% of cases (Koboyashi et al. 2006). The 
mushroom body is functional comparable to the mammalian cerebral cortex (Sitara et al. 
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2015), which is responsible for higher cognitive thought processes such as memory, thinking, 
perceiving or language. Neuroanatomical changes in this region; such as decreased cortical 
thickness, decreased dendrite length, and overall decrease in brain volume has been 
associated with psychiatric disorders like SZ (Nesvag et al. 2007; Iritani 2013). 
HSPA2 is the ortholog of Drosophila gene hsc70-2. The gene encodes heat shock 70d 
protein 2, which is expressed abundantly in the brain, heart, and other muscles (Roux et al. 
1994). The protein has been implicated with sperm maturation, with cells not expressing 
sufficient amounts of HSPA2 showing cytoplasmic retention (Huszar et al. 2000). The 
protein was also found in elevated amounts in breast cancer tissues, both primary and 
metastatic (Rohde et al. 2005). The family of heat shock proteins have been linked to SZ and 
are thought to play a protective role for the CNS (Kim et al. 2008). Furthermore, these 
proteins are chaperones responsible for repair, growth, and maintenance of cellular structures 
that may be damaged from stress conditions (Welch 1991; Kim et al. 2008). It is thought that 
there is a potential for such cellular stresses to increase the likelihood of developing SZ and 
associated disorders, as expression of oxidative stress and metabolism genes differentiated in 
patients suffering from SZ (Prabakoran et al. 2004). Reducing the expression of both HSPA1 
and HSPA2 in cancer cells produced an antiproliferative effect on the cells and, when 
downregulated individually, produced growths with different morphologies. In mice, 
knockout of the gene has produced partial sterility of the males without affecting the females 
(Dix et al. 1996). In the fruit fly, the enzyme is known to function as a chaperone to promote 
proper post-transcriptional folding of proteins. In flies with RNAi driven knockdown of 
hsc70-2 through development, the larva develops anatomically smaller and feature 
fragmented mitochondria (Zhou et al. 2019). 
RNASEH1 is the human ortholog of Drosophila gene rnh1. The gene encodes an 
endonuclease expressed in both the nucleus and mitochondria, which digests the RNA 
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component of RNA-DNA double-stranded hybrids (Reyes et al. 2015). Heterozygous double 
mutants of the RNASEH1 gene was found in some individuals who developed muscle 
paralysis around the eyes as a result of loss of RNASEH1 function. The cells were shown to 
have fragmented mitochondria and lower action potential across the mitochondrial 
membrane, synonymous with mitochondrial dysfunction (Reyes et al. 2015). In mice, 
deletion of the rnaseh1 ortholog caused developmental arrest at around 8 days, due to a 
decrease in mitochondrial DNA and subsequent apoptotic cell death (Ceritelli et al. 2003). 
Partial deletion of the genomic sequence of rnh1 in D. melanogaster causes severe 
developmental defects including a delay in developmental time, pre-pupal and pupal 
developmental lethality, and melanotic tumours (Filippov et al. 2001). 
Putting either the human genes or the fly genes into DAVID did not produce any 
significant results for pathway enrichment, however Gene Mania produced some additional 
genes which are linked to the 3 candidates. These include members of the TOR family in a 
pathway with HSPA2 (Wu et al. 2010), predicted links between EDH1/3 and AKR1B1 (Stuart 
et al. 2013), and pathways between SYCE1 and HSPA2 (Jassal et al. 2020). Members of the 
TOR family have been linked to dystonia, an involuntary muscle movement disorder 
(Charlesworth et al. 2017). EDH3 is linked to MDD in Chinese population studies (Shi et al. 
2012), and dysfunction of the fly ortholog past1 creates neuromuscular junction synapse 
abnormalities and developmental delay of ~20% (Olswang-Kutz et al. 2008; Koles et al. 
2015). The candidate genes are separated in the gene network map, indicating little overlap in 
the mechanisms that they are involved in. This could be indicative of the complexity of 
miRNA regulation networks and the difficulty in comparing two organisms. 
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8.3.4 Conclusion: FlyChip vs Stem cell data 
In conclusion, the attempt to find overlap between the genetic changes in human 
CTXOE03 and D. melanogaster heads demonstrate did not produce significant results, 
meaning the acceptance of the null hypothesis from Objective E hypothesis 1 (Chapter 1.8). 
The initial comparison of the entire FlyChip to the significant genes produced from miR-137 
analysis in CTXOE03 cells had a high potential to produce false results and therefore the 
method was changed to look at higher significance target genes only. Overall, there were not 
many similarities between the significant data sets, with a calculated 0.25% correlation 
coefficient. This produced a select subset of just 3 genes across the ~14000 FlyChip genes 
(30 with a p-value <0.05) and over 1000 genes from Hill et al. study (2014). Arguably, there 
are many differences within the experimental designs of the studies producing the datasets 
that this result is not surprising. However, the results interestingly demonstrate a heat shock 
protein which is significantly expressed differently across both experiments but in different 
expression directions. This could be evidence of a coping mechanism within the flies, as heat 
shock proteins are known to have protective properties for the nervous system (Kim et al. 
2008). The three genes identified as significant across both data sets shows some potential 
implications for miR-137 expression regulating pathways particularly HSPA2, and its 
apparent involvement with TOR and EDH genes. The phenotypes associated with dysfunction 
of these genes are synonymous with some symptoms of degenerative neurological diseases 
and psychiatric disorders, creating a putative method of action for the locomotor defect 
exhibited in Chapter 5. 
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8.4 Comparison to human GWAS 
With many of miR-137 target genes already implicated with neurological diseases and 
psychiatric disorders, further comparison of the significant FlyChip genes with 
phenotypically relevant GWAS could bring new links between miR-137 and these human 
diseases. 
 
8.4.1 UKBiobank/FINNGEN Neale Lab published datasets 
The UK biobank is an ongoing project to provide an open database of some 500000 
people who were subjected to a series of medical tests and measurements alongside a self-
answered questionnaire. The project was started in 2006 and aims to follow many of the 
individuals for up to 30 years accumulating additional data to be added to the biobank. 
Currently there is a wealth of data alongside the genomes including body measurements, 
medical diagnoses, activity monitoring, MRI scans, and more. The UK biobank data has 
some obvious flaws with the method of self-reported and online questionnaire style of data 
gathering, however some parameters are much more robust and useful for studying. These 
can be particularly useful alongside more specific databases searching for correlations. 
Finngen is a Finnish project which is accumulating a holistic dataset from novel data 
and the existing biobanks in collaboration with hospitals, universities, and pharmaceutical 
companies. The project ultimately aims to produce a similar database to the UKBiobank with 
500000 participants, each with genomic data and health registry diagnoses information. 
Unlike the UKbiobank, the diagnoses are clinical based and therefore likely to be more 
reliable than self-reported participant measures. However, the Finngen project started in 2016 
and is still in early stages of collecting data which makes it a smaller database currently. 
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While many studies have been conducted utilising the data put out, researchers within 
the Ben Neale lab have outputted cleaned and imputed data from their GWAS research that 
are open source to anybody that wants to download and use them. This data is accessible 
from www.nealelab.is/. The data has been separated into the individual questions/parameters 
that were put into the database, such as “self-reported schizophrenia” or “smokes tobacco on 
most days”.  
GWAS data was selected for parameters associated with neurological or psychiatric 
disorders (table 8.7). This data was further edited and then put through an online platform to 
calculate significant SNPs and produce Manhattan plots of genes with genome wide 
significance for each parameter. The resulting SNPs and genes were then cross referenced 
again the candidate gene list (table 8.5). 
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Table 8.7: Selected neurological UKBiobank and FINNGEN parameters. 
Database Identifier Category 
UKBiobank 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
20002_1262 Self-reported: Parkinson’s disease 
20002_1286 Self-reported: depression 
20002_1289 Self-reported: schizophrenia 
20002_1291 Self-reported: mania/bipolar disorder/manic depression 
20002_1482 Self-reported: chronic fatigue syndrome 
20002_1614 Self-reported: stress 
20003_1140867490 Medicine: lithium product 
20126_1 Bipolar I Disorder 
20126_3 Probable Recurrent major depression (severe) 
20544_1 Diagnosed: Social anxiety or phobia 
20544_10 Diagnosed: mania/bipolar disorder/manic depression 
20544_11 Diagnosed: Depression 
20544_14 Diagnosed: Autism, Asperger's 
20544_15 Diagnosed: Anxiety 
20544_2 Diagnosed: schizophrenia 
23104_irnt Body mass index (BMI) 
G20 Diagnoses - main ICD10: G20 Parkinson's disease 
G47 Diagnoses - main ICD10: G47 Sleep disorders 
AD Alzheimer’s disease 
F5_ALLANXIOUS All anxiety disorders 
FINNGEN 
  
  
  
  
F5_DEMENTIA Dementia 
 
F5_DEPRESSIO Depression 
 
 
F5_SCHIZO Schizophrenia, schizotypal and delusional disorders 
 
8.4.1.1 Python editing of GWAS results data 
Editing of Neale’s public access clean and imputed GWAS data was done in python 3 
programming language using Anaconda PC platform (See supplementary information for 
script). The original download files are not compatible with FUMA as the site requires 
separated chromosome and case-pair position columns, which in Neale’s download files were 
conjugated as “chromosome:position:amino:substitute” in a single column.  
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The code was written to produce the minimum required for the FUMA input, which 
was stated as chromosome, position, and p-value only. The code mainly utilised the “pandas” 
library ability to manipulate dataframes. It was written to read and decrypt the .bgz file with 
the gzip library, then extract and separate the variant column, and then create a new 
dataframe with only the three necessary columns (figure). This dataframe was then outputted 
to a .csv file which was compatible with FUMA in both size and filetype. 
The original python code extracted the “variant” column and created a new dataframe 
separating the column at the “:” separator and then joined them to the original dataframe. 
This created 4 new columns at the beginning named “Chromosome”, “position”, “amino1”, 
and “amino2”. This dataframe was then exported to .csv file and then zipped with GZIP 
function to be used with FUMA. Unfortunately, the filesize even when zipped was too large 
for the website as it takes a maximum of 600mb per upload. 
The next code created the same end dataframe with the new columns but removed rows 
which had a p-value of over 0.01 and were therefore not of interest. As a result, the dataframe 
was significantly shorter and when zipped released a file of a size compatible with the FUMA 
site. However, it was unclear if the selective deletion of GWAS data had implications for the 
average p-value calculations conducted within FUMA that would have given false results. 
Upon development of the final code and following testing it was found that selective deletion 
of the GWAS data had no effect on the significant output results. 
The final code which simply created a new dataframe of just chromosome, position, 
and p-value, was found to provide a small enough filesize while also not selectively deleting 
non-significant SNPs.  
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8.4.1.2 Calculating significant SNP and genes 
The Complex Genetic Traits lab at VA university in Amsterdam runs an online 
Functional mapping and annotation (FUMA) platform available for public use at 
fuma.ctglab.nl/. The platform is primarily split into 3 sections: GENE2FUNC, Cell Type, and 
SNP2GENE. FUMA utilises several different pre-existing data sets and tools for these 
analyses including PLINK and the 1000 genomes project for calculating r2 and MAF, 
MAGMA for gene set analyses, GTEX for tissue-based gene expression, and MsigDB for 
gene sets grouping (Purcell et al.  2007; Liberzon et al. 2011; 1000 genomes project 
consortium 2015; Leeuw et al. 2015; GTEX consortium 2015). 
SNP2GENE takes GWAS results and analyses them for significant SNPs and 
subsequent related genes. The output includes a gene-based Manhattan plot, and easily 
downloadable lists of significant SNPs and associated information like genomic location. The 
minimalist GWAS files created from python manipulation of the Neale data were uploaded 
into SNP2GENE. The number of samples was added to the settings (361141) but no other 
parameters were changed. The total results were downloaded from the download tab and the 
“snps.txt” file was opened and copied to excel. The SNPS and correlating nearest genes of all 
significant hits were checked for matches within the target gene list created from the 
directional matched CTXOE03 and FlyChip data. 
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8.4.1.3 Results 
The SNP2GENE programme produced a total of 2508 significant SNPs or genes across 
the selected parameters. The outcomes which have a matched gene against the candidate gene 
list (directionally matched FlyChip and Hill genes) are listed here, while the others are in 
supplementary materials. 
Parameter 20002_1289 refers to the initial UKBiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional. There were 642 people who reported a history of SZ out of 383782 
participants. This data was then cleaned and imputed by Neale et al. into 361194 samples, of 
which 391 cases against 360750 controls. Genome wide significance was defined at P = 
0.05/19712 = 2.537e-6, identifying significant genesTCEAL1, VHLL, and CSF3L (figure 
8.4).
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Figure 8.4: Manhattan plot for UKBiobank 20002_1289; Reported schizophrenia 
The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome 
Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan 
plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was 
defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: TCEAL1, VHLL, and CSF3L. 
 
  
201 
 
Parameter 20544_11 refers to participants disclosing if they had any current or 
historical diagnoses for depression. The question was part of an online follow-up 
questionnaire revolving around mental health. There were 50099 participants, of which 
33422 claimed to have been diagnosed at some point in their life. This data was cleaned and 
imputed by Neale et al. and a total of 117782 was analysed, with 25087 cases against 92695 
controls. Significant genes above the determined genome wide significant level were: 
SLC25A20, CCDC71, C3orf84, CCDC36, BTN3A2, BTN1A1, HIST1H2BL, HIST1H2AJ, 
HIST1H2BN, OR2B2, ZKSCAN4, PGBD1, TMEM106B, RHOF, SETD1B, METTL9, 
SLC47A1, and SUPT4H1 (figure 8.5). 
 
Parameter 20544_2 refers to participants disclosing if they had any current or historical 
diagnoses for SZ. The question was part of an online follow-up questionnaire revolving 
around mental health. There were 50099 participants, of which 157 claimed to have been 
diagnosed at some point in their life. This data was cleaned and imputed by Neale et al. and a 
total of 117716 was analysed, with 103 cases against 117603 controls. Significant genes 
above the determined genome wide significant level were: AL645608.2, RYBP, DHFRL1, 
RGS14, RING1, RP11-89N17.1, OR1L3, SETD1B, PPP4R4, SERPINA10, RP11-17M16.1, 
FAM187B, MAOB, and CDK16 (figure 8.6) 
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Figure 8.5: Manhattan plot for UKBiobank 20544_11; Diagnosed Depression. 
The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome 
Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan 
plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was 
defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: SLC25A20, CCDC71, C3orf84, CCDC36, BTN3A2, 
BTN1A1, HIST1H2BL, HIST1H2AJ, HIST1H2BN, OR2B2, ZKSCAN4, PGBD1, TMEM106B, RHOF, SETD1B, METTL9, SLC47A1, and SUPT4H1. 
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Figure 8.6: Manhattan plot for UKBiobank 20544_2; Diagnosed schizophrenia.  
The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome 
Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan 
plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was 
defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: AL645608.2, RYBP, DHFRL1, RGS14, RING1, RP11-
89N17.1, OR1L3, SETD1B, PPP4R4, SERPINA10, RP11-17M16.1, FAM187B, MAOB, and CDK16. 
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Comparison of the matched expression direction candidate gene list and the results 
from FUMA analysis revealed a select few genes present in both (table 8.8). The FUMA 
output also included SNP locations within the genes, of which two (rs7607527 and 
rs114534142) are exonic while rs79253132 is intergenic and rs149013672 is intronic with no 
likely subsequent gene effect. Of the two exonic SNPs, only rs114534142 was reported to 
influence the gene where it would cause a missense variant and subsequent coding sequence 
change through dbSNP. 
 
Table 8.8: Genes in neurological GWAS and candidate list 
GWAS group GWAS meaning Associated gene 
20002_1289 Self-reported: Schizophrenia HADHB 
20544_11 Diagnosed: Depression SLC25A20 
20544_2 Diagnosed: Schizophrenia SDAD1 
20544_2 Diagnosed: Schizophrenia NUP54 
G20 Diagnosis: ICD10 Parkinson's disease HIST1H4C 
 
8.4.1.4 Discussion 
Comparison of the candidate gene list and outputs from the FUMA SNP2GENE 
function (both Manhattan plots and significant SNPs) offered a select list of 5 human genes. 
Four of these genes are from psychiatric disorder related parameters (SZ and Depression), 
with the other being neurological diseases (Parkinson’s disease). The SNPs do not currently 
have reported clinical significance on ClinVar, but further investigation of the genes provided 
some options for mechanism through which miR-137 may cause the locomotor or sleep 
defects. 
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HADHB, or Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex 
Subunit Beta, is the beta subunit of the mitochondrial trifunctional protein (MTP), which 
catalyses the last three steps of mitochondrial beta-oxidation of long chain fatty acids (Das et 
al. 2006). This oxidation is the major metabolic system to catabolize fatty acids producing 
energy for many cellular processes (Das et al. 2006; Kishita et al. 2012). In humans, 
problems with the MTP is diagnosed as mitochondrial trifunctional protein deficiency, 
characterised with symptoms of lethargy and hypoglycaemia (Das et al. 2006; Choi et al. 
2007). Furthermore, if not treated the build-up of fatty acid metabolites can cause tissues 
damage to major organs. Mutations specifically within the HADHB gene can cause similar 
problems to MTP-deficiency, alongside hypotonia, neuropathy, myopathy, liver problems, 
and even sudden death in infant sufferers (Das et al. 2006; Choi et al. 2007). The gene was 
identified in relation to SNP rs7607527, which was found to be significant in the GWAS 
parameter “self-reported schizophrenia” from the UKBiobank in Section 8.3.5.2 of this 
project. HADHB proteins were found to bind to dysbindin-1 in mice skeletal muscle, a 
known SZ related protein (Oyama et al. 2009).  In both the FlyChip experiment and Hill et al. 
study the expression levels of HADHB (or fly ortholog FBgn0025352 thiolase) decreased 
when miR-137 levels were decreased/removed. The thiolase gene shares a 66.2% identity 
with the human HADHB gene and removal of genomic thiolase has been seen to negatively 
influence Drosophila lifespan and locomotor ability (Kishita et al. 2012). The phenotype and 
expression change direction match up with miR-137 deficient flies in this project, providing a 
possible mechanism for miR-137 involvement in the locomotor defect. 
The SLC25A20 gene encodes carnitine-acylcarnitine translocase (CACT), a component 
of the carnitine cycle, which is necessary to shuttle long-chain fatty acids from the cytosol 
into the intramitochondrial space for mitochondrial beta-oxidation of fatty acids. In humans, 
problems within the CACT gene can lead to CACT-deficiency-disease, which is characterised 
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with symptoms of drowsiness, skeletal muscle weakness, hepatic abnormalities, increased 
ammonia in the blood and subsequent death from multiorgan failure and neuropathy (Huizing 
et al. 1998; Rubio-Gozalbo et al. 2004; Yan et al. 2017). The SLC25A20 gene expression has 
also been investigated as a blood marker for Parkinson’s disease, and furthermore was 
significantly enriched within a sleep regulating pathway (Jiang et al. 2019). The SLC25A20 
gene has multiple likely orthologs in Drosophila; FBgn0031881 mme1, FBgn0032219 
CG4995, and FBgn0039525 CG5646. In both the Flychip results and the data from Hill et al. 
(2014) these genes showed an increase in expression with removal/inhibition of genomic 
miR-137 expression. In drosophila, knockdown of mme1 gene via RNAi based silencing 
caused a decrease in lifespan of approximately 30% (Cui et al. 2016). The decrease in 
lifespan matches phenotype data from this study of miR-137 KO, however the phenotype was 
exhibited with a decrease in drosophila mme1 while the Flychip/hill data suggests the gene 
expression would have been higher in the miR-137KO strain. 
SDAD1 or SDA containing domain 1 gene belongs to the SDAD family, which has been 
recently discovered (Zeng et al. 2017; Jing et al 2019). In humans, SDAD1 gene expression 
has been found to positively correlate with the proliferation of colon cancer cells (Zeng et al. 
2017) and in mice the gene was shown to influence cardiac hypertrophy (Jing et al 2019). In 
drosophila FBgn0033379 mys45a, both flychip and Hill et al. data showed an increase in 
expression when miR-137 was removed. In Drosophila, manipulating the expression of 
mys45a gene with the UAS/Gal4 constructs results in neuroanatomy defects and shorter 
lifespans (Neely et al. 2010; Neumuller et al. 2011). However, these phenotypes were 
displayed when the expression of mys45a was decreased, which contrasts with the gene 
expression and phenotype behaviour of this study. 
 
207 
 
NUP54 encodes nucleoporin54, part of the complex protein structures which create 
pores in the nuclear membrane in eukaryotic cells. This subunit is known to bind directly to 
the nuclear import factors NUP97 and NTF2 (Hu et al. 1996). Loss of genomic NUP54 
increased DNA ionising radiation susceptibility, resulting in an increase in cell death and an 
increase in chromosome aberrations (Rodriguez-Berriguete et al. 2018). Furthermore, NUP54 
is directly involved in DNA repair during homologous recombination, as demonstrated by a 
lack of RAD51 activity in NUP54-deficient HeLa (human cervical cancer) cell cultures 
(Rodriguez-Berriguete et al. 2018). In both humans and C. elegans the NUP54 proteins have 
been found to directly recruit polo-like kinase 1 (PLK1) proteins in breakdown of the nuclear 
envelope during mitosis, a process vital for proper chromosomal separation and ultimately 
successful cell replication (Martino et al. 2017). This project identified the NUP54 gene from 
its association with SNP rs79253132 in the GWAS data for UKBiobank participants with a 
medical diagnosis for SZ. In drosophila, the NUP54 gene ortholog is FBgn0033737 nup54, 
and in both flychip and Hill et al. data there was an increase in expression when miR-137 was 
downregulated/ablated. Studies into Drosophila nup54 have shown that RNAi mediated 
knockdown of expression in the CNS does not affect stock viability or behavioural response 
to high temperatures (Neely et al. 2010). At present, although NUP54 appears to be involved 
in vital cellular processes there are no phenotype matches to this project or those of 
neurological diseases and psychiatric disorders 
HIST1H4C is a member of the histone family. The gene encodes a protein which is 
involved in the wrapping of DNA in eukaryotic chromatin during cell division. Methylation 
and acetylation of specific parts of the HIST1H4C protein are common epigenetic features in 
cancer cells (Fraga et al. 2005; Savage et al. 2008). Dang et al. (2009) reported a correlation 
with HIST1H4C expression and age, along with SIRT1 protein abundance, resulting in 
compromised transcriptional silencing in older cells. The HIST1H4C gene was highlighted as 
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significant within the Parkinson’s disease GWAS data from the UKBiobank. In both the 
human cells in Hill et al. and in the Flychip from this study, the gene expression (in the 
human or Drosophila gene ortholog FBgn0013981 his4r) increased with the removal of MIR-
137. Studies into his4r gene expression in Drosophila has shown that introducing a 
hypomorphic allele has a partially lethal effect on stocks and complete sterility (McKay et al. 
2015).  
 
8.4.1.5 UKBiobank GWAS limitations and data set refinement 
Through communications with Dr Richard Anney of Cardiff University, discrepencies 
were identified within the datasets used from the Neale lab releases of the UKBiobank data. 
This was likely due to incomplete processing of the publicly available data, leading to 
potential false positive results. Alongside this, the UKBiobank is potentially flawed in terms 
of data collection metric. Enrolment into the database was on a voluntary basis, and if you 
have illnesses you are unlikely to participate in such a study, producing a skew in the 
population spread. Therefore, parameters such as “diagnosed with schizophrenia” may not 
truly be representative, and selection of parameters should be less specific to disease and 
diagnoses.  
 
8.4.2 UKBiobank Sleep Parameters 
Through communication with Richard Anney of Cardiff University, lists of top genes 
from some pre-analysed UKBiobank GWAS data were obtained (table 8.9). The parameters 
were in relation to sleep based characteristics, rather than specifically searching for disease 
diagnoses as identified as problematic in Chapter 8.4.1. The genes were pre-filtered to only 
those which have minimum reported p-value of 0.00001. These were then cross-referenced to 
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the significant FlyChip gene list to identify other potential links with the FlyChip information 
and other human parameters/diseases/disorders. 
Table 8.9: Sleep parameters used from UKBiobank. 
UKBioBank ID Parameter 
1160 Sleep duration 
1170 Getting up in the morning 
1180 Morning/evening person 
1190 Nap during day 
1200 Sleeplessness / insomnia 
1220 Daytime dozing / sleeping 
 
8.4.2.1 Method 
The lists of top GWAS significant genes were copied into Microsoft Excel and 
compared to the human orthologs calculated by putting the significantly DEGs from the 
FlyChip into DIOPT. If the gene name was found in both list then this constituted as a match, 
and the list of these genes were separated for further analysis. 
Dr Richard Anney conducted gene set enrichment analysis by using the Multi-marker 
Analysis of Genomic Annotation (MAGMA) programme on the genes which were found in 
both the top GWAS results and the FlyChip significant orthologs. MAGMA uses a multiple 
regression approach to properly incorporate linkage disequilibrium between markers and to 
detect multi-marker effects, therefore producing better statistics for the association of a gene 
set to the GWAS SNPs. 
The fly genes identified in both the GWAS results and the FlyChip orthologs were put 
into DAVID to assess any enrichment in pathways. The fly genes were used because the 
conversion of fly to human genes creates multiple related genes which falsely identify as 
enriched within the gene set. The human genes were used in Gene Mania to identify any 
additional genes involved in the pathway.  
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8.4.2.2 Results 
Comparison of the UKBiobank sleep parameters and the significant FlyChip gene 
orthologs have identified a list of 28 human genes from 7 D. melanogaster genes which exist 
in both the top GWAS results and DEGs from the FlyChip (table 8.10). 
 
Table 8.10: Genes in sleep related GWAS and significant candidate list 
Human Gene Drosophila ortholog ID Drosophila gene 
FlyChip expression 
change (Log2 3dp) 
ABCG5 FBgn0003996 w 3.830 
ABCG8 FBgn0003996 w 3.830 
AKR1A1 FBgn0036183 CG6083 -1.788 
AKR1C1 FBgn0036183 CG6083 -1.788 
AKR1C2 FBgn0036183 CG6083 -1.788 
AKR1C3 FBgn0036183 CG6083 -1.788 
AKR1C4 FBgn0036183 CG6083 -1.788 
AKR1E2 FBgn0036183 CG6083 -1.788 
CES2 FBgn0027584 CG4757 2.281 
CES3 FBgn0027584 CG4757 2.281 
CES4A FBgn0027584 CG4757 2.281 
CES5A FBgn0027584 CG4757 2.281 
GLB1L3 FBgn0260746 Ect3 -1.774 
HSPA1A FBgn0001217 Hsc70-2 2.300 
HSPA1B FBgn0001217 Hsc70-2 2.300 
HSPA1L FBgn0001217 Hsc70-2 2.300 
HSPA2 FBgn0001217 Hsc70-2 2.300 
HSPA5 FBgn0001217 Hsc70-2 2.300 
HSPA6 FBgn0001217 Hsc70-2 2.300 
HSPA8 FBgn0001217 Hsc70-2 2.300 
LGR6 FBgn0267435 Chp -1.852 
LRRC1 FBgn0267435 Chp -1.852 
LRRC4 FBgn0267435 Chp -1.852 
LRRC7 FBgn0267435 Chp -1.852 
MCF2L FBgn0050456 CG30456 -2.492 
NLGN1 FBgn0027584 CG4757 2.282 
PLEKHG4 FBgn0050456 CG30456 -2.492 
SLC26A10 FBgn0050456 CG30456 -2.492 
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The MAGMA analysis conducted at Cardiff University shows that there was not a 
significant enrichment of matched genes found in any of the GWAS results (table 8.11). 
 
Table 8.11: MAGMA enrichment analysis of sleep related GWAS. 
GWAS P-value (3dp) Standard Error (3dp) 
1160-Sleep duration 0.539 0.097 
1170-Getting up in the morning 0.763 0.098 
1180-Morning/evening person 0.456 0.11 
1190-Nap during day 0.798 0.098 
1200-Sleeplessness / insomnia 0.964 0.094 
1220-Daytime dozing / sleeping 0.403 0.089 
 
 
DAVID did not produce any enriched pathways from the 7 candidate genes, however 
Gene Mania identified additional genes including KCNAB proteins, HSPA proteins, and AKR 
proteins. The network map shows 3 main clusters of interactions around similar protein 
domains, as expected from multiple orthologs coming from one fly gene (figure 8.7). 
212 
 
 
Figure 8.7: Genetic network of FlyChip DEGs in sleep related GWAS. 
Genetic network of the 28 human orthologs of the 7 significant DEGs in the FlyChip and UKBiobank Sleep 
related GWAS results. The analysis and visualisation were created by Gene Mania (accessible from: 
genemania.org). Additional genes are in full black while inputted genes are in stripes. The colours of lines 
represent different links: Beige = Shared protein domains, Purple = co-localisation, Red = Physical interactions, 
Blue = Pathways, Green = Shared protein domains, Orange = Predicted interactions. The weight of the lines is 
in proportion to biological process involvement with the 3 inputted genes. 
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8.4.3 Schizophrenia and major depressive disorder 
Through communication with Dr Richard Anney at Cardiff University, a list of top 
genes was obtained for GWAS studies into MDD and SZ (Pardinas et al. 2016; Ripke et al. 
2018). The genes were pre-filtered to only those which have minimum reported p-value of 
0.00001. These were then cross-referenced to the significant FlyChip gene ortholog list to 
identify genes of interest. 
 
8.4.3.1 Method 
The lists of top GWAS significant genes were copied into Microsoft Excel and 
compared to the human orthologs calculated by putting the significantly DEGs from the 
FlyChip into DIOPT. If the gene name was found in both list then this constituted as a match, 
and the list of these genes were separated for further analysis. 
Dr Richard Anney conducted gene set enrichment analysis by using the Multi-marker 
Analysis of Genomic Annotation (MAGMA) programme on the genes which were found in 
both the top GWAS results and the FlyChip significant orthologs. MAGMA uses a multiple 
regression approach to properly incorporate linkage disequilibrium between markers and to 
detect multi-marker effects, therefore producing better statistics for the association of a gene 
set to the GWAS SNPs (De Leeuw et al. 2014). 
The fly genes identified in both the GWAS results and the FlyChip orthologs were put 
into DAVID to assess any enrichment in pathways. The fly genes were used because the 
conversion of fly to human genes creates multiple related genes which falsely identify as 
enriched within the gene set. The human genes were used in Gene Mania to identify any 
additional genes involved in the pathway. 
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8.4.3.2 Results 
Comparison of the MDD and SZ GWAS results and the significant FlyChip gene 
orthologs have identified a list of 13 human genes from 7 D. melanogaster genes which exist 
in both the top GWAS results and DEGs from the FlyChip (table 8.12). 
 
Table 8.12: Genes in psychiatric disorder GWAS and significant candidate list 
 
Human Gene 
 
Drosophila ortholog ID 
 
Drosophila gene 
 
FlyChip expression 
change (Log2 3dp) 
GLB1L FBgn0260746 Ect3 -1.774 
GLB1L2 FBgn0260746 Ect3 -1.774 
GLB1L3 FBgn0260746 Ect3 -1.774 
HSPA1A FBgn0001217 Hsc70-2 2.300 
HSPA1B FBgn0001217 Hsc70-2 2.300 
HSPA1L FBgn0001217 Hsc70-2 2.300 
IGSF9B FBgn0010473 Tutl 0.603 
LRRC4 FBgn0267435 Chp -1.852 
NDUFS5 FBgn0031228 ND-15 2.573 
NLGN4X FBgn0027584 CG4757 2.281 
PLEKHG4 FBgn0050456 CG30456 -2.492 
SCRIB FBgn0267435 chp -1.852 
SLC26A10 FBgn0050456 CG30456 -2.492 
 
The MAGMA analysis conducted at Cardiff University shows that there was not a 
significant enrichment of matched genes found in either of the GWAS results (table 8.13). 
 
Table 8.13 MAGMA enrichment analysis of psychiatric disorder GWAS. 
GWAS P-value (3dp) Standard Error (3dp) 
Major depressive disorder 0.826 0.092 
Schizophrenia 0.608 0.11 
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DAVID did not produce any enriched pathways from the 7 fly genes; however, Gene 
Mania added several genes to the pathway including GLB1, SLC26 proteins, and HSPA 
proteins. The network map shows 3 main clusters of interactions around similar protein 
domains, as expected from multiple orthologs coming from one fly gene (figure 8.8). 
 
 
Figure 8.8: Genetic network of FlyChip DEGs in psychiatric disorder GWAS. 
Genetic network of the 13 human orthologs of the 7 significant DEGs in the FlyChip and UKBiobank Sleep 
related GWAS results. The analysis and visualisation were created by Gene Mania (accessible from: 
genemania.org). Additional genes are in full black while inputted genes are in stripes. The colours of lines 
represent different links: Beige = Shared protein domains, Purple = co-localisation, Red = Physical interactions, 
Blue = Pathways, Green = Shared protein domains, Orange = Predicted interactions. The weight of the lines is 
in proportion to biological process involvement with the 3 inputted genes. 
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8.5 Discussion 
Comparison of the significant FlyChip orthologs to GWAS data proved fruitful in 
identifying genes which should be prioritized in future work. There are several genes which 
exist in both the UKBiobank sleep parameters and the MDD and SZ studies, likely due to the 
overlap of sleep and psychiatric disorders causation or symptom. Of the significant DEGs 
isolated by comparing the top FlyChip results and the data from Hill et al., both CG6083 and 
hsc70-2 (or the human orthologs) were found to be in the top sleep related GWAS gene list. 
Furthermore, hsc70-2 and it’s orthologs were found in both the sleep and the psychiatric 
studies GWAS results. Gene Mania produced a connection between AKR1A1 and KCNAB1, 
which is a member of the potassium voltage gated ion channels linked with psychiatric 
disorders. Alongside the published data implicating CG6083 with mushroom body 
development and the function of HSPA2 to prevent oxidative stress and subsequently 
psychiatric disorders, these genes are clearly putative causes of the phenotype displayed in 
Chapter 5. 
Many of the genes found to correlate between the FlyChip and the GWAS data appear 
to exist in quite separate clusters on the network maps created by Gene Mania and did not 
produce significant enrichment in DAVID. This reinforces the notion that there is not a single 
network affected by the loss of genomic miR-137, but instead the miRNA is involved in 
regulating multiple pathways. This also provides some explanation as to the lack of results 
comparing the two wet lab studies, as the complexity of such networks must become quite 
confounding and ultimately difficult to determine. 
None of the 5 genes identified as part of the psychiatric disorders UKBiobank GWAS 
were found in the GWAS from the SZ or MDD studies, adding weight to the argument of the 
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UKBiobank data having a population bias. However, with such a small subset of the results 
being compared there is not enough evidence to say this with certainty. 
 
8.6 Conclusion 
Overall, the use of bioinformatical analysis has provided a new aspect to his project 
which has demonstrated the difficulties of cross-species data comparisons, the overlap of 
sleep and psychiatric disorder significant GWAS results and provided a set of candidate 
genes with plausible biological importance in either psychiatric disorders or specifically the 
phenotypes exhibited in the miR-137KO flies. The lack of significant enrichment of the 
Flychip DEGs and any of the GWAS gene sets ultimately means that the null hypotheses 1, 2, 
and 3 from objective F must be accepted (Chapter 1.8). 
Through the repeated identification of D. melanogaster genes hsc70-2 and CG6083 in 
several of the GWAS results as well as significant DEGs in both studies, this project selects 
these as genes of high importance to assess as part of a follow-on project. 
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9 The link between miR-137, psychiatric disorders, and sleep 
The focus of this project was to investigate the link between miR-137 and psychiatric 
disorders, specifically SZ which is already associated with the miRNA through GWAS 
studies (Ripke et al. 2011; Duan et al. 2014). There are already several experimental studies 
connecting the miRNA to psychiatrically relevant phenotypes like brain morphology, 
cognitive function, and synaptic plasticity (Cummings et al. 2013; Green et al. 2013; 
Kuswanto et al. 2015; Cosgrove et al. 2017). miR-137 is also highly localised within the 
brain, further reinforcing the contribution of the miRNA to the aetiology of psychiatric 
disorders. There is a substantial overlap between the symptoms of psychiatric disorders, such 
as SZ, and those of neurological diseases like Parkinson’s disease. This overlap could also 
lead to linking miR-137 to a wider range of human illnesses.  
The model organism, D. melanogaster, was chosen as a suitable research subject due to 
the comparable genetics and already published phenotypes synonymous with psychiatric and 
neurological symptoms. Firstly, the purpose of miR-137 had to be established, which was 
achieved by investigating the effect of total removal of genomic expression from the flies. 
Further research then implicated specific genes and mechanisms through which these 
phenotypes may be caused. 
This project investigated miR-137 with a holistic organism-level aspect, providing a 
wider picture of the functional relevance of miR-137 in relation to overall health and 
behaviour. 
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9.1 The effect of miR-137 knockout 
The simplest starting point was to associate the loss of genomic miR-137 with any 
behavioural phenotypes to evaluate if the miRNA is significant enough to produce any 
observable behaviour changes. The fly strain obtained from the BDSC had the miR-137 locus 
substituted for an insertion which presented a red-eye phenotype. This information was 
successfully verified through presence/absence PCR genotyping, DNA sequencing, and local 
alignment against the expected sequences (Chapter 3). QPCR attempts also found zero miR-
137 expression within the miR-137KO strain (Chapter 6), further proving complete miR-137 
gene LOF. 
While the miR-137KO stock lacked miR-137 expression, it was not guaranteed that this 
was the cause of the behavioural phenotypes. Ablation of a miRNA molecule was unlikely to 
not have had any consequences and, with the constant interbreeding of the strain at the 
BDSC, background modifiers could have accumulated to help cope with the effects. The 
modifiers would be stock specific, and through a set of crosses the total sleep phenotype was 
attributed to miR-137 LOF (chapter 6.1). Furthermore, the heterozygous loss of miR-137 
produced a phenotype of approximately 50% severity to the full knockout. 
In this research, the complete removal of the miR-137 gene presented significant 
phenotypes across several aspects of general fly health and behaviour. These phenotypes 
include a significant developmental delay at the pupal stage and severe overall hypoactivity. 
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9.1.1 Developmental phenotype 
There was a developmental delay identified in the pupal stage of the fly life cycle 
(Chapter 4.2), where miR-137KO flies reached adulthood slower than controls after spending 
an average of 0.8 days longer in chrysalis. Furthermore, there was also evidence that this 
delay was accompanied by an increase in mortality. During the pupal stage, the larva undergo 
metamorphosis that transforms the entire anatomy into that of an adult fly. It is known that 
the CNS is dramatically remodelled at this time, converting and creating neurons to function 
within the adult nervous system (Robertson 1936; Technau and Heisenberg 1982; Truman 
1990; Tully et al. 1994; Hartenstein et al. 2008; Veverytsa and Allen 2013). These neurons 
require a high degree of synaptic plasticity to enable complex processes like axon and 
dendritic remodelling or integration into adult neuron circuits (Hartenstein et al. 2008; 
Veverytsa and Allen 2013). The apparent importance of miR-137 at this stage of the fly 
reaffirms the role of miR-137 and its targets in neuroanatomical development and formation 
as discussed in Chapter 1. 
Two of the DEGs identified by transcriptome analysis of the miR-137KO flies already 
have developmental phenotypes associated with them. Turtle LOF in flies causes partial 
lethality during pupation (Bodily et al. 2001), and partial deletion of rnh1 causes a delay in 
developmental time and pupal stage lethality (Filippov et al. 2001). Of these, rnh1 
(ribonuclease inhibitor 1) was significantly downregulated with a log2 factor of 
approximately -2.6, which correlates with a deletion causing LOF. While exact method of 
rnh1 effecting development is not clear, this provides a logical hypothesis for the mechanism 
of miR-137 on pupal-stage lethality. 
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9.1.2 Behavioural phenotypes 
Behaviourally, the miR-137KO flies had a severely hypoactive phenotype when 
compared to w1118 controls. The actogram produced from DAMS analysis shows that 
throughout the knockout flies have a significantly lower activity across the entire 24-hour 
period, most exaggerated at the morning peak, compared to controls (chapter 5). Separation 
of sleep and locomotor phenotypes was largely achieved by directly assessing movement 
through video recording and tracking individual flies. This identified periods of quiescence in 
the miR-137KO flies alongside locomotor defects (chapter 5), indicating that the actogram 
result was a combined effect of both locomotor and sleep defects. 
 
9.1.2.1 Locomotor ability 
 Overall, the miR-137KO flies had a slower velocity at peak activity times than the w1118 
controls. The knockout strain also performed worse in a negative geotaxis assay, another 
simple assay to evaluate movement ability. At this point it is not clear as to how miR-137 
LOF causes this phenotype as this project did not investigate further. However, the 
localisation of miR-137 expression at the synapses and importance for synaptic plasticity 
would infer that the phenotype is related to neuron signalling rather than muscular problems. 
However, several of the DEGs in the miR-137KO stock were functionally relevant to 
metabolism and mitochondria function. Of these genes, four were found to correlate with 
human orthologs identified as significant within SZ and MDD GWAS (ND-15, Hsc70-2, 
CG6083, and Ect3). As some psychiatric disorders also have aspects of locomotor defects, 
these could potentially be genes affected by miR-137 and subsequently causing the 
phenotype. 
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9.1.2.2 Sleep-like behaviour 
The change in sleep-like behaviour appeared to be the most severe of the phenotypes 
found in the miR-137KO strain and became the focus of this project. The DAMS identified 
total sleep amount in the miR-137KO flies to be approximately 86% of the 24-hour period, 
which is a significant increase when compared to w1118 which sleep circa 57%. Sleep 
governed by genetics and is regulated by two largely independent mechanisms; the circadian 
and the homeostat pathways (Cirelli 2009; Crocker and Sehgal 2010; Sehgal and Mignot 
2011; Donlea et al. 2013). Initial investigation was to establish which mechanism was 
affected by miR-137 LOF. 
The actogram (chapter 5.1) and sleep graph (chapter 5.4) demonstrate that despite the 
obvious different in overall sleep/activity, both the strains exhibit a similar behavioural 
pattern and therefore do not have a circadian defect. The flies were also put into constant 
darkness to investigate if the circadian clock could keep the entrained 12-hour rhythm, 
though with the overall activity count in the miR-137KO this proved difficult to assess.  
Lack of a circadian phenotype indicates that the role of miR-137 is within the 
homeostatic regulation of sleep. This is responsible for the need to sleep following periods of 
wakefulness and the sleep rebound effect after sleep-deprivation (Donlea et al. 2014). In D. 
melanogaster, the fan-shaped body is responsible for homeostatic sleep regulation. This 
region is functionally comparable to the mammalian hypothalamus and hypothalamic 
ventrolateral preoptic nuclei (Donlea et al. 2014). Artificial stimulation of the fan-shaped 
body induces sleep on command and the region is negatively modulated by dopamine 
signalling (Lui et al.2012).  
The DEGs in the FlyChip included a gene, slim, which showed a sleep defect in flies 
with RNAi mediated downregulation of the gene in the CNS (Lobell et al. 2017). This 
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matches the miR-137KO data which had a Log2 factor of -2.357 (3dp). The gene functions to 
positively regulate the stress-activated MAPK cascade, an evolutionarily conserved pathway 
vital for transduction pathways responsible for cell growth and proliferation (Morrison 2012; 
Sekine et al. 2012).  
 
9.1.3 Genetic pathways 
The high number of predicted and proven targets of direct miR-137 regulation provides 
many logical options for the genes and pathways that could result in the phenotypes identified 
in Chapters 4 and 5. It is obvious that miR-137 is part of a complex genetic network and 
therefore it is unreasonable to assume there is a singular pathway responsible for the 
behaviour changes in miR-137KO flies. Having multiple phenotypes also reinforces the 
likelihood of several factors contributing to the overall effect. 
Transcriptome analysis of miR-137KO flies identified several genes which already have 
phenotype associations relatable to locomotor, neuroanatomy, and sleep (chapter 8.2). 
Adding these genes to DAVID for ontology did not produce any significantly enriched 
pathways, demonstrating that the identified genes are not related in terms of function.   
 The sleep phenotype is associated with the homeostatic control pathway (chapter 5.5 
and 9.1.2), which is regulated by the neurotransmitter dopamine. This is a sleep regulating 
molecule that is known to promote wakefulness. The hypoactive phenotype specifically in the 
morning peak in the actogram (chapter 5.1) suggests a dopamine pathway problem, and this 
is known to be regulated by dopamine (Lui et al. 2012). Dopamine regulates the activation of 
the fan-shaped body and the mushroom body through upward or downward dopamine 
neurons (Sitaraman et al. 2015). The FB promotes sleep which upon polarization sends 
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signals to sleep (Donlea et al. 2011; Lui et al. 2012). The MB exists in multiple subregions, 
some of which promote sleep, and some promote wakefulness (Sitaraman et al. 2015). 
Pharmaceutical treatments were used to try recover the sleep phenotype, as the effect of 
the drug can be used as test for normal action of the related pathway. Caffeine was used as a 
stimulant to reduce sleep but produced an unexpected increase in total sleep amount across 
the 24-hour period (chapter 7.2.1). Dopamine is mostly known for its role in promoting 
wakefulness, and miR-137 is predicted to downregulate genes in the dopamine pathway such 
as the pale gene which is the rate-limiting enzyme producing dopamine. It was hypothesized 
that without correct miR-137 expression, the flies would be exposed to increased dopamine 
signalling throughout development leading to dopamine desensitisation. A pale inhibitor, 
3IY, was administered to w1118 and miR-137KO flies to test this hypothesis. 3IY is known to 
promote sleep (Catterson et al. 2010), an effect that was observed in control flies when 
treated acutely (chapter 7.2.2). Chronic treatment of 3IY presented no significant change in 
the total sleep of controls, but it significantly decreased the sleep in miR-137KO flies during 
the day and total 24-hour period. This counter-intuitive change reinforces the hypothesis of 
dopamine tolerance due to miR-137 LOF. 
 
9.1.4 Specific brain regions 
miR-137 is known to be widely expressed within the brain, making this the likely 
location for the miRNA to function (Willemsen et al. 2011; Yin et al. 2014). The miR-137KO 
stock used has a genomic substitution resulting in complete LOF across the entire organism, 
which does not associate the sleep phenotype to just the brain. Specific downregulation of 
miR-137 expression within the CNS caused a significant increase in sleep to circa 80% of the 
24-hour period (chapter 6.2). A decrease of miR-137 expression in the brain of these flies was 
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also verified through qPCR, confirming that miR-137 function is associated with the CNS. 
Although the phenotype was somewhat less than that of the miR-137KO, this can likely be 
attributed to the difference between full knockout and downregulation in this region. 
Investigation into the sleep behaviour and the genetic pathways of the phenotype 
implicated miR-137 function with the fan-shaped and mushroom shaped bodies (chapter 
9.1.3). Selective downregulation of miR-137 in the fan-shaped body and the mushroom body 
both caused a significant increase in total sleep amount (~73% of the 24-hour period). While 
not as severe as the knockout phenotype, this increase was caused by downregulation in a 
very specific area, indicating that the FB and MB are regions which are relevant to sleep in 
the miR-137KO flies. Unfortunately, the level of downregulation was not possible to measure 
due to the lack of ability and equipment to perform such dissections and RNA expression 
analysis. 
Reintroduction of miR-137 to the FB only within the miR-137KO background further 
reinforced the importance of the FB region in the regulation of sleep by miR-137 (Chapter 
7.1). The excessive sleep phenotype was significantly reduced by ~12% (p-value < 0.05), 
while reintroduction of miR-137 in the whole CNS did not produce a significant result. 
Similarly, to the targeted downregulation, it is not possible to assess the level of gene 
reintroduction in the FB region alone. However, to produce a significant reduction in sleep 
within the knockout background further validates the regulation of sleep by miR-137 through 
the fan-shaped body. 
 
 
226 
 
9.2 Human relevance 
The purpose of a model organism in genetic research is to be able to relate the results 
back to humans, most often for the purpose of investigating the mechanisms behind diseases. 
The fruit fly is a proven model for research into the genetics behind many diseases ranging 
from cardiovascular disease to neurological symptoms. The aim of this project was originally 
built upon GWAS results statistically linking miR-137 to SZ in humans (Ripke et al. 2011; 
Duan et al. 2014), and the final area of research cross referenced the differentially expressed 
genes in the miR-137KO flies to other GWAS (Chapter 8). The phenotypes observed in the 
miR-137KO strain are all comparable to human symptoms within psychiatric disorders, 
potentially implying these are associated with miR-137 in humans. 
Due to the nature of GWAS based studies, there is a rapidly increasing volume of data 
quickly becoming available to researchers. At the time of this research, data from the GWAS 
studies regarding MDD and SZ, by Pardinas et al. (2016) and Ripke et al. (2018), and the 
UKBiobank was used because of availability. There are many more studies regarding 
neurological diseases, psychiatric disorders, and sleep parameters which could provide 
alternate data sets worth cross-comparing to the FlyChip output. Some examples of such 
include: Jones et al. (2019) study into circadian rhythm using the UKBiobank plus 23andMe 
datasets, Howard et al. (2019) study into depression using an accumulation of 3 major 
depression studies, and studies by Doherty et al. (2018) and Dashti et al. (2019) study 
physical activity and sleep duration using fitness tracker data and the UKBiobank.  
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9.2.1 Psychiatric disorders 
It is known that the aetiology of psychiatric disorders has a genetic basis and are often a 
result of a complex network of many risk factors cumulatively creating the symptoms. The 
results from the bioinformatics (chapter 8) identified some key genes which have a plausible 
link between miR-137 expression knockdown/knockout and human disease statistics. The 
miR-137 gene is highly conserved across many species, with the mature miRNA construct 
being just one nucleotide different between D. melanogaster and humans. The high sequence 
homology implies that the function of miR-137 is comparable across species. 
Comparison of DEGs in the miR-137KO flies to human SZ and MDD GWAS produced 
a list of 7 genes: ect3, hsc70-2, tutl, ND-15, CG4757, CG30456, and chp. Turtle (tutl) 
functions roles include axonal tiling, dendrite self-avoidance, axonal pathfinding and 
coordinated motor control. Loss of function in flies causes locomotor and behavioural 
defects, plus partial lethality during pupation (Bodily et al. 2001). Issues with movement and 
fatigue are symptoms of psychiatric disorders such as SZ patients demonstrating slow 
movement (Jakubowski et al. 2012; Lee et al. 2013). 
An alternative method of researching the genetics behind psychiatric disorders is the 
sequencing of genomes for the identification of rare risk variants. GWAS identify common 
risk alleles from large groups, however the aetiology of psychiatric disorders is known to 
exist as an accumulation of genetic variations increasing susceptibility. The combined 
polygenic effect of the common risk alleles identified in GWAS studies accounted for a small 
portion of disease liability and therefore this network of risk alleles must also include rare 
variants (Loh et al. 2015; Singh et al. 2017). Studies on rare variants have reported some 
have a far larger effect on individual risk than common variants and both rare and common 
variants can occur in the same genes or pathways (Zhu et al. 2014; Pocklington et al. 2014; 
Singh et al. 2016; Singh et al. 2017). These studies sequence the exome or genome of cases 
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and controls to identify low-frequency and rare variants with a minor allele frequency of less 
than 0.5% (Panoutsopoulou et al. 2013; Duan et al. 2014; Pocklington et al. 2014; Rees et al. 
2014; Sidore et al. 2015; Singh et al. 2017). There are studies identifying rare miR-137 risk 
variants for SZ. Duan et al. (2014) sequenced the miR-137 locus of ~2600 SZ patients and 
control cases and identified 133 variants with minor allele frequency of <0.5%. One of these, 
1: g.98515539 A>T, was found in just 11 of the SZ cases and influenced the enhancer region 
to ultimately decrease miR-137 expression. This differing approach could likely provide a 
more directly relevant dataset to compare against. For example, the flies in this project had 
genomic ablation of the miR-137 gene and this was used to evaluate the genes overall 
importance and function, and then any transcriptome changes were compared to other genes 
in the GWAS data. However, a comparison of the fly results to the transcriptome of a human 
dataset with any rare LOF variant in the miR-137 locus could provide a stronger link between 
fly and human. Furthermore, rare variant functional study data could be cross-referenced to 
the FlyChip results in this study and identify new genes of interest in addition to what has 
already been identified in this project. 
 
9.2.2 Sleep 
Sleep is a vital process required for life. In terms of fundamental survival, the action of 
sleep contradicts common sense by voluntarily becoming less environmentally aware and 
generally vulnerable for an extended period. A sleep-like state is found across many species, 
even insects like D. melanogaster further emphasising its importance. The fruit fly has a 
documented sleep state that is comparable to human sleep in many aspects. During sleep, 
both fruit flies and humans have increased arousal thresholds and decreased environmental 
awareness. Furthermore, both species have homeostatic and circadian regulation mechanisms 
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governing sleep, which implement similar molecular pathways like dopamine signalling 
(Shaw et al 2000; Bushey et al 2010; Tomita et al. 2015).  
Taking the DEGs from the FlyChip results and comparing them to the top genes from 
sleep-phenotype parameters of the UKBiobank resulted in 6 genes: w, ect3, hsc70-2, chp, 
CG30456, and CG4757. None of these genes currently have experimental links to a sleep-
related phenotype reported on Flybase but provide direction for future work. 
Sleep is a symptom of psychiatric disorders such as SZ and BD. These exhibit 
differences in sleep behaviour than would be expected of “normal” sleep (Benca et al. 1992; 
Monti and Monti 2004; Lee and Douglass 2010; Krystal 2012). Alongside differences in 
sleep/wake cycle, symptoms such as catatonia are comparable to being sleepy and fatigued. 
The implication of miR-137 regulating sleep also relates to not just psychiatric 
disorders, but also many other diseases. Neurological diseases like Parkinson’s disease, 
Dementia, and Huntington’s disease also include changes in sleep pattern such as excessive 
daytime sleepiness or insomnia (Happe et al. 2002; Garcia-Borreguero et al. 2003; Rose et al. 
2010; Herzog-Krzywoszanska and Krzywoszansk 2019). While sleep problems can be 
symptoms, sleep dysregulation is also associated with increased risk of obesity, diabetes, 
heart disease, and strokes (Spiegel et al. 2005; Knutson and Cauter 2008; Khandelwal et al. 
2017; Young et al. 2019). Chronic sleep deprivation has even been statistically correlated 
with increased suicide ideation in teenagers (Whitmore and Smith 2018). 
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9.3 Conclusion 
The complex nature of miRNA regulation dictates that biological link between miR-137 
and psychiatric disorders will include many genetic pathways. This complicates the research 
into the miRNA function, particularly in genetic recovery experiments, as the overall 
phenotype defect will not be contributable to any single gene. This project identified 
behavioural and developmental defects in miR-137KO flies and found that the activity 
phenotype was a compound effect of locomotor and sleep-like behaviour abnormalities.  
Results of investigating the development in miR-137KO flies infer importance of miR-
137 in the pupal stage, which is when the larva undergo metamorphosis into an adult fly. This 
period is associated with dramatic remodelling of the CNS, where a high degree of synaptic 
plasticity is required for conversion of existing neurons to function in adult fly CNS. 
Identifying the importance of miR-137 in this process reaffirms the miRNAs role synaptic 
plasticity regulation and neurogenesis. 
The data collected in this project suggests that miR-137 is required for proper function 
of the sleep regulation by the Drosophila melanogaster fan-shaped body and mushroom 
body, brain regions functionally comparable to the human cerebral cortex, hypothalamic 
ventrolateral preoptic nuclei, and hypothalamus. Furthermore, in the absence of the miRNA, 
this defect is due to dopamine desensitisation and an increase in mental pressure by the 
homeostatic control to sleep. Chronic treatment with a dopamine inhibitor decreased the sleep 
amount in the miR-137KO flies, while dopamine inhibition promotes sleepiness in the 
controls. In normal conditions, voltage-gated potassium ion channels are regulated by 
dopamine when controlling the activation of the D. melanogaster fan-shaped body, and 
subsequently the sleep signals sent from this brain region. These potassium channels and 
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dopamine receptors and transporters are also putative targets of miR-137 and linked via 
human AKR1 proteins to sleep-phenotype UKBiobank GWAS data in this work. 
Comparing the phenotype of miR-137 LOF in D. melanogaster to the symptoms of 
psychiatric disorders and neurological diseases in humans results in some obvious overlap, as 
many diseases are associated with sleep or locomotor defects. In terms of human genetics, the 
statistical evidence of the GWAS implicated a select group of genes vital for general life such 
as heat shock proteins and potassium channels. Furthermore, several DEGs in the miR-137KO 
strain were also identified as statistically significant in sleep phenotype and psychiatric 
disorder GWAS. 
In conclusion, identifying the link between miR-137 and psychiatric disorders is a 
difficult task due to the complex nature of miRNA regulation, the lack of clear psychiatric 
diagnostic criteria, and the overall intricacy of the brain. Nonetheless, this project identified 
several genes and mechanisms behind phenotypes in the fly synonymous to those of 
psychiatric disorders. Furthermore, the project then focused on investigating the excessive 
sleep amount in miR-137KO flies and discovered that miR-137 regulates proper sleep through 
maintaining the balance of dopamine within the homeostatic control pathways, a completely 
novel finding. Additionally, this regulation is likely through interacting with voltage-gated 
potassium ion channels and dopamine transporters in two D. melanogaster brain regions; the 
fan-shaped body and the mushroom body. These regions are functionally comparable to 
human brain regions associated with the development of neurological symptoms, reinforcing 
the relevance of miR-137 with sleep and psychiatric disorders.  
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10 Future work 
This project identified a novel role for miR-137 in regulating sleep. However, there is a 
lot more research that can be done to further refine the mechanisms involved. While this 
work focused on association between sleep and psychiatric disorders, sleep dysfunction is 
also linked with increased risk of obesity, diabetes, heart disease, and strokes. There is 
potential for miR-137 to have implications with a much wider range of human ailments if 
these links can be further studied. 
Unsuccessful gene expression experiments for the sponge-mediated miR-137 
knockdown and miR-137 overexpression is an unfortunate outcome of this thesis (chapter 
6.2). Future work would include repeats of these experiments to evaluate the level of 
expression change caused by the sponge construct and correlate the results with the 
behavioural data for a better understanding of enough miR-137 for “normal” sleep. It is 
obvious that the method used was flawed, and future work should consider improvements 
mentioned in Chapter 6.2. 
The hypothesis of the dopamine desensitisation in the flies through increased activation 
of the fan-shaped body requires more work to fully establish. The measurement of sleep in 
this study was primarily through associating 5-minutes of no activity to 1 “count of sleep”. 
Better methods of measuring sleep could help elucidate this phenotype. The dopamine 
component could be strengthened through quantification of dopamine levels, or genetic 
dopamine pathway inhibition in the KO background to rescue the phenotype similarly to 3IY 
treatment in chapter 7.2. 
The bioinformatics section intended to help bridge the gap between D. melanogaster 
genetics and human diseases, identifying several genes of interest as a result of novel 
transcriptome data and comparison to GWAS results. More investigation is required into the 
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DEGs found, especially CG6083 and hsc70-2 which were identified in multiple experimental 
data sets and psychiatric GWAS results. Additionally, as mentioned in Ch9.2, there are many 
other GWAS study datasets that could be retrieved to cross compare with the FlyChip results, 
potentially indicating additional genes of interest. 
Ultimately, I hope this work will prove useful for the continued efforts into deciphering 
the complex genetic aetiology behind psychiatric disorders. There is novel data produced 
within this project, particularly the sleep phenotype exhibited with complete miR-137 
ablation, which can be further developed and used as part of the wider picture in neurological 
research.  
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12 Supplementary information 
12.1 Targetscan miR-137 target comparison 
Table: The predicted targets of human and Drosophila melanogaster miR-137 were downloaded from 
Targetscan.org, and the human targets were converted into Drosophila orthologs using DIOPT. These 
orthologs were then checked against the fly miR-137 targets to create a list of 278 genes which were 
predicted to be directly regulated by miR-137 in both species. 
Human gene fly Human gene fly gene Human gene fly gene Human gene fly gene 
ABCC9 MRP FLI1 Ets21C PAQR3 CG33203 SLC22A23 CG3690 
ABCG4 Atet FNBP1L nwk PAQR3 AdipoR SLC24A2 Nckx30C 
ADRB1 Octbeta3R GABBR2 GABA-B-R3 PDE10A Pde6 SLC24A3 Nckx30C 
AGO1 AGO1 GABBR2 GABA-B-R1 PDE1B Pde1c SLC25A5 sesB 
AGO3 AGO1 GAN kel PDE4A dnc SLC46A3 CG8008 
AGO4 AGO1 GBP2 atl PDE4A Pde6 SLC4A7 CG8177 
AKT2 Akt1 GLRA3 Rdl PDE4D dnc SMURF1 Su(dx) 
AKT2 Pkc53E GPR22 SIFaR PDE4D Pde6 SMURF2 Su(dx) 
AKT2 S6k HCN2 Ih PDE7A Pde6 SNX27 CG32758 
ANKRD44 Tnks HIPK2 Hipk PHACTR4 CG32264 SOCS6 Socs16D 
ANO4 CG10353 HLF Pdp1 PHF20 upSET SOX11 Sox100B 
ANO8 CG10353 HNRNPDL sqd PITPNA vib SPATA13 RhoGEF3 
ARF6 Arf51F HNRNPDL Rbp6 PKN2 Pkc53E SRC Csk 
BCL11B CG9650 HNRNPDL msi PLCB1 Plc21C SRGAP3 nwk 
BHLHE22 Oli IGLON5 DIP-theta PLEKHB2 CG11000 SSBP2 Ssdp 
BICRAL CG11873 IGLON5 CG13506 PLEKHG3 GEFmeso SSBP3 Ssdp 
BRD1 rno IL1RAPL1 CG13506 PLPPR4 CG11426 STK3 hpo 
CACFD1 fwe IL1RAPL1 CG45263 PLXDC2 l(1)G0289 STRBP Zn72D 
CACNA1C cac JADE1 rno PPP1CB flw STRN Cka 
CACNA1C para JADE2 rno PPP1CB Pp1alpha STYX CG7378 
CACNA1C NaCP60E JDP2 kay PPP1R16B MYPT-75D SUZ12 Su(z)12 
CACNA1C Ca-alpha1T KCNAB3 Hk PPP6R2 fmt SV2A CG3690 
CACNA1D cac KCNC1 Shaw PPP6R3 fmt SYN3 Syn 
CACNA1D para KCNC2 Shaw PRKAR2B Pka-R2 SYNCRIP Syp 
CACNA1D NaCP60E KCNC3 Shaw PROX1 pros SYNJ1 CG6805 
CACNA1D Ca-alpha1T KCNH1 eag PTPN2 Ptp61F TBC1D12 CG5916 
CACNA1G Ca-alpha1T KDM1A Su(var)3-3 PTPRD Ptp36E TBC1D12 GAPsec 
CACNA1G cac KLF12 CG42741 PTRH2 CG1307 TBC1D12 CG42795 
CACNA1H Ca-alpha1T KLHL3 kel RAB8A Rab10 TBX15 bi 
CACNA1H cac LCOR Eip93F RAD54L2 CG4049 TBX18 bi 
CACNA1I Ca-alpha1T LIFR Dscam1 RASIP1 cno TBX3 bi 
CACNA1I cac LMTK2 InR RASIP1 didum TCF12 da 
CADM2 dpr6 LRP12 arr RBM24 Rbp6 TCF3 da 
CADM2 beat-VII LRP6 arr RBM24 msi TCF4 da 
CCNG2 CycE LRRN3 Fili RBM24 sqd TCHP CG17230 
CCNI CycE LRRN3 caps RGS7BP CG34351 TEAD1 sd 
CCNJ CycE LVRN CG8773 RHOBTB1 RhoBTB TEF Pdp1 
CD2AP cindr MAF tj RNF150 mura TENT4A Trf4-1 
CD69 rgn MAFK tj RNF152 mei-P26 TMED5 opm 
CHD1 Chd1 MAN2A1 alpha-Man RNF152 wech TMEM132B dtn 
CHRM2 mAChR-A MAP2K4 Mkk4 RNF38 mura TMSB15B cib 
CHRM3 mAChR-A MAX Max RNF4 elfless TPCN1 para 
CHST1 CG31637 MBD5 sba RORA Hr3 TPCN1 cac 
CISD1 Cisd2 MBD6 sba RORB Hr3 TPCN1 Ca-alpha1T 
CNOT6L twin MEGF11 CG7381 RREB1 peb TPCN1 NaCP60E 
CPLX1 cpx MSI1 Rbp6 RYR2 RyR TRIM3 wech 
CREB5 kay MSI1 sqd RYR3 RyR TRIM3 mei-P26 
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CUL3 Cul5 MSI1 msi SASH3 SKIP TRPS1 GATAd 
CUL4A Cul5 MSI2 Rbp6 SASH3 CG34377 TTC28 pins 
DAG1 Dg MSI2 msi SCN1A para UBE2H UbcE2H 
DENND4B Crag MSI2 sqd SCN1A NaCP60E WWP2 Su(dx) 
DENND5B Crag MXD1 Max SCN2A para YTHDF3 Ythdf 
DFFB Drep4 MXD1 Myc SCN2A NaCP60E ZBTB18 CG12605 
DNMT3A sba MYO1B Myo95E SCN8A para ZBTB21 erm 
DSCAML1 Dscam1 MYO1C Myo95E SCN8A NaCP60E ZBTB34 ab 
DUSP1 CG7378 MYO1D Myo95E SCN8A cac ZBTB37 ab 
DUSP10 CG7378 MYO1F Myo95E SCN8A Ca-alpha1T ZBTB4 CG10274 
DUSP16 CG7378 NACC2 erm SCRT1 scrt ZBTB4 Cf2 
DUSP4 CG7378 NBEAL2 CG43367 SCRT1 CG12605 ZBTB7B erm 
DUSP5 CG7378 NEFH Lam SCRT2 scrt ZCCHC2 CG10492 
DUSP8 CG7378 NEGR1 DIP-theta SCRT2 CG12605 ZNF148 CG12773 
DYRK1A Hipk NEGR1 CG13506 SEMA4D Sema2a ZNF217 CG9650 
EIF1 eIF1 NEUROD1 Oli SEMA4D Sema2b ZNF449 CG32772 
EIF4E3 eIF4EHP NEUROD2 Oli SEMA4D Sema1a ZNF496 CG32772 
ELAVL3 fne NEUROD4 Oli SGPL1 Sply ZNF516 CG9650 
ELAVL3 Rbp9 NLGN4X alpha-Est8 SLC16A10 CG13907 ZNF76 CG32772 
ELFN2 Fili OPCML DIP-theta SLC16A10 CG8034 ZNF770 CG4374 
ERBIN Lap1 OPCML CG13506 SLC17A6 VGlut ZSWIM4 CG34401 
ERBIN scrib OSBPL8 CG42668 SLC22A18 Glut1 - - 
ERG Ets21C PAPLN nolo SLC22A23 CG44098 - - 
 
12.2 T-tests 
12.2.1 Deficiency Crosses 
24-hour w1118 ko/+ w1118 mirko 
Mean 816.7205 966.25 816.7205 1240.403 
Variance 15247.25 10435.42 15247.25 30034.66 
Observations 322 32 322 77 
Hypothesized Mean Difference 0  0  
df 352  95  
t Stat -6.62602  -20.2579  
P(T<=t) one-tail 6.47E-11  1.5E-36  
t Critical one-tail 1.649194  1.661052  
 sig  sig  
 
24-hour w1118 w/df w1118 ko/df 
Mean 816.7205 996.3333 816.7205 1214.742 
Variance 15247.25 5972 15247.25 2527.331 
Observations 322 18 322 31 
Hypothesized Mean Difference 0  0  
df 22  73  
t Stat -9.22452  -35.0603  
P(T<=t) one-tail 2.57E-09  1.01E-47  
t Critical one-tail 1.717144  1.665996  
 sig  sig  
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24-hour mirko ko/df ko/+ w/df 
Mean 1240.403 1214.742 966.25 996.3333 
Variance 30034.66 2527.331 10435.42 5972 
Observations 77 31 32 18 
Hypothesized Mean Difference 0  0  
df 100  48  
t Stat 1.181644  -1.08509  
P(T<=t) one-tail 0.120075  0.14165  
t Critical one-tail 1.660234  1.677224  
 not sig  not sig  
 
Day w1118 ko/+ w1118 mirko 
Mean 316.3602 413.75 316.3602 602.9091 
Variance 6061.988 5992.258 6061.988 11290.14 
Observations 322 32 322 77 
Hypothesized Mean Difference 0  0  
df 352  96  
t Stat -6.75192  -22.2774  
P(T<=t) one-tail 3.02E-11  5.17E-40  
t Critical one-tail 1.649194  1.660881  
 sig  sig  
 
Day w1118 w/df w1118 ko/df 
Mean 316.3602 482.6111 316.3602 595.3226 
Variance 6061.988 3539.428 6061.988 1030.292 
Observations 322 18 322 31 
Hypothesized Mean Difference 0  0  
df 338  71  
t Stat -8.90993  -38.6623  
P(T<=t) one-tail 1.61E-17  9.78E-50  
t Critical one-tail 1.649374  1.6666  
 sig  sig  
 
Day mirko ko/df ko/+ w/df 
Mean 602.9091 595.3226 413.75 482.6111 
Variance 11290.14 1030.292 5992.258 3539.428 
Observations 77 31 32 18 
Hypothesized Mean Difference 0  0  
df 101  48  
t Stat 0.565685  -3.26524  
P(T<=t) one-tail 0.286431  0.001011  
t Critical one-tail 1.660081  1.677224  
 not sig  sig  
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Night w1118 ko/+ w1118 mirko 
Mean 500.3602 552.5 500.3602 637.4935 
Variance 5179.789 3527.806 5179.789 5911.622 
Observations 322 32 322 77 
Hypothesized Mean Difference 0  0  
df 352  397  
t Stat -3.96461  -14.821  
P(T<=t) one-tail 4.45E-05  3.62E-40  
t Critical one-tail 1.649194  1.648701  
 sig  sig  
 
Night w1118 w/df w1118 ko/df 
Mean 500.3602 513.7222 500.3602 619.4194 
Variance 5179.789 1783.154 5179.789 1109.318 
Observations 322 18 322 31 
Hypothesized Mean Difference 0  0  
df 23  62  
t Stat -1.2452  -16.5311  
P(T<=t) one-tail 0.112799  1.05E-24  
t Critical one-tail 1.713872  1.669804  
 not sig  sig  
 
Night mirko ko/df ko/+ w/df 
Mean 637.4935 619.4194 552.5 513.7222 
Variance 5911.622 1109.318 3527.806 1783.154 
Observations 77 31 32 18 
Hypothesized Mean Difference 0  0  
df 105  48  
t Stat 1.703602  2.439886  
P(T<=t) one-tail 0.045707  0.009218  
t Critical one-tail 1.659495  1.677224  
 not sig  sig  
 
12.2.2 Gal4/UAS sponge knockdown 
24-hour w1118 elav/sponge w1118 fb/sponge 
Mean 816.7205 1151.533 816.7205 1037 
Variance 15247.25 8476.436 15247.25 7224.667 
Observations 322 45 322 16 
Hypothesized Mean 
Difference 0  0  
df 68  18  
t Stat -21.8075  -9.86212  
P(T<=t) one-tail 1.04E-32  5.53E-09  
t Critical one-tail 1.667572  1.734064  
 sig  sig  
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24-hour w1118 mb/sponge w1118 mirsponge/+ 
Mean 816.7205 1035.067 816.7205 811.5625 
Variance 15247.25 17133.35 15247.25 10372.8 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 335  336  
t Stat -6.67711  0.164262  
P(T<=t) one-tail 5.07E-11  0.434812  
t Critical one-tail 1.649415  1.649401  
 sig  not sig  
     
24-hour w1118 elav/+ w1118 fb/+ 
Mean 816.7205 762.0667 816.7205 811.4375 
Variance 15247.25 9427.495 15247.25 8819.196 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 335  336  
t Stat 1.689177  0.168632  
P(T<=t) one-tail 0.046058  0.433094  
t Critical one-tail 1.649415  1.649401  
 sig  not sig  
     
24-hour w1118 mb/+ mirko elav/sponge 
Mean 816.7205 725.0625 1240.403 1151.533 
Variance 15247.25 13659.93 30034.66 8476.436 
Observations 322 16 77 45 
Hypothesized Mean 
Difference 0  0  
df 336  119  
t Stat 2.904796  3.695113  
P(T<=t) one-tail 0.001959  0.000167  
t Critical one-tail 1.649401  1.657759  
 sig  sig  
     
24-hour mirko fb/sponge mirko mb/sponge 
Mean 1240.403 1037 1240.403 1035.067 
Variance 30034.66 7224.667 30034.66 17133.35 
Observations 77 16 77 15 
Hypothesized Mean 
Difference 0  0  
df 45  90  
t Stat 7.011373  4.345778  
P(T<=t) one-tail 4.9E-09  1.82E-05  
t Critical one-tail 1.679427  1.661961  
 sig  sig  
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Day w1118 elav/sponge w1118 fb/sponge 
Mean 316.3602 516.8 316.3602 441.125 
Variance 6061.988 5535.118 6061.988 2868.25 
Observations 322 45 322 16 
Hypothesized Mean 
Difference 0  0  
df 365  18  
t Stat -16.2616  -8.86459  
P(T<=t) one-tail 2.07E-45  2.76E-08  
t Critical one-tail 1.649039  1.734064  
 sig  sig  
 
Day w1118 mb/sponge w1118 mirsponge/+ 
Mean 316.3602 470 316.3602 344.1875 
Variance 6061.988 10007.29 6061.988 2978.829 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 335  336  
t Stat -7.37102  -1.4115  
P(T<=t) one-tail 6.68E-13  0.079512  
t Critical one-tail 1.649415  1.649401  
 sig  not sig  
 
Day w1118 elav/+ w1118 fb/+ 
Mean 316.3602 356.5333 316.3602 319.5 
Variance 6061.988 1490.552 6061.988 2956 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 20  336  
t Stat -3.69516  -0.15927  
P(T<=t) one-tail 0.000717  0.436775  
t Critical one-tail 1.724718  1.649401  
 sig  not sig  
 
Day w1118 mb/+ mirko elav/sponge 
Mean 316.3602 286.0625 602.9091 516.8 
Variance 6061.988 4890.863 11290.14 5535.118 
Observations 322 16 77 45 
Hypothesized Mean 
Difference 0  0  
df 336  116  
t Stat 1.525855  5.244048  
P(T<=t) one-tail 0.063993  3.58E-07  
t Critical one-tail 1.649401  1.658096  
 not sig  sig  
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Day mirko fb/sponge mirko mb/sponge 
Mean 602.9091 441.125 602.9091 470 
Variance 11290.14 2868.25 11290.14 10007.29 
Observations 77 16 77 15 
Hypothesized Mean 
Difference 0  0  
df 44  90  
t Stat 8.961894  4.47172  
P(T<=t) one-tail 8.77E-12  1.13E-05  
t Critical one-tail 1.68023  1.661961  
 sig  sig  
 
Night w1118 elav/sponge w1118 fb/sponge 
Mean 500.3602 634.7333 500.3602 595.875 
Variance 5179.789 2745.109 5179.789 3093.717 
Observations 322 45 322 16 
Hypothesized Mean 
Difference 0  0  
df 365  336  
t Stat -12.0788  -5.22858  
P(T<=t) one-tail 8.63E-29  1.5E-07  
t Critical one-tail 1.649039  1.649401  
 sig  sig  
 
Night w1118 mb/sponge w1118 mirsponge/+ 
Mean 500.3602 565.0667 500.3602 467.375 
Variance 5179.789 2449.781 5179.789 4828.383 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 335  336  
t Stat -3.44181  1.792058  
P(T<=t) one-tail 0.000326  0.037012  
t Critical one-tail 1.649415  1.649401  
 sig  sig  
 
Night w1118 elav/+ w1118 fb/+ 
Mean 500.3602 405.5333 500.3602 491.9375 
Variance 5179.789 6659.124 5179.789 3754.196 
Observations 322 15 322 16 
Hypothesized Mean 
Difference 0  0  
df 335  336  
t Stat 4.958586  0.45974  
P(T<=t) one-tail 5.65E-07  0.323  
t Critical one-tail 1.649415  1.649401  
 sig  not sig  
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Night w1118 mb/+ mirko elav/sponge 
Mean 500.3602 439 637.4935 634.7333 
Variance 5179.789 3790.267 5911.622 2745.109 
Observations 322 16 77 45 
Hypothesized Mean 
Difference 0  0  
df 336  117  
t Stat 3.348705  0.235152  
P(T<=t) one-tail 0.000452  0.407251  
t Critical one-tail 1.649401  1.657982  
 sig  not sig  
 
Night mirko fb/sponge mirko mb/sponge 
Mean 637.4935 491.9375 637.4935 565.0667 
Variance 5911.622 3754.196 5911.622 2449.781 
Observations 77 16 77 15 
Hypothesized Mean 
Difference 0  0  
df 91  29  
t Stat 7.107434  4.674226  
P(T<=t) one-tail 1.29E-10  3.13E-05  
t Critical one-tail 1.661771  1.699127  
 sig  sig  
 
12.2.3 Caffeine treatment 
24-hour w1118 w1118 + caff mirko mirko + caff 
Mean 784.125 593.25 1257.625 1286.25 
Variance 1907.267857 51062.21429 2003.125 2774.5 
Observations 8 8 8 8 
Pooled Variance 26484.74107  2388.8125  
Hypothesized Mean Difference 0  0  
df 14  14  
t Stat 2.345747056  -1.171344006  
P(T<=t) one-tail 0.017119902  0.130505482  
t Critical one-tail 1.761310136  1.761310136  
 sig  not sig  
Day w1118 w1118 + caff mirko mirko + caff 
Mean 251 215.125 588 643.25 
Variance 1828 12659.55 1912.857 1896.786 
Observations 8 8 8 8 
Pooled Variance 7243.777  1904.821  
Hypothesized Mean Difference 0  0  
df 14  14  
t Stat 0.843023  -2.53183  
P(T<=t) one-tail 0.206694  0.011973  
t Critical one-tail 1.76131  1.76131  
 not sig  sig  
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Night w1118 w1118 _caff mirko mirko + caff 
Mean 533.125 378.125 669.625 643 
Variance 1651.268 21982.13 750.8393 909.4286 
Observations 8 8 8 8 
Pooled Variance 11816.7  830.1339  
Hypothesized Mean Difference 0  0  
df 14  14  
t Stat 2.851764  1.848185  
P(T<=t) one-tail 0.006403  0.042904  
t Critical one-tail 1.76131  1.76131  
 sig  sig  
 
12.2.4 LiCl treatment 
24-hour w1118 w1118 _licl mirko mirko + licl 
Mean 944.8571429 792.875 1314.375 1279.25 
Variance 1493.142857 4454.125 2880.553571 2811.928571 
Observations 7 8 8 8 
Pooled Variance 3087.517857  2846.241071  
Hypothesized Mean 
Difference 0  0  
df 13  14  
t Stat 5.284893117  1.316771712  
P(T<=t) one-tail 7.38353E-05  0.104531897  
t Critical one-tail 1.770933396  1.761310136  
 sig  not sig  
 
Day w1118 w1118 _licl mirko mirko + licl 
Mean 365.8571 304 658 638.75 
Variance 727.1429 859.4286 1027.714 1997.071 
Observations 7 8 8 8 
Pooled Variance 798.3736  1512.393  
Hypothesized Mean Difference 0  0  
df 13  14  
t Stat 4.229949  0.989985  
P(T<=t) one-tail 0.000492  0.169492  
t Critical one-tail 1.770933  1.76131  
 sig  not sig  
 
Night w1118 w1118 _licl mirko mirko + licl 
Mean 579 488.875 656.375 640.5 
Variance 866.6667 2746.696 552.8393 2434 
Observations 7 8 8 8 
Pooled Variance 1878.99  1493.42  
Hypothesized Mean Difference 0  0  
df 13  14  
t Stat 4.017273  0.821586  
P(T<=t) one-tail 0.000732  0.212542  
t Critical one-tail 1.770933  1.76131  
 sig  not sig  
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12.2.5 3IY treatment 
24-hour w1118 w1118 + 3IY mirko mirko+3IY 
Mean 841.5 821.625 1239.75 1105 
Variance 19555.14286 27309.69643 2769.642857 17436.5 
Observations 8 8 8 5 
Pooled Variance 23432.41964  8103.045455  
Hypothesized Mean Difference 0  0  
df 14  11  
t Stat 0.259674058  2.625807931  
P(T<=t) one-tail 0.399447454  0.011791491  
t Critical one-tail 1.761310136  1.795884819  
 not sig  sig  
 
Day w1118 w1118+3IY mirko mirko+3IY 
Mean 321.5 308.375 647 544.4 
Variance 7011.143 8532.839 656 9671.8 
Observations 8 8 8 5 
Pooled Variance 7771.991  3934.473  
Hypothesized Mean Difference 0  0  
df 14  11  
t Stat 0.297758  2.86921  
P(T<=t) one-tail 0.38513  0.007632  
t Critical one-tail 1.76131  1.795885  
 not sig  sig  
 
Night w1118 w1118 + 3IY mirko mirko+3IY 
Mean 520 513.25 592.75 560.6 
Variance 7424.857 6413.643 2347.357 1246.3 
Observations 8 8 8 5 
Pooled Variance 6919.25  1946.973  
Hypothesized Mean Difference 0  0  
df 14  11  
t Stat 0.162295  1.278084  
P(T<=t) one-tail 0.436696  0.113766  
t Critical one-tail 1.76131  1.795885  
 not sig  not sig  
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12.3 qPCR results and standard curves 
12.3.1 qPCR attempt 1 
Samples of 20 fly brains were dissected for w1118, miR-137KO, elav-Gal4/UAS-miR-
137-sponge, Oregon-R, and elav-Gal4/UAS-miR-137 genotypes and subjected to RNA 
extraction, reverse transcription, and comparative qPCR as described in chapter 2.5. 
 
Figure: Comparative expression values of miR-137 in the over expression, Oregon-R, sponge knockdown, 
and w1118 controls. 
Values were calculated automatically by Applied biosystems Step-One plus software using standard curve 
dilution values of a housekeeping gene. No expression was found in the miR-137KO strain and as such is not 
displayed.  
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Figure: Standard curves from comparative miR-137 qPCR  
Oregon (red), w1118 (dark blue), miR-137KO (green), elav-Gal4/UAS-miR-137-sponge (light blue), and elav-
Gal4.UAS-miR-137 (yellow) D. melanogaster brains were dissected subjected to RNA extraction, reverse-
transcription, and comparative qPCR to assess the change in expression levels. The cDNA samples were mixed 
together from each genotype and then dilutions in a ratio of 1:2 for 6 steps were used as a standard curve (grey). 
The upper line is automatically calculated from the dots for miR-137 expression, and the lower line is rps17 
housekeeping gene control. The dots are the measured readings for the samples. CT is the “threshold cycle” 
value that is indicative of the number of cycles before fluorescence levels were above the threshold for reading, 
and Quantity is a comparative figure based on the standard curve dilution factors starting at “100” and 
decreasing in a ratio of 1:2. 
 
 
12.3.2 qPCR attempt 2 
Samples of 20 fly brains were dissected for w1118, miR-137KO, elav-Gal4/UAS-miR-
137-sponge, Oregon-R, and elav-Gal4/UAS-miR-137 genotypes and subjected to RNA 
extraction, reverse transcription, and comparative qPCR as described in chapter 2.5. 
miR-137 
Rps17 
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Figure: Comparative expression values of miR-137 in the over expression, Oregon-R, sponge knockdown, 
and w1118 controls. 
Values were calculated automatically by Applied biosystems Step-One plus software using standard curve 
dilution values of a housekeeping gene. No expression was found in the miR-137KO strain and as such is not 
displayed.  
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Figure: Standard curves from comparative miR-137 qPCR  
Oregon (blue), w1118 (dark green), miR-137KO (beige), elav-Gal4/UAS-miR-137-sponge (light green), and elav-
Gal4.UAS-miR-137 (yellow) D. melanogaster brains were dissected subjected to RNA extraction, reverse-
transcription, and comparative qPCR to assess the change in expression levels. The cDNA samples were mixed 
together from each genotype and then dilutions in a ratio of 1:2 for 6 steps were used as a standard curve (grey). 
The upper line is automatically calculated from the dots for miR-137 expression, and the lower line is rps17 
housekeeping gene control. The dots are the measured readings for the samples. CT is the “threshold cycle” 
value that is indicative of the number of cycles before fluorescence levels were above the threshold for reading, 
and Quantity is a comparative figure based on the standard curve dilution factors starting at “100” and 
decreasing in a ratio of 1:2. 
 
 
12.3.3 qPCR attempt 3 
Samples of 20 fly brains were dissected for w1118, miR-137KO, elav-Gal4/UAS-miR-
137-sponge, presumed backcross KO, and heterozygous KO genotypes and subjected to RNA 
extraction, reverse transcription, and comparative qPCR as described in chapter 2.5. 
miR-137 
Rps17 
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Figure: Comparative expression values of miR-137 in the presumed backcross KO, heterozygous KO, 
sponge knockdown, and w1118 controls. 
Values were calculated automatically by Applied biosystems Step-One plus software using standard curve 
dilution values of a housekeeping gene. No expression was found in the miR-137KO and backcross strains and as 
such are not displayed.  
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Figure: Standard curves from comparative miR-137 qPCR  
Presumed backcross KO (blue), w1118 (red), miR-137KO (purple), elav-Gal4/UAS-miR-137-sponge (dark blue), 
and heterozygous KO (green) D. melanogaster brains were dissected subjected to RNA extraction, reverse-
transcription, and comparative qPCR to assess the change in expression levels. The cDNA samples were mixed 
together from each genotype and then dilutions in a ratio of 1:2 for 6 steps were used as a standard curve (grey). 
The upper line is automatically calculated from the dots for miR-137 expression, and the lower line is rps17 
housekeeping gene control. The dots are the measured readings for the samples. CT is the “threshold cycle” 
value that is indicative of the number of cycles before fluorescence levels were above the threshold for reading, 
and Quantity is a comparative figure based on the standard curve dilution factors starting at “100” and 
decreasing in a ratio of 1:2. 
 
  
miR-137 
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12.4 Manhatten Plots from SNP2GENE 
20002_1262 Non-cancer related illness: Self-reported Parkinson’s Disease 
Parameter 20002_1262 refers to the initial UKbiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional. 
There were 974 people who reported a history of Parkinson’s disease out of 383782 
participants. This data was then cleaned and imputed by Neale et al. into 361194 samples, of 
which 652 cases against 360489 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20002_1262 Non-cancer related illness self-reported Parkinson’s 
Disease. The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run 
FUMA (Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the 
data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting 
the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance 
(red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome 
wide significant level were: STARD8, CHMP1B, CTTNBP2, IRF4, CCDC151, PRKCSH, and AL035681.1. 
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20002_1286 Non-cancer related illness: Self-reported Depression 
Parameter 20002_1286 refers to the initial UKbiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional. 
There were 32965 people who reported a history of Depression out of 383782 
participants. This data was then cleaned and imputed by Neale et al. into 361194 samples, of 
which 20648 cases against 340493 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20002_1286 Non-cancer related illness self-reported Depression. 
The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA 
(Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The 
programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the 
significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red 
dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide 
significant level were: RERE, TMEM106B, and MMS22L. 
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20002_1291 Non-cancer related illness: Self-reported Mania/Bipolar Disorder/Manic 
Depression 
Parameter 20002_1291 refers to the initial UKbiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional. 
There were 1530 people who reported a history of Mania/Bipolar Disorder/Manic 
Depression out of 383782 participants. This data was then cleaned and imputed by Neale et 
al. into 361194 samples, of which 1008 cases against 360133 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20002_1291 Non-cancer related illness self-reported 
Mania/Bipolar Disorder/Manic Depression. The data was cleaned and imputed by the Neale lab then made available for 
public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome Wide Association Studies) 
online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a 
gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein 
coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant 
genes above the determined genome wide significant level were: SLC27A3, CXCL1, PFDN5, GCN1L1, RPLP0, PXN, 
HCRT, and DCAF15. 
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20002_1482 Non-cancer related illness: Self-reported Chronic fatigue syndrome 
Parameter 20002_1482 refers to the initial UKbiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional.  
There were 2397 people who reported a history of Chronic fatigue syndrome out of 
383782 participants. This data was then cleaned and imputed by Neale et al. into 361194 
samples, of which 1659 cases against 359482 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20002_1482 Non-cancer related illness self-reported Chronic 
fatigue syndrome. The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije 
Universiteit run FUMA (Function Annotation and Mapping of Genome Wide Association Studies) online programme was 
used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan 
plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome 
wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the 
determined genome wide significant level were: LPGAT1, SVOP, and SLC25A15. 
 
20002_1614 Non-cancer related illness: Self-reported Stress 
Parameter 20002_1614 refers to the initial UKbiobank assessment centre whereupon 
the participant was asked to disclose any history of medical disorders to a qualified nurse or 
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doctor in a verbal interview. Participants who were unable to remember, or were uncertain of, 
the specific disorder were able to describe the symptoms, and this was later classified by the 
medical professional. 
There were 1083 people who reported a history of Stress out of 383782 participants. 
This data was then cleaned and imputed by Neale et al. into 361194 samples, of which 428 
cases against 360713 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20002_1614 Non-cancer related illness self-reported Stress. The 
data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA 
(Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The 
programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the 
significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red 
dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide 
significant level were: SPATA31D1 and KRTAP5-3. 
 
 
20003_1140867490 Treatment/Medication code: Lithium Product 
Parameter 20003_1140867490 refers to the initial UKbiobank assessment centre 
whereupon the participant was asked to disclose any regular prescription medications to a 
qualified nurse in a verbal interview.  
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There were 520 people who reported regular use of a lithium-based medication out of 
371433 participants. This data was then cleaned and imputed by Neale et al. into 361141 
samples, of which 350 cases against 360791 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20003_1140867490 Treatment/Medication code: Lithium 
Product. The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run 
FUMA (Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the 
data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting 
the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance 
(red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome 
wide significant level were: PCDHA2, PCDHA3, PCDHA4, PCDHA8, NLRX1, PFDN5, WDR89, ELL3, MYOCD, 
AC005358.1, POLDIP3, and AC002365.1. 
 
20126_1 Bipolar and major depression status: Bipolar I disorder  
Parameter 20126_1 refers to a diagnosis by a mental health group headed by Professor 
Jill Pell from the Institute of Health & Wellbeing, University of Glasgow. The participants of 
the original UKBiobank survey were asked questions on a variety of general lifestyle factors, 
such as daily activity or average hours of sleep, and on previous feelings or moods, such as 
“Does your mood often go up and down?”. The results were assessed and used to calculate 
probable diagnoses ranging from “single lifetime episode” to “probable disorder” as 
described in the paper by Smith et al. 2013. 
Depressive and manic symptoms questionnaire results were collected for 172751 of the 
participants in the UKBiobank, of which 122982 were assessed by the mental health group 
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and found 808 people who were characterised as probable lifetime bipolar disorder I 
sufferers. This data was then cleaned and imputed by Neale et al. into 86895 samples, of 
which 556 cases against 86339 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20216_1 Bipolar and major depression status: Bipolar I 
Disorder.  The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run 
FUMA (Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the 
data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting 
the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance 
(red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome 
wide significant level were: SLC27A3, C1orf116, DYNC1I2, AC068039.1, METAP1D, METTL12, PFDN5, and LTB4R2. 
 
20126_3 Bipolar and major depression status: Probable recurrent major depression 
(severe)  
Parameter 20126_3 refers to a diagnosis by a mental health group headed by Professor 
Jill Pell from the Institute of Health & Wellbeing, University of Glasgow. The participants of 
the original UKBiobank survey were asked questions on a variety of general lifestyle factors, 
such as daily activity or average hours of sleep, and on previous feelings or moods, such as 
“Does your mood often go up and down?”. The results were assessed and used to calculate 
probable diagnoses ranging from “single lifetime episode” to “probable disorder” as 
described in the paper by Smith et al. 2013. 
290 
 
Depressive and manic symptoms questionnaire results were collected for 172751 of the 
participants in the UKBiobank, of which 122982 were assessed by the mental health group 
and found 8904 people who were characterised as probable lifetime recurrent severe major 
depression episode sufferers. This data was then cleaned and imputed by Neale et al. into 
86895 samples, of which 6304 cases against 80591 controls. 
 
Figure: Manhattan plot for UKBiobank parameter 20216_3 Bipolar and major depression status: Bipolar I 
Disorder.  The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run 
FUMA (Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the 
data. The programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting 
the significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance 
(red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome 
wide significant level were: DMGDH, TRMT61A, KLC1, APOPT1, RP11-73M18.2, and XRCC3. 
 
20517 Trouble falling or staying asleep, or sleeping too much 
Parameter 20517 refers to a self-reported parameter where the participants were 
emailed a survey. This parameter are the people who answered positively to the question: 
“Over the last 2 weeks, how often have you been bothered by any of the following 
problems?”. 
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There were 157356 participants, with approximately 80000 refusing to answer or 
answering, “not at all”. This data was cleaned and imputed by Neale et al. and a total set of 
117822 was analysed. 
 
Figure: Manhattan plot for UKBiobank parameter 20517 Trouble falling or staying asleep or sleeping too much. 
The data was cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA 
(Function Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The 
programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the 
significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red 
dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide 
significant level were: IPO9, PKP4, CACNA2D2, LSAMP, PEX3, CYP2W1, and SLTM. 
20534 Sleeping too much 
Parameter 20534 refers to the responses of a chain of questions: “Have you had 
prolonged feelings of sadness or loss of interest in activities or hobbies?”, then “Did your 
sleep change?” and ultimately “Was that sleeping too much?”. The questions were asked as 
part of a mental health based online follow up questionnaire. 
There were 60909 responses, with 12693 confirming too much sleep. This data was 
cleaned and imputed by Neale et al. and a total set of 45540 was analysed, with 9354 cases 
against 36186 controls. 
292 
 
 
Figure: Manhattan plot for UKBiobank parameter 20534 sleeping too much. The data was cleaned and imputed by 
the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of 
Genome Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA 
to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs 
were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 
0.05/19712 = 2.537e-6. There were no genes that reached above the genome wide significance level. 
 
20544_1 Mental health problems ever diagnosed by a professional: Social anxiety or social 
phobia 
Parameter 20544_1 refers to participants disclosing if they had any current or historical 
diagnoses for social anxiety or phobias. The question was part of an online follow-up 
questionnaire revolving around mental health. 
There were 50099 participants, of which 1962 claimed to have been diagnosed at some 
point in their life. This data was cleaned and imputed by Neale et al. and a total of 117716 
was analysed, with 1474 cases against 116242 controls. 
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Figure: Manhattan plot for UKBiobank parameter 20544_1 Mental health problems ever diagnosed by a 
professional: Social anxiety or social phobia. The data was cleaned and imputed by the Neale lab then made available for 
public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome Wide Association Studies) 
online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP data to compute a 
gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 19712 protein 
coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant 
genes above the determined genome wide significant level were: SWT1 and HCRT. 
 
 
20544_10 Mental health problems ever diagnosed by a professional: Mania, hypomania, 
bipolar or manic-depression. 
Parameter 20544_10 refers to participants disclosing if they had any current or 
historical diagnoses for mania, hypomania, bipolar, or manic-depression. The question was 
part of an online follow-up questionnaire revolving around mental health. 
There were 50099 participants, of which 837 claimed to have been diagnosed at some 
point in their life. This data was cleaned and imputed by Neale et al. and a total of 117708 
was analysed, with 604 cases against 117104 controls. 
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Figure: Manhattan plot for UKBiobank parameter 20544_10 Mental health problems ever diagnosed by a 
professional: mania, hypomania, bipolar, or manic-depression. The data was cleaned and imputed by the Neale lab then 
made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome Wide 
Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP 
data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 
19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 
2.537e-6. Significant genes above the determined genome wide significant level were: HIST1H3A, IQSEC3, and PSPC1. 
 
 
20544_14 Mental health problems ever diagnosed by a professional: Autism, Asperger's or 
autistic spectrum disorder. 
Parameter 20544_14 refers to participants disclosing if they had any current or 
historical diagnoses for Autism, Asperger's or autistic spectrum disorder. The question was 
part of an online follow-up questionnaire revolving around mental health. 
There were 50099 participants, of which 223 claimed to have been diagnosed at some 
point in their life. This data was cleaned and imputed by Neale et al. and a total of 117707 
was analysed, with 166 cases against 117541 controls. 
295 
 
 
Figure: Manhattan plot for UKBiobank parameter 20544_14 Mental health problems ever diagnosed by a 
professional: Autism, Asperger's or autistic spectrum disorder. The data was cleaned and imputed by the Neale lab then 
made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome Wide 
Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP 
data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 
19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 
2.537e-6. Significant genes above the determined genome wide significant level were: BCL2L11, DRD4, THOC6, 
AC005544.1, and NDUFB11. 
 
20544_15 Mental health problems ever diagnosed by a professional: Anxiety, nerves, or 
generalized anxiety disorder. 
Parameter 20544_15 refers to participants disclosing if they had any current or 
historical diagnoses for Anxiety, nerves, or generalized anxiety disorder. The question was 
part of an online follow-up questionnaire revolving around mental health. 
There were 50099 participants, of which 22035 claimed to have been diagnosed at 
some point in their life. This data was cleaned and imputed by Neale et al. and a total of 
117751 were analysed, with 16730 cases against 101021 controls. 
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Figure: Manhattan plot for UKBiobank parameter 20544_15 Mental health problems ever diagnosed by a 
professional: Anxiety, nerves, or generalized anxiety disorder. The data was cleaned and imputed by the Neale lab then 
made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of Genome Wide 
Association Studies) online programme was used analyse the data. The programme includes use of MAGMA to analyse SNP 
data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs were mapped to 
19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 0.05/19712 = 
2.537e-6. Significant genes above the determined genome wide significant level were: TMEM106B and GTF2IRD1. 
 
G20 ICD10 characterised Parkinson’s disease 
Parameter G20 is a summary of the specific diagnoses codes each participant had in 
their medical files from their episodes in hospital. The diagnoses codes are written in 
accordance with the World Health Organization International classification of disease version 
10 (ICD10)  
There were 410293 participants, of which 1935 had been diagnosed with G20 
Parkinson’s disease. This data was cleaned and imputed by Neale et al. and a total of 361194 
were analysed, with 206 cases against 360988 controls. 
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Figure: Manhattan plot for UKBiobank parameter G20 ICD10 characterised Parkinson’s disease. The data was 
cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function 
Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The 
programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the 
significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red 
dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide 
significant level were: TMOD4, GRM2, HIST1H4C, PGAM1, WNT1, and ZNF260. 
 
G47 ICD10 characterised Sleep disorders 
Parameter G47 is a summary of the specific diagnoses codes each participant had in 
their medical files from their episodes in hospital. The diagnoses codes are written in 
accordance with the World Health Organization International classification of disease version 
10 (ICD10)  
There were 410293 participants, of which 8708 had been diagnosed with G47 Sleep 
disorders. This group contains a collection of disorders such as sleep apnoea, insomnia, and 
catalepsy. This data was cleaned and imputed by Neale et al. and a total of 361194 were 
analysed, with 2723 cases against 358471 controls. 
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Figure: Manhattan plot for UKBiobank parameter G47 ICD10 characterised sleep disorders. The data was cleaned 
and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation 
and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The programme includes 
use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this 
dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) 
was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: 
NPAS2 and TEX11. 
 
AD Alzheimer’s Disease 
This parameter is clinical diagnoses of Alzheimer’s disease from the Finngen 
accumulative database. Neale lab cleaned and imputed the data creating a total of 361194 
samples, with 119 cases against 361075 controls. 
 
Figure: Manhattan plot for Finngen parameter AD Alzheimer’s disease. The data was cleaned and imputed by the 
Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of 
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Genome Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA 
to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs 
were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 
0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: C2orf53, PVRL2, 
TOMM40, APOE, APOC1, THBD, CD93, and MPPED1. 
 
F5_Schizo: SZ, Schizotypal, and delusional disorders 
This parameter is clinical diagnoses of SZ and delusion symptoms from the Finngen 
accumulative database. Neale lab cleaned and imputed the data creating a total of 361194 
samples, with 461 cases against 360733 controls. 
 
Figure: Manhattan plot for Finngen parameter f5_Schizo SZ, Schizotypal, and delusional disorders. The data was 
cleaned and imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function 
Annotation and Mapping of Genome Wide Association Studies) online programme was used analyse the data. The 
programme includes use of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the 
significant genes in this dataset.  Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red 
dashed line in the plot) was defined at P = 0.05/19712 = 2.537e-6. Significant genes above the determined genome wide 
significant level were: VHLL, HIST1H4D, OPN1SW, OR8B8, C20orf26, TPD52L2, and KLHDC7B. 
 
F5_Depressio: Depression 
This parameter is clinical diagnoses of Depression from the Finngen accumulative 
database. Neale lab cleaned and imputed the data creating a total of 361194 samples, with 
1145 cases against 360049 controls. 
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Figure: Manhattan plot for Finngen parameter f5_Depressio: Depression. The data was cleaned and imputed by the 
Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of 
Genome Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA 
to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs 
were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 
0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: LRRC37A3 and P2RY4. 
 
F5_Dementia: Dementia 
This parameter is clinical diagnoses of Depression from the Finngen accumulative 
database. Neale lab cleaned and imputed the data creating a total of 361194 samples, with 
157 cases against 361037 controls. 
 
Figure: Manhattan plot for Finngen parameter f5_Dementia: Dementia. The data was cleaned and imputed by the 
Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and Mapping of 
Genome Wide Association Studies) online programme was used analyse the data. The programme includes use of MAGMA 
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to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  Input SNPs 
were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined at P = 
0.05/19712 = 2.537e-6. Significant genes above the determined genome wide significant level were: OR2T12, NIPAL1, 
CNGA1, OBP2B, C9orf172, MAMDC4, FBXW5, PTGDS, C9orf169, C15orf62, AC116407.2, FASN, PVRL2, TOMM40, 
APOE, APOC1, and THBD. 
 
F5_AllAnxious: All anxiety disorders 
This parameter is and accumulation of clinical diagnoses of anxiety disorders from the 
Finngen accumulative database. Neale lab cleaned and imputed the data creating a total of 
361194 samples, with 532 cases against 360662 controls. 
 
Figure: Manhattan plot for Finngen parameter f5_Allanxious: All anxiety disorders. The data was cleaned and 
imputed by the Neale lab then made available for public use. The Vrije Universiteit run FUMA (Function Annotation and 
Mapping of Genome Wide Association Studies) online programme was used analyse the data. The programme includes use 
of MAGMA to analyse SNP data to compute a gene-based Manhattan plot, highlighting the significant genes in this dataset.  
Input SNPs were mapped to 19712 protein coding genes. Genome wide significance (red dashed line in the plot) was defined 
at P = 0.05/19712 = 2.537e-6. The significant gene above the determined genome wide significant level was MAPK3. 
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12.5 Richard Anney Cardiff University UKBiobank Parameters 
UKBB Code 1160 
UKBB Name Sleep duration 
Question 
"About how many hours sleep do you get in every 24 hours? (please include 
naps)" 
N in GWAS 335410 
N (missing) 1789 
Post 
Processing 
 
drop if <1 
drop if >23 
prompt to confirm if <3 
prompt to confirm if >12 
Post 
Processing 
Categorisation 
  
0 = <7 (n = 123280) 
1 = [7,8] (n = 192438) 
2 >=8 (n = 182697) 
 
 
UKBB Code 1170 
UKBB Name Getting up in the morning 
Question "On an average day, how easy do you find getting up in the morning?” 
N in GWAS 336510 
N (missing) 698 
Post 
Processing 
 
If this varies a lot then answer this question in relation to last 4 weeks 
 
 
Post 
Processing 
Categorisation 
  
1 = not at all easy ( n = 19763) 
2 = not very easy (n = 69995) 
3 = fairly easy (n = 246698) 
4 = very easy (n = 160536) 
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UKBB Code 1180 
UKBB Name Morning / evening person (Chronotype) 
Question "Do you consider yourself to be?” 
N in GWAS 301143 
N (missing) 36056 
Post 
Processing 
 
If this varies a lot then answer this question in relation to last 4 weeks 
 
 
Post 
Processing 
Categorisation 
  
1 = definitely a morning person ( n = 120401) 
2 = more a morning than an evening person (n = 157414) 
3 = more a evening than an morning person (n = 126359) 
4 = definitely an evening person (n = 40118) 
 
UKBB Code 1190 
UKBB Name Nap during day 
Question "Do you have a nap during the day?” 
N in GWAS 335410 
N (missing) 1789 
Post 
Processing 
 
If this varies a lot then answer this question in relation to last 4 weeks 
 
 
Post 
Processing 
Categorisation 
  
1 = Never/ rarely (n = 281145) 
2 = Sometimes (n = 192704) 
3 = Usually (n = 26888) 
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UKBB Code 1200 
UKBB Name Sleeplessness / insomnia 
Question 
“Do you have trouble falling asleep at night or do you wake up in the middle of 
the night?” 
N in GWAS 336965 
N (missing) 235 
Post 
Processing 
 
If this varies a lot then answer this question in relation to last 4 weeks 
 
 
Post 
Processing 
Categorisation 
  
1 = Never/ rarely (n = 120811) 
2 = Sometimes (n = 238899) 
3 = Usually (n = 141418) 
 
 
UKBB Code 1220 
UKBB Name Daytime dozing / sleeping (narcolepsy) 
Question 
"How likely are you to doze off or fall asleep during the daytime when you don't 
mean to? (e.g. when working, reading or driving)" 
N in GWAS 336965 
N (missing) 234 
Post 
Processing 
 
If this varies a lot then answer this question in relation to last 4 weeks 
 
 
Post 
Processing 
Categorisation 
  
0 = Never/ rarely (n = 378813) 
1 = Sometimes (n = 105988) 
2 = Usually (n = 14053) 
3 = All of the time (n = 43) 
 
 
